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ABSTRACT 
 
Depression is a complex psychiatric disorder. It is recognized as a cyclical disease 
with multiple episode relapses. Many preclinical animal models have been utilized to study 
the behavioral and neurobiological characteristics of depression, however, almost without 
exception, these models do not recapitulate the recurrent nature of this disorder. It is 
suggested that the relationship between major depression and stress, which is the important 
risk factor for depression, changes over time: the depressive episodes either become 
increasingly autonomous of stress and occur spontaneously, or the depressed individual 
becomes increasingly sensitized to stress so that smaller stressors can trigger subsequent 
episode relapses. Therefore, a close examination of potential mechanisms evoking recurrent 
depressive episodes is needed. 
The primary goals of this dissertation were to develop an animal model of recurrent 
depression using repeated and cyclic corticosterone (CORT) administration and to gain a 
better understanding of the consequences of such treatment on behavioral and 
neurobiological alterations in rodents. To begin, in Chapter 2, I examined the effect of two 
cycles of repeated CORT injections on rat behavior measured via repeated forced swim 
testing. I found that CORT produced increasingly greater effects on the depression-like 
behavior of rats during the second cycle of CORT exposure. These data suggested the 
development of a sensitized behavioral vulnerability in rats following CORT re-exposure. In 
Chapter 3, non-repeated behavioral testing of naïve rats was employed to examine the 
influence of cyclic CORT treatment on several measures of depression-like behavior, the 
number and maturation rate of immature dentate granule cells, as well as changes in 
hippocampal REST protein expression. Consistent with the results of the first experiment, 
CORT produced larger increases in depression-like and anhedonia-like behaviors in second 
	 iii
and third cycles, without changes in general locomotor behavior. Aggravation of depression-
like behavior was accompanied by an accumulated decline in neurogenesis and dendritic 
complexity of newborn neurons in the dentate gyrus. Additionally, I discovered that 
glucocorticoid treatment also exerted its adverse effects on transcriptional regulation in the 
hippocampus, characterized by hippocampal REST protein levels. Finally, Chapter 4 
included a preliminary examination of the effects of cyclic CORT exposure on changes in 
hippocampal microglia. CORT produced cumulative decreases in hippocampal microglia 
area fraction and cell morphology, which are closely coupled with microglial activation and 
neuroinflammatory processes. These changes were strongly correlated with decreases in 
dentate granule neuron maturation and increases in depression-like behavior, suggesting that 
the activation of hippocampal microglia may be associated with exacerbation of depressive 
symptoms and paralleled decreases in the number and complexity of hippocampal immature 
neuron population.  
The overall findings of this dissertation provide evidence that repeated and cyclic 
glucocorticoid treatment can be used as an animal model of recurrent depression, as it 
provides a means to investigate the neurobiological changes governing depressive symptom 
relapse. Data presented in this dissertation further advance our understanding of the effects of 
CORT on brain and behavior, and provide support for a relationship between increasingly 
severe depression-like symptoms, decreases in neurogenesis and newborn cell maturation 
rate, as well as alterations in hippocampal REST levels and microglial cell activation. 
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CHAPTER 1 
General Introduction 
1.1. Thesis Outline 
 
 Depression is estimated to affect approximately 350 million people worldwide (World 
Health Organization, 2012). In Canada, the lifetime prevalence rate of depression is 
approximately 11% (Patten et al., 2009). Depressive disorders often develop at a young age, 
typically recur and impair an individual’s functioning and quality of life. For these reasons, 
depressive disorders are considered the leading cause of global disability in terms of years 
lost due to disability. Two major characteristic symptoms of depression include depressed 
mood and anhedonia (Nestler, Barrot, et al., 2002). Additionally, depressed individuals have 
increased risks of other physical illnesses, impaired social functioning, and higher morbidity 
(Nemeroff, 1998). Depression is further complicated by several comorbidities, such as 
anxiety disorders (Hirschfeld, 2001; Kessler et al., 1996; Oquendo et al., 2003; Zimmerman 
et al., 2013), which can influence the course of disease, delay recovery, and increase risks of 
relapses (Hirschfeld, 2001). Given the prevalence, and enormous personal and societal 
burden of depression, it is critical that research focuses on enhancing our understanding of 
the etiology and adequate treatment of this disorder. 
The existing knowledge argues against the singular cause of depression, therefore, it 
is hypothesized that a combination of environmental factors (chronic stress, child adversity), 
psychosocial factors (personality traits, absence of social support), and biological factors 
(alterations in neurotransmission, hormone levels, genetics) impact the development of 
depression (Barnhofer & Chittka, 2010; George, Blazer, Hughes, & Fowler, 1989; Kalia, 
2005; Nestler, Barrot, et al., 2002). Current antidepressant medications still rely on the 
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concepts of the earliest monoamine theory of depression that suggests altered activity of the 
monoamine neurotransmitters in depressed patients (Schildkraut, 1965). This hypothesis has 
faced considerable criticism over the past few decades (Ruhé, Mason, & Schene, 2007), and 
alternative hypotheses about the etiology of depression have been proposed. These 
hypotheses focus on changes in transcriptional regulation, proteins and growth factors that 
modulate plasticity in the adult brain. A wealth of clinical and preclinical evidence support 
new theories by demonstrating volumetric reductions in human brain regions known to 
regulate emotion and cognition (Sheline, Gado, & Kraemer, 2003), as well as decreases in 
cell proliferation, survival and neuronal morphology in the analogous brain regions in animal 
models of depression (Bambico & Belzung, 2013; Sterner & Kalynchuk, 2010). Although our 
knowledge of the many cellular and molecular changes associated with depression has 
significantly improved over several decades (Conrad, LeDoux, Magariños, & McEwen, 
1999; McEwen & Magarinos, 2001), our understanding of the neurobiological mechanisms 
underlying the development of major depression and its continual episode relapse is still very 
limited. 
This dissertation comprises a collection of experiments that investigates the effects of 
repeated and cyclic exposure to glucocorticoids on depressive behaviors and hippocampal 
function (brain region known to be involved in stress response). The first experiment focused 
on introducing an animal model of recurrent depression with repeated forced swim 
behavioral testing. In the second experiment, I refined the model and further examined the 
effects of repeated and cyclic corticosterone treatment on several measures of depressive 
behavior. I have also investigated the effects of glucocorticoids on neurogenesis and newborn 
neuron morphology in relation to treatment duration (one, two, and three cycles of 21-day 
corticosterone exposure). In addition, I examined alterations in REST expression in 
hippocampus. Finally, in the third experiment, I have assessed changes in microglial 
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activation in hippocampus after one and three cycles of glucocorticoid exposure to study a 
potential mechanism for cumulative loss of neurogenic function and sensitized depressive 
symptomatology in this model of recurrent depression. 
The remaining sections of this chapter will provide an overview of the hypothalamic-
pituitary-adrenal (HPA) axis and its relationship to major depression. Further, I will discuss 
how animal models provide an essential means for studying the etiology and progression of 
depression pathology. I will then discuss the structural and functional abnormalities linked to 
the depressive disorder, and the influence of stress on hippocampal plasticity and 
neurogenesis in relation to depression. Finally, I will give an overview of current literature on 
the role of hippocampal REST and microglial activation in neurogenesis and depression. This 
chapter concludes with a discussion of important questions that remain unanswered in the 
field of stress and depression research.  
Chapters 2, 3 and 4 describe the experimental data that address the questions outlined 
in this chapter. Chapter 5 includes an overview and discussion of my experimental research, 
its implications and limitations, as well as directions for future investigation. 
 
1.2. Hypothalamic-Pituitary-Adrenal Axis (HPA) and Stress Response 
 
 Stress is an significant risk factor for developing depressive disorders as described in 
both the clinical (Kendler, Karkowski, & Prescott, 1999; Shrout et al., 1989) and animal 
literature (Checkley, 1996; Cheeta, Ruigt, van Proosdij, & Willner, 1997; Daquila, Brain, & 
Willner, 1994; Iñiguez et al., 2014). There is increasing evidence of a strong correlation 
between the number of major stressful life events and the onset of depressive symptoms 
(Kendler et al., 1999; McLaughlin, Conron, Koenen, & Gilman, 2010; Muscatell, Slavich, 
Monroe, & Gotlib, 2009; Ormel, Oldehinkel, & Brilman, 2001; Parker, Schatzberg, & Lyons, 
2003). Moreover, existing data demonstrate that over 80% of patients experience stress 
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before the onset of their depressive episode (Parker et al., 2003). 
 Physical and psychological stressors initiate activation of the HPA axis (Herman & 
Cullinan, 1997). The normal physiological stress response is well characterized in the 
literature. Briefly, the stress response initiates a cascade of secretory events (see Figure 1-1). 
Neurons in the paraventricular nucleus (PVN) of the hypothalamus release corticotropin-
releasing hormone (CRH) onto the anterior pituitary, where CRH stimulates the secretion of 
adrenocorticotropic hormone (ACTH) from the anterior pituitary into the general 
bloodstream. ACTH targets the adrenal cortex, where it stimulates the production of 
glucocorticoids (cortisol in humans; corticosterone in rats). The released glucocorticoids help 
activate body functions and mobilize energy to cope with stressors. In the brain, 
glucocorticoids bind to mineralocorticoid (type I) and glucocorticoid (type II) receptors and 
exert an inhibitory effect on the PVN to terminate HPA axis activity through a negative 
feedback system (Herman & Cullinan, 1997). 
Glucocorticoids have a widespread control over a number of body systems, such as 
musculoskeletal, cardiovascular, and immune systems. In addition, they also have important 
effects on the nervous system. The hippocampus, amygdala, and prefrontal cortex (PFC) are 
particularly abundant in glucocorticoid receptor expression (Feldman & Weidenfeld, 1999; 
Morimoto, Morita, Ozawa, Yokoyama et al., 1996). Therefore, these structures are known to 
be greatly involved in regulating HPA axis activity (Herman & Cullinan, 1997; Jacobson & 
Sapolsky, 1991; Sapolsky, Krey, & McEwen, 1984; Sapolsky, Krey, & McEwen, 1986). In 
particular, there is evidence to suggest that under normal physiological conditions, the 
hippocampus negatively affects HPA activity; in contrast, the amygdala exerts a stimulatory 
influence (Jacobson & Sapolsky, 1991; Nestler, Barrot, et al., 2002). For example, 
stimulation of the hippocampus has been shown to decrease glucocorticoid secretion, 
whereas stimulation of the amygdala elevated glucocorticoid levels  
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Figure 1-1. Hypothalamic-Pituitary-Adrenal Axis. In response to stressful stimuli the 
hypothalamus paraventricular nucleus (PVN) releases corticotrophin-releasing hormone 
(CRH), which targets the anterior pituitary gland. Adrenocorticotrophic hormone (ACTH) is 
then released into the circulation by the pituitary gland. In turn, the adrenal cortex secretes 
cortisol (in humans) or corticosterone (in rodents). Glucocorticoids bind to the receptors in 
the hippocampus providing the negative feedback to the HPA, whereas binding in the 
amygdala provides excitation to neurons in PVN enhancing the HPA activity. Figure adapted 
from (Hyman, 2009) under copyright license agreement #4007150059362.  
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(Dunn & Orr, 1984; Rubin, Mandell, & Crandall, 1966; Dunn & Whitener, 1986). 
Interestingly, total hippocampectomy, hippocampal excitotoxic lesions, and hippocampal 
glucocorticoid receptor depletion can increase corticosterone (CORT) and ACTH production 
(Fendler, Karmos, & Teledy, 1961; Knigge & Hays, 1963; Knigge, 1961; Sapolsky et al., 
1986). 
Short-term HPA axis activation is critical for an organism’s survival and homeostasis; 
however, sustained and excessive glucocorticoid production resulting from chronic stress is 
associated with negative feedback loop malfunction and the development of various 
pathologies. Prolonged HPA axis activation is associated with multiple disorders including 
sleep dysfunction, memory impairments, reduced sexual behavior, immune related disorders, 
and dysphoria (Lau et al., 2012; McEwen, 1998; McEwen, 2006). Chronic exposure to stress 
brings about pathological changes in the brain, particularly in the structures involved in the 
stress response, such as the PFC, hypothalamus, and hippocampus. For example, repeated 
exposure to high levels of glucocorticoids was reported to reduce adult neurogenesis, increase 
excitotoxicity and cell death, and alter dendritic and spine morphology (Dranovsky & Hen, 
2006). Interestingly, numerous studies have demonstrated that hippocampal damage resulting 
from chronic stress is correlated with several behavioral changes including depression- and 
anxiety-like behaviors, and impaired learning and memory function in rodents (Daniel, 2002; 
Duman, Malberg, & Nakagawa, 2001; Duman, 2002; McEwen, 1999; McEwen & 
Magarinos, 2001; Nestler, Barrot, et al., 2002). 
 
1.3. Depression 
 
Major Depressive Disorder is a highly prevalent neuropsychiatric disorder, and it is 
estimated to affect 16.6% of the general population (Kessler & Wang, 2008). It is 
characterized by the persistence of one or two core symptoms: decreased mood (sad feelings) 
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and anhedonia (inability to experience pleasure); and several minor symptoms, which may 
include changes in weight and appetite, changes in sleep behaviour, fatigue (loss of energy), 
diminished ability to think and /or concentrate, feelings of worthlessness, and suicidal 
ideations. Major depression is diagnosed in accordance with the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-V), which postulates that a diagnosis is made when the 
patient experiences one or more of the core symptoms and at least five of minor symptoms 
for greater than two weeks. Moreover, individuals suffering from depression have reduced 
social functioning and increased mortality rate (Nemeroff, 1998). Finally, proper diagnosis 
and successful treatment of this disorder are further complicated by the absence of 
biomarkers and its comorbidity with other neuropsychiatric conditions, such as anxiety, 
bipolar disorder, and posttraumatic stress disorder (Hirschfeld, 2001; Oquendo et al., 2003; 
Zimmerman et al., 2013). 
 It is widely acknowledged that stress is a major risk factor for depression. Evidence 
from numerous research lines supports the involvement of stress in depression. For example, 
individuals who experienced stressful environment in childhood have a sensitized HPA 
response (Essex, Klein, Cho, & Kalin, 2002), and have an increased likelihood of developing 
major depression as adults and adolescents (Espejo et al., 2007; Lenze, Xiong, & Sheline, 
2008; McLaughlin et al., 2010). Likewise, patients suffering from depression often have 
hypercortisolemia, exhibit changes in cortisol rhythmicity (Sachar & Baron, 1979), and 
sensitized increases in cortisol release in response to stress  (Belmaker & Agam, 2008; 
Burke, Davis, Otte, & Mohr, 2005; Checkley, 1996; De Kloet, Vreugdenhil, Oitzl, & Joëls, 
1998; R M Sapolsky et al., 1984a). There is also evidence of elevated levels of CRH in 
cerebrospinal fluid and elevated urinary free cortisol in depressed individuals (Nestler, 
Barrot, et al., 2002; Southwick, Vythilingam, & Charney, 2005). Furthermore, individuals 
with Cushing’s disease, a disorder characterized by chronically elevated levels of cortisol, 
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have unusually high rates of major depression (Sonino & Fava, 2001). Additionally, 
depressed individuals that did not show stabilization of ACTH and cortisol secretion after 
administration of dexamethasone (the synthetic glucocorticoid), also had a depressive episode 
relapse after antidepressant treatment (Nestler, Barrot, et al., 2002; Southwick et al., 2005). 
The involvement of stress in depression is further supported by research demonstrating that 
various classes of common antidepressants that modulate monoaminergic neurotransmission 
can also affect HPA axis function (Heuser et al., 1996; Linkowski et al., 1987; Schüle et al., 
2009). Additionally, an antidepressant, metyrapone, which directly regulates cortisol 
production, is efficacious in treating major depression (O’Dwyer, Lightman, Marks, & 
Checkley, 1995). Taken together, clinical literature provides substantial support for the 
influence of a dysregulated stress response system in the development of major depression. 
 
1.4. Recurrent Depression 
 
Major depression is recognized as a highly recurrent and chronic condition. Over 70% 
of individuals suffering from depression experience more than one episode (Hollon et al., 
2006; Solomon et al., 2000).  Patients with recurrent depression have longer episodes and 
more severe symptomatology (Karp et al., 2004; Keller et al., 1992) and do not have a 
complete recovery during remissions (Judd et al., 1998, 2000).  
According to the review by Hardeveld et al., the two primary predictors of recurrence 
are the number of previous depressive episodes and the presence of residual symptoms after 
recovery (Hardeveld, Spijker, De Graaf, Nolen, & Beekman, 2010). For example, with the 
increased number of depressive episodes, the number of prior episodes predicts future 
episodes. It is estimated that 60% of individuals who have had one depressive episode will 
have another, 70% of individuals with two depressive episodes will have a third, and 90% of 
individuals with three episodes will have a fourth episode (Kendler, Thornton, & Gardner, 
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2000). In contrast, demographic variables, i.e., sex, age, socioeconomic status, and marital 
status were not found to be associated with depression relapse and recurrence (Eaton et al., 
1997; Gopinath, Katon, Russo, & Ludman, 2007; Kanai et al., 2003; Maj, Veltro, Pirozzi, 
Lobrace, & Magliano, 1992). However, some research studies do provide some evidence of 
influence of demographic factors on depression recurrence. For instance, Mueller et al. and 
Winokur et al. demonstrated that women had an increased risk of recurrence (Mueller et al., 
1999; Winokur, Coryell, Keller, Endicott, & Akiskal, 1993). A greater risk of recurrence was 
observed among patients who were single (never been married).  
Clinical literature suggests that the relationship between stress and depression 
changes over time. Although the initial depressive episode onset is strongly correlated with 
major life stressful events (Kendler et al., 1999; McLaughlin et al., 2010; Muscatell et al., 
2009; Ormel et al., 2001; Parker et al., 2003), the subsequent episodes are rarely predicted by 
the major life stressors (Gonzales, Lewinsohn, & Clarke, 1985; Harkness, Monroe, Simons, 
& Thase, 1999; Kendler, Thornton, & Gardner, 2001; Kendler, Karkowski, & Prescott, 1999; 
Kendler et al., 2000). Two hypotheses have been put forward in the attempt to explain the 
changing relationship between stress and depression episode recurrence. The kindling 
hypothesis suggests that over the course of a lifetime of depressive episodes, the successive 
episodes become increasingly autonomous of stress and occur spontaneously (Monroe & 
Harkness, 2005; Post, 1992). This hypothesis is supported by several research studies 
demonstrating that major life stress is not a predictor of subsequent depression episodes 
(Gonzales et al., 1985; Harkness et al., 1999; Kendler et al., 2001; Kendler et al., 1999; 
Kendler et al., 2000). The stress sensitization hypothesis suggests that an individual’s 
threshold of stress lowers with every successive episode of depression, therefore, the 
sensitivity to stress increases, leaving the depressed individual susceptible to depression 
relapse caused by minor stressors (Post, 1985). Several studies support this hypothesis 
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demonstrating that a relapse into a depressive episode is correlated with minor, but not major 
life stressors (Kendler et al., 1999; Ormel et al., 2001). Additionally, adolescent individuals 
were reported to have a depression relapse associated with both major and minor life 
stressors (Morris, Ciesla, & Garber, 2010). Furthermore, the preclinical literature also 
demonstrates support for the stress sensitization theory by reporting that animals pre-exposed 
to stress exhibit a sensitized release of catecholamines and elevated CORT levels following a 
subsequent stress re-exposure (Gresch, Sved, Zigmond, & Finlay, 1994; Grippo, Cushing, & 
Carter, 2007). Finally, findings from developmental research also demonstrate that animals 
stressed in utero or during adolescence develop depression-like symptoms in adulthood 
(Morley-Fletcher et al., 2003; Zurita, Martijena, Cuadra, Brandão, & Molina, 2000). 
Both the kindling and stress sensitization theories of recurrent depression imply that 
certain changes at the biological level occur during the initial episode of depression, inducing 
a persistent change and increasing the susceptibility of the depressed individual to relapse 
into future episodes of depression. Interestingly, a longer course of depression (greater 
number and duration of episodes) is correlated with larger neurobiological changes, such as 
reduced volume of the hippocampus (Bremner et al., 2000; Sheline, Sanghavi, Mintun, & 
Gado, 1999; Sheline, Gado, & Kraemer, 2003). This observation further supports the idea 
that depression could be a progressive disorder, with increasingly larger neurobiological 
alterations leading to increasingly profound symptomatology and episode relapse.   
Despite the significant impact and devastating consequences of depression on the 
patient and the public, the exact neurobiological mechanisms of depression etiology and its 
recurrent disease course remain unknown. Interestingly, cognitive-based therapeutic 
interventions, that have been designed specifically to reduce relapse or recurrence of major 
depressive disorder (Segal, Williams, & Teasdale, 2002), have shown some success. 
Research studies (Teasdale et al., 2000) and meta-analyses (Piet & Hougaard, 2011) report 
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that mindfulness-based cognitive therapy (MBCT) benefits patients with three or more 
depressive episodes in lowering the risk of relapse. Therefore, investigation of the 
neurobiological mechanisms of depression relapse and its effective prevention needs to be a 
high priority in mental health research. 
 
1.5. Animal Models of Depression 
 
 Although clinical research has improved our understanding of risk factors, 
symptomatology, and neural correlates of depression, methods of clinical investigation are 
limited; the data are correlational and confounded with subject variability. Preclinical models 
are highly challenging, but they are essential tools for studying the etiology of mental 
disorders, the neurobiological changes associated with such disorders, biomarker 
development, and finding efficacious novel treatment programs. Animal models allow for 
subject homogeneity and control over experimental manipulation. Most psychiatric disorders, 
including major depression, are very heterogeneous syndromes, characterized by numerous 
symptoms that can be inferred with substantial limitations in animal preparations. It is 
virtually impossible to develop an animal model that reproduces a whole psychiatric 
syndrome; therefore, researchers typically focus on endophenotypes or discrete traits of the 
disorders (Gottesman & Gould, 2003). In depression preclinical research, a number of 
behavioral measures have been employed to identify a depression-like state in rodents (e.g., 
helplessness behaviors, anhedonia, weight loss, memory impairments, sleep disturbances, 
changes in sexual behavior), of which depression-like behavior (learned helplessness) and 
anhedonia are the most commonly used. Anhedonia (i.e., a lack of interest in pleasurable 
activity) is inferred by assessing an animal’s preference for a sucrose solution over regular 
water. Healthy rodents typically prefer the sucrose solution, so a reduction in sucrose 
preference is considered to be indicative of anhedonic behavior (David et al., 2009; Gorzalka, 
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Hanson, Harrington, Killam, & Campbell-Meiklejohn, 2003; Gourley, Kiraly, Howell, 
Olausson, & Taylor, 2008). Rodent learned helplessness behavior can be measured in several 
ways, but the most common and reliable method is the use of the forced swim test (FST). In 
the FST, rats are forced to swim in a tank filled with water with no opportunity of escape. 
Depression-like behavior is inferred from longer time spent immobile (passive behavior) and 
shorter time spent swimming or climbing (active behaviors) (Lucki, 1997). Both the sucrose 
preference test (SPT) and the FST are thought to be valid tests for depression because various 
antidepressant treatment programs, including typical and atypical antidepressant drugs, 
electroconvulsive therapy (ECT), and rapid eye movement (REM) sleep deprivation reduce 
immobility in the FST (Armario, Gavaldà, & Martí, 1988; Porsolt, Anton, Blavet, & Jalfre, 
1978) and increase preference for sucrose (Willner, 1997). Interestingly, the clinical potency 
of antidepressants in humans is significantly correlated with their potency as tested in the 
FST (Borsini & Meli, 1988; Porsolt, Le Pichon, & Jalfre, 1977). 
Specific criteria have been developed to judge the validity of the various animal 
models of human disorders: (1) face validity - the presence of the precipitating factors for 
developing the disorder, behavioral symptomatic similarities with the clinical disorder, 
common neurobiological changes; (2) predictive validity - therapeutic intervention results in 
similar changes that are seen in patient populations; and (3) construct validity - suggests that 
animal models should be defined so that a rational theory can be constructed to explain and 
test hypotheses regarding the etiology and pathogenesis of the disease (Geyer & Markou, 
2002; McKinney & Bunney 1969; Willner, 2005). These criteria help to evaluate new models 
and compare existing models, although they do have several flaws (Nestler & Hyman, 2010). 
For example, the evaluation of construct validity is rather restricted, because our 
understanding of etiology of most psychiatric disorders is rudimentary. Additionally, the 
assessment of reversibility of the modeled symptoms with known drugs has limited value, as 
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many medications, such as monoamine-based antidepressants, have poor efficacy in a large 
subgroup of depressed patients (Berton & Nestler, 2006). 
 Several animal models have been utilized to investigate the etiology and pathogenesis 
of depression. Taking into consideration the well-characterized involvement of stress in 
depression, researchers have developed a number of stress-induced animal models of 
depression. The most common ones include chronic mild/unpredictable stress (CMS), 
repeated restraint stress, social defeat stress, repeated glucocorticoid exposure, and early-life 
stress (Cryan & Slattery, 2007). In the CMS model, rodents are subjected to various mild 
stressors (e.g., food/water deprivation, reversed light cycle, cage tilting, noise, cold stress) 
over a period of several weeks (Willner, 1997; Willner, 2005). Repeated restraint stress is one 
of the oldest models of depression used in research; it involves physically restraining an 
animal for a specific duration (usually hours) repeatedly over several days or weeks 
(Buynitsky & Mostofsky, 2009; Selye, 1976). Social defeat stress refers to a repeatedly 
(direct or indirect) exposing an animal to an aggressive and dominant animal (Hollis & 
Kabbaj, 2014). In early life stress models of depression, the animals are subjected to prenatal 
stress, maternal separation, or a combination of these stressors (Schmidt, Wang, & Meijer, 
2011). Finally, the exogenous glucocorticoid exposure model involves the administration of 
glucocorticoids via pellet implantation, infusions, subcutaneous injections, or the drinking 
water (Nestler, Gould, & Manji, 2002; Sterner & Kalynchuk, 2010). Although some of these 
models have the advantages of producing more naturalistic stress (CMS, social defeat, and 
early life stress; Nestler, Gould, et al., 2002), many of the existing stress-induced models of 
depression lack reliability in producing robust and reliable increases in depression-like 
behavior. For example, conflicting results have been reported in several studies using CMS 
(Willner, 1997; Willner, 2005) and restraint stress (Gregus, Wintink, Davis, & Kalynchuk, 
2005; Joo et al., 2009; Lussier, Caruncho, & Kalynchuk, 2009; Perrot-Sinal, Gregus, 
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Boudreau, & Kalynchuk, 2004; Regenthal, Koch, Köhler, Preiss, & Krügel, 2009; Veena, 
Srikumar, Raju, & Shankaranarayana Rao, 2009). The procedural variability (e.g., CMS), 
individual differences in HPA axis responses, and potential habituation effects (restraint 
stress) could account for inconsistencies across laboratories (Willner, 2005).  
 
1.6.  Exogenous CORT Administration Model of Depression 
 
A large body of evidence demonstrates that exogenous CORT administration results 
in robust and reliable changes in depression-like and anhedonia-like behaviors (for a review, 
see Sterner & Kalynchuk, 2010). For example, rodents subjected to exogenous CORT 
(Brummelte, Pawluski, & Galea, 2006; David et al., 2009; Gourley et al., 2008; Gregus et al., 
2005; Hill, Brotto, Lee, & Gorzalka, 2003; Johnson, Fournier, & Kalynchuk, 2006; 
Kalynchuk, Gregus, Boudreau, & Perrot-Sinal, 2004; Marks, Fournier, & Kalynchuk, 2009; 
Murray, Smith, & Hutson, 2008; Zhao, Ma, et al., 2008) display depression-like behaviors: a 
reduced latency to immobility, a reduced time spent swimming, and an increased time spent 
immobile in the FST. Our laboratory (Johnson, Fournier, & Kalynchuk, 2006) and others 
(Zhao, Ma, et al., 2008; Zhao, Shen, et al., 2008) have shown that CORT increases 
depression-like behavior in dose- (10, 20 and 40 mg/kg) and time-dependent (7, 14, and 21 
days) manner (Lussier et al., 2013). Specifically, rats treated with 40 mg/kg CORT showed 
greater immobility than rats treated with CORT 20 mg/kg and CORT 10 mg/kg, with CORT 
20 mg/kg group demonstrating intermediate immobility rate (Johnson, Fournier, & 
Kalynchuk, 2006). In contrast, a single injection of CORT was found to produce no effect on 
the FST behavior (Gregus et al., 2005). In addition, CORT was shown to have a time-
dependent effect: rats treated with CORT demonstrate gradual increases in time spent 
immobile at 7, 14, and 21 days of treatment, reaching a statistically significant difference 
from control rats after 21 days of treatment (Lussier et al., 2013). Collectively, these findings 
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suggest that repeated CORT administration is a reliable method of inducing a depressive 
phenotype in rodents. 
In addition to altering FST behavior, CORT can also produce other rodent behavioral 
and physiological changes that are similar to those seen in a human depression syndrome. For 
example, rats subjected to exogenous CORT often display impaired sexual behavior 
(Gorzalka, Brotto, & Hong, 1999; Gorzalka, Hanson, & Hong, 2001; Gorzalka & Hanson, 
1998; Hanson & Gorzalka, 1999), decreased sucrose preference or intake (David et al., 2009; 
Gorzalka et al., 2003; Gourley et al., 2008), and inhibited grooming behaviors (David et al., 
2009), all of which are anhedonic-like behaviors. Additionally, repeated CORT exposure can 
increase anxiety-like behaviors in rodents (David et al., 2009; Kalynchuk et al., 2004; Lee, 
Shim, Lee, Yang, & Hahm, 2009; Murray et al., 2008; Myers & Greenwood-Van Meerveld, 
2007; Pêgo et al., 2008; Shepard, Barron, & Myers, 2000). Clinical depression is highly 
comorbid with anxiety disorders; therefore, the anxiety-like behaviors observed in the CORT 
model further improve its face validity (Hirschfeld, 2001). The physiological changes 
produced by CORT administration include decreased weight gain (Barr, Brotto, & Phillips, 
2000; Brummelte et al., 2006; Bush, Middlemiss, Marsden, & Fone, 2003; Coburn-Litvak, 
Pothakos, Tata, McCloskey, & Anderson, 2003; Gregus et al., 2005; Johnson et al., 2006; 
Pêgo et al., 2008), dysregulated HPA axis functioning (Johnson et al., 2006), and reduced 
adrenal weight (Bush et al., 2003; Meijer et al., 1997; Murray et al., 2008). Importantly, the 
CORT-induced behavioral changes discussed above can be reversed by antidepressant 
treatment (David et al., 2009; Fenton et al., 2015), reinforcing the predictive validity of 
glucocorticoid exposure as a preclinical model of major depression. Finally, it is important to 
note that glucocorticoid administration models have an advantage of simulating exposure to 
stressful stimuli without the confounds associated with habituation effects and subject 
response variability (as seen in CMS and restraint stress models), ensuring that each animal 
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receives the same amount of glucocorticoids (Gregus et al., 2005; Grissom, Iyer, Vining, & 
Bhatnagar, 2007). Taken together, repeated CORT exposure offers a useful way to study the 
effects of glucocorticoids on brain and behavior in a preclinical setting.  
 
1.7. Modeling Recurrent Depression in Animals 
 
Despite the wealth of research using animal models of depression, very few studies 
have attempted to model the clinical course of the depression disorder. As discussed earlier, 
major depression is a chronic and recurrent disorder (Hollon et al., 2006; Kendler et al., 2000; 
Solomon et al., 2000). To our knowledge, only one study examined the sensitization of 
depression-like behavior using the CMS animal model of recurrent depression (Remus, 
Jamison, & Johnson, 2013). Remus and colleagues hypothesized that the experience of a 
prior depressive episode would sensitize rats to future depressive episodes. Indeed, rats 
exposed to CMS for 35 days, followed by a 20-day recovery period, and then re-exposed to 
the second session of CMS for 15 days, exhibited a more rapid (sensitized) decline in sucrose 
consumption compared with non-stressed control rats. The researchers interpreted these 
results as a sensitized depression-like behavior and a model of recurrent depression (Remus 
et al., 2013). 
To better understand the neurobiological mechanisms underlying the recurrent nature 
of major depression, an animal model with repeated and cyclic stress treatment would be 
beneficial. This dissertation is, therefore, focused on developing a CORT model of recurrent 
depression and studying the effects of repeated and cyclic CORT administration on rodent 
depression-like behaviors and related neurobiological changes. 
 
1.8. Hippocampal Anatomy and Circuitry 
 
 The hippocampal formation is located in the temporal lobe of the mammalian brain; it 
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comprises the hippocampus proper, or Cornu Ammonis (CA), dentate gyrus (DG), the 
subicular cortex (subiculum, presubiculum, and parasubiculum) and the entorhinal cortex 
(EC) (Amaral & Witter, 1989; Amaral, Dolorfo, & Alvarez-royo, 1991).  
The hippocampus proper has three main divisions: CA1, CA2 and CA3 (Figure 1-2). 
The stratum pyramidale is the principal cell layer in the CA subfields, consisting of 
pyramidal neurons (the primary excitatory cells in the hippocampus) and some interneurons 
projecting to adjacent pyramidal cells and interneurons in the CA. The stratum oriens is the 
next layer superficial to the stratum pyramidal; it houses inhibitory interneuron cell bodies as 
well as the basal dendrites of pyramidal neurons. Above the pyramidal layers are the stratum 
radiatum and stratum lacunosum-moleculare. The stratum radiatum consists of Shaffer 
collateral fibers projecting forward from CA3 to CA1 and interneuron cell bodies projecting 
to neighboring excitatory and inhibitory neurons. The stratum lacunosum-moleculare is the 
most peripheral layer in the hippocampus proper, where perforant path fibers form synapses 
at the apical dendrites of pyramidal cells (Amaral & Witter, 1989).  
The DG is the major area of cortical input to the hippocampus. This region comprises 
three layers: the stratum granulosum (or granule cell layer, GCL), the polymorphic layer (or 
hilus), and the stratum moleculare (Amaral & Witter, 1989; Insausti & Amaral, 2004). A 
small area between the hilus and GCL is identified as the subgranular zone (SGZ), one of the 
two neurogenic sites in the mammalian brain. The GCL is the principal cell layer of the DG; 
it contains tightly packed excitatory granule neurons, extending apical processes into the 
molecular layer and axons into the hilus. The hilus consists of several types of neurons 
including inhibitory interneurons and excitatory mossy cells. The hilar pyramidal basket cells 
are the most studied interneurons in this region. In addition, the hilus contains other types of 
inhibitory interneurons innervating both excitatory and inhibitory cells in the DG (Freund & 
Buzsáki, 1996). The stratum moleculare is mainly comprised of dendritic processes of  
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Figure 1-2. Schematic representation of rodent hippocampal formation and its circuitry. The 
image depicts laminar organization of the dentate gyrus (DG), Cornu Ammonis CA1 and 
CA3. The dentate gyrus is comprised of three layers: stratum moleculare, granule cell layer 
(GCL), and hilus. The stratum pyramidale consists of primarily cell bodies of pyramidal 
neurons. Just below the pyramidal cell layer is stratum oriens. Strata radiatum is located 
above the pyramidal cell layer and contains Schaffer collateral fibers, which are the primary 
projection from CA3 to CA1. Just above stratum radiatum is stratum lacunosum-moleculare, 
which contains synapses of perforant path fibers on dendrites of pyramidal cells. The tri-
synaptic pathway: neurons in entorhinal cortex (EC) project to the DG via the perforant path, 
i.e., major hippocampal input; granule cells in DG give rise mossy fibers synapsing onto the 
pyramidal cells of CA3; axons of CA3 pyramidal neurons project to CA1 via the Schaffer 
collateral fibers; finally, axons of CA1 pyramidal neurons project to subiculum and EC, 
comprising the major hippocampal excitatory output. For details see text.  
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granule, basket, and hilar neurons; EC cell axons; inhibitory interneurons innervating granule 
neurons and adjacent inhibitory cells (Amaral & Witter, 1989; Freund & Buzsáki, 1996; 
Insausti & Amaral, 2004). 
The intrahippocampal circuit is mainly unidirectional, in which the cortical input 
reaching the DG does so via the EC. Specifically, EC neurons have axons that project to the 
DG, forming the perforant path (the primary hippocampal input pathway). Then the 
excitatory granule cells of the DG form synapses via mossy fibers onto the cell bodies of 
pyramidal neurons in the CA3 subfield; in turn, the axons of CA3 pyramidal cells (or 
Schaffer collateral axons) project to the CA1 subfield, forming synaptic connections with 
adjacent dendrites of CA1 pyramidal cells. Finally, the axons of CA1 pyramidal neurons then 
provide input to the subiculum and EC, which are the primary excitatory output for the 
hippocampus (Amaral, Ishizuka, & Claiborne, 1990; Amaral & Witter, 1989; Insausti & 
Amaral, 2004). The synaptic connections in the perforant path, mossy fibers and Schaffer 
collaterals in the hippocampal network form the trisynaptic circuit (Felleman & Van Essen, 
1991).	
	
1.9. Adult Hippocampal Neurogenesis  
Neurogenesis, or birth of new neurons, was initially believed to be an exclusively 
developmental process. However, in the 1960s Altman reported the first evidence that the 
adult brain has dividing cells that differentiate into cells with neuron-like morphology 
(Altman & Das, 1965; Altman, 1969). More evidence emerged later in support of adult 
neurogenesis in several species, such as rats (Altman & Das, 1965; Altman, 1969; Gould, 
Cameron, Daniels, Woolley, & McEwen, 1992), rabbits (Gueneau, Privat, Drouet, & Court, 
1982), cats (Wyss & Sripanidkulchai, 1985), mice (Kempermann, Kuhn, & Gage, 1997a), 
non-human primates (Gould, Reeves, Fallah, et al., 1999; Gould, Reeves, Graziano, & Gross, 
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1999), and humans (Eriksson et al., 1998). It is well known today that mature neurons are not 
capable of division, however, in two distinct regions of adult brain, a population of stem cells 
can divide and differentiate into neurons or glial cells.  
 
1.9.1. Stages of Neurogenesis  
	
Neurogenesis is a process that with multiple stages: proliferation, differentiation, 
migration, maturation, and integration (Kempermann & Gage, 2000). Radial glial cells are 
the most commonly found stem cells in the adult mammalian brain and are typically referred 
to as type-1 cells. Radial glia have similar morphological and electrophysiological properties 
as astrocytes (Doetsch, 2003; Seri, García-Verdugo, McEwen, & Alvarez-Buylla, 2001), and 
they express glial fibrillary acidic protein (GFAP) and the neural stem cell marker nestin 
(Filippov et al., 2003; Fukuda et al., 2003). Radial glial cells generate three neuronal 
lineages: oligodendrocytes, astrocytes, and neurons. Importantly, the proliferation of type-1 
cells is thought to be uninfluenced by environmental factors (Encinas & Enikolopov, 2008; 
Kronenberg et al., 2003). 
Type-1 cells produce progenitor cells: type-2 and type-3. Type-2 cells, or neural 
progenitor cells (NPC) express nestin, but not GFAP, and have a high probability of being 
BrdU-positive, and therefore, highly proliferative (Filippov et al., 2003; Kronenberg et al., 
2003). Type-2a and type-2b are two common subtypes of these cells. Type-2a cells express 
nestin, but not doublecortin (DCX), whereas type-2b cells express both nestin and DCX 
(Kronenberg et al., 2003). DCX expression signifies the commitment to neuronal 
differentiation and migration (Francis et al., 1999). DCX co-expresses with polysialylated 
form of the neural adhesion molecule (PSA-NCAM) (Von Bohlen Und Halbach, 2007). 
Newborn granule cells go through a temporary period of PSA-NCAM and DCX expression 
(Brandt et al., 2003; Rao & Shetty, 2004). Type-2b cells take on the neuronal determination 
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by expressing the neuron-specific nuclear protein (NeuN) and Prospero-homeobox-1 
transcription factor (Prox1). At this stage of development, various environmental factors, 
including exercise (Praag, Christie, Sejnowski, & Gage, 1999; Praag, Shubert, Zhao, & Gage, 
2005; Wu et al., 2008), environmental enrichment (Veena, Srikumar, Mahati, et al., 2009; 
Veena, Srikumar, Raju, et al., 2009), learning (Kee, Teixeira, Wang, & Frankland, 2007), 
stress (Brummelte & Galea, 2010; Duman et al., 2001; Gould, McEwen, Tanapat, Galea, & 
Fuchs, 1997; Pham, Nacher, Hof, & McEwen, 2003), and antidepressant treatment (Anacker, 
Zunszain, Carvalho, & Pariante, 2011; Kee et al., 2007; Perera et al., 2007) can alter neuronal 
progenitor cell survival. It was reported that the survival of progenitor cells can be affected 
by elevations in gamma-aminobutyric acid (GABA) levels (Ge et al., 2006), or the induction 
of N-methyl-D-aspartate (NMDA) receptor subunits NR2B and NR1 (Nácher et al., 2007), 
increasing the levels of vascular endothelial growth factor (VEGF) fibroblast growth factor-2 
(FGF-2) (Greene, Banasr, Lee, Warner-Schmidt, & Duman, 2009; Palmer, Markakis, 
Willhoite, Safar, & Gage, 1999; Warner-Schmidt & Duman, 2007), and brain-derived 
neurotrophic factor (BDNF) (Huang & Reichardt, 2001). 
Type-3 cells (commonly referred to as neuroblasts) express DCX but cease to express 
nestin (Von Bohlen Und Halbach, 2007). Cells in this stage radially migrate into the inner 
third of the GCL and begin exhibiting neuron-like morphology (Kempermann & Kronenberg, 
2003). Type-3 cells exit the cell cycle with the transient expression of the calcium-binding 
protein calretinin (Brandt et al., 2003). These cells are also Prox1-positive throughout granule 
cell development; Prox1 is found in mature granule cells as well (Filippov et al., 2003). 
DCX- and calretinin-positive immature neurons start projecting apical dendrites forming 
synapses in the outer molecular layer, and axons – projecting toward the CA3 region. In this 
phase of maturation, immature neurons are favorably recruited for activation by external 
stimuli from learning processes (Kee et al., 2007) and environmental enrichment (Brown et 
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al., 2003; Kempermann, Kuhn, & Gage, 1997b) due to their plasticity, higher excitability, 
and reduced threshold for long-term potentiation (Ge et al., 2006; Ge, Yang, Hsu, Ming, & 
Song, 2007; Wang, Scott, & Wojtowicz, 2000). Finally, mature neurons expressing calbindin 
(instead of calretinin) and the neuronal nuclei (NeuN) protein display extended dendritic 
morphology and become fully integrated into the circuitry (Piatti, Espósito, & Schinder, 
2006). DCX and PSA-NCAM are no longer expressed by these cells (Brown et al., 2003). 
The recent acknowledgment of adult neurogenesis by the scientific community has 
given rise to multiple areas of research examining the potential roles of this process in 
various conditions, including depression.  
 
1.10. Hippocampus, Neurogenesis and Depression 
 
The hippocampus has become an extensively studied brain region in depression for 
several reasons. First, it was found that depressed individuals show reduced hippocampal 
volume (Bremner et al., 2000; Sheline, Wang, Gado, Csernansky, & Vannier, 1996; Sheline 
et al., 2003; Sapolsky, 2001) and that this decrease was correlated with the number 
depressive episodes, suggesting that patients suffering from a longer depression course 
exhibit smaller hippocampal volume (Frodl et al., 2006, 2008; Jaracz, 2008; Lorenzetti, 
Allen, Fornito, & Yücel, 2009; MacQueen et al., 2003). Second, the hippocampus expresses a 
high number of glucocorticoid and mineralocorticoid receptors, indicating that it is highly 
involved in regulating stress responses and HPA axis function, and therefore, it is particularly 
susceptible to stress-related changes (Arriza, Simerly, Swanson, & Evans, 1988; Chao et al., 
1989; Herman et al., 2003; Herman, Ostrander, Mueller, & Figueiredo, 2005; Jacobson & 
Sapolsky, 1991; Sapolsky, Krey, & McEwen, 1984b). Interestingly, some evidence suggests 
that levels of cortisol are associated with reduced hippocampal volume in patients suffering 
from major depression (Lorenzetti et al., 2009; Pariante & Miller, 2001; Pariante et al., 2003; 
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Sheline, 2000). Third, studies using preclinical models of depression consistently reveal 
stress-induced decreases in hippocampal proliferation and survival of newborn neurons, as 
well as increases in dendritic atrophy in the hippocampus (Brummelte & Galea, 2010; David 
et al., 2009; Galea et al., 1997; Gould, Tanapat, McEwen, Flügge, & Fuchs, 1998; 
Magariños, Verdugo, & McEwen, 1997; Magariños, McEwen, Flügge, & Fuchs, 1996; 
Magariños & McEwen, 1995; Mayer et al., 2006; Murray et al., 2008; Nestler, Barrot, et al., 
2002; Pham et al., 2003; Sapolsky, 2004; Watanabe, Gould, & McEwen, 1992). Finally, 
various antidepressant treatment programs, including antidepressant medication, 
electroconvulsive shock therapy, and exercise, were found to reverse the effects of prolonged 
stress on neurogenesis and hippocampal cell atrophy, as well as decrease depressive-like 
behaviors in rodents (Czéh et al., 2001; Malberg, Eisch, Nestler, & Duman, 2000; Malberg & 
Duman, 2003; Mayer et al., 2006; Praag, Kempermann, & Gage, 1999; Scott, Wojtowicz, & 
Burnham, 2000). Likewise, antidepressant treatment was reported to protect against 
hippocampal volume loss in depressed patients (Sheline et al., 2003). 
The findings discussed above comprise evidence and support for the neurogenesis 
hypothesis of depression, which posits that major depressive symptomatology results from 
chronic stress through the mechanisms of decreased neurogenic capacity (Dranovsky & Hen, 
2006; Duman et al., 2001; Jacobs, van Praag, & Gage, 2000). However, despite strong 
support for this hypothesis from a variety of research studies, the neurogenesis hypothesis of 
depression is challenged by the absence of direct evidence of decreased neurogenesis in 
human depression. For instance, no significant reduction in cell proliferation and no cell loss 
were found in post-mortem analyses of brain tissue from depressed individuals (Müller et al., 
2001; Reif et al., 2006; Stockmeier et al., 2004). In addition, several preclinical reports 
demonstrated that ablation of neurogenesis, using irradiation (Santarelli et al., 2003; Surget et 
al., 2008) or genetic techniques (Zhao, Deng, & Gage, 2008), is not necessary to induce a 
	 24	
depressive phenotype. Considering this evidence, it is implausible to suggest that impaired 
hippocampal neurogenesis is the sole determinant of depression, however, the idea that 
deficient neurogenesis plays a significant role in the pathogenesis of depression is widely 
accepted. More research is needed to investigate the link between impaired neurogenesis and 
the specific symptoms of depression, as well as antidepressant properties of restored 
neurogenic function (Sahay & Hen, 2007). Additionally, there is evidence to suggest that the 
etiology of depression could be associated not only with deficits in cell proliferation and 
survival, but rather, with abnormalities of the surviving dentate granule cells, i.e., their 
altered morphology (Lussier et al., 2009), improper migration and circuit integration (Duan et 
al., 2007), as well as abnormal transcriptional and molecular regulation (Duman & 
Monteggia, 2006; Nestler, Barrot, et al., 2002). Moreover, these abnormalities can potentially 
accumulate, rendering the individual vulnerable to other life events. For example, it was 
shown that repeatedly stressed rats displaying dendritic retraction within the CA3 region of 
hippocampus also exhibited exacerbated hippocampal damage following an excitotoxin 
metabolic challenge, suggesting that stress compromises the ability of hippocampus to resist 
the metabolic challenge and other adverse environments (Conrad, Jackson, & Wise, 2004). 
These observations are promising but incomplete; therefore, more research is needed to 
explore the cellular and molecular mechanisms promoting impaired hippocampal plasticity 
and depressed symptomatology. 
 
1.11. Repressor Element-1 Silencing Transcription Factor (REST) and Depression 
 
Long-term molecular changes and alterations in transcriptional regulation have been 
implicated in mood disorders and antidepressant action (Coyle & Duman, 2003; Duman & 
Monteggia, 2006; Manji et al., 1999; Nestler, Barrot, et al., 2002). Repressor element-1 
silencing transcription factor (REST), also referred to as neuron-restrictive silencing factor 
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(NRSF), is a modular zinc finger protein that contains two independent repression domains at 
the N- and C-terminals of the molecule (Chong et al., 1995; Schoenherr & Anderson, 1995; 
Tapia-Ramírez, Eggen, Peral-Rubio, Toledo-Aral, & Mandel, 1997). Upon binding to DNA, 
REST works as an assembling frame, positioning its complexes, such as histone deacetylases 
and the demethylase LSD1. The resulting complexes allow repression of the transcription of 
large numbers of target genes by modifying critical sites of their histones (Ballas & Mandel, 
2005; Chong et al., 1995; Huang, Myers, & Dingledine, 1999; Ooi & Wood, 2007; 
Schoenherr & Anderson, 1995). Initially, REST was known as a repressor of neuronal (RE-1 
containing) genes during embryonic development only, serving as a switch that aids 
differentiation between neuronal and non-neuronal cell types. REST was thought to be down-
regulated once terminal neuronal differentiation occurred (Ballas, Grunseich, Lu, Speh, & 
Mandel, 2005; Chong et al., 1995; Kraner, Chong, Tsay, & Mandel, 1992; Mori, Schoenherr, 
Vandenbergh, & Anderson, 1992; Schoenherr & Anderson, 1995). However, recent evidence 
determined that the RE-1 sequence is a subset of a large number of REST-binding motifs 
(Bernstein et al., 2012; Johnson, Mortazavi, Myers, & Wold, 2007; Otto et al., 2007). 
Consequentially, a larger number of REST target genes have been discovered, including 
target genes coding for various mRNAs, microRNAs, short hairpin RNAs, and long 
noncoding RNAs (Johnson et al., 2009; Rossbach, 2011; Volvert et al., 2014). REST 
induction in mature neurons is a subject of plasticity. This is evidenced by observations that 
adult hippocampal granule and pyramidal neurons express high levels of REST (Calderone et 
al., 2003; Gao et al., 2011; Kuwabara, Hsieh, Nakashima, Taira, & Gage, 2004; Palm, 
Belluardo, Metsis, & Timmusk, 1998; Sun et al., 2005), that adult neurons upregulate REST 
and specific target genes in response to ischemia or seizures (Calderone et al., 2003; 
Jessberger et al., 2007; Palm et al., 1998), and that increased REST expression was reported 
in normal aging in human cortical and hippocampal neurons (Lu et al., 2014). In addition, 
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REST and its target genes play a role in adult neurogenesis and synaptic plasticity (Ballas et 
al., 2005; Westbrook et al., 2008, Schoenherr & Anderson, 1995). 
Dysregulation of REST has been associated with several pathological conditions, 
including Down’s syndrome (Bahn et al., 2002), Alzheimer’s disease  (Lu et al., 2014; 
Okazaki et al., 1995), Huntington’s disease (Zuccato et al., 2007), ischemic insults 
(Calderone et al., 2003), epilepsy (Garriga-Canut et al., 2006; Hu et al., 2011), schizophrenia 
(Loe-Mie et al., 2010), and Parkinson’s disease (Siegel, Saba, & Schratt, 2011; Yu et al., 
2013). However, the potential role of REST in the pathogenesis of mood disorders remains 
unknown. A recent study reported that REST targets several genes that are known to be 
largely implicated in depression (Duman & Monteggia, 2006; Lemonde et al., 2003; Nestler, 
Barrot, et al., 2002); these genes include CRH, the serotonin (5-HT) 1A receptor, and BDNF 
(Otto et al., 2007). In addition, REST was found to participate in transcriptional regulation of 
cortisol/corticosterone synthesis (Somekawa et al., 2009). Further evidence of REST 
involvement in stress signaling comes from a study demonstrating that a variety of stressors 
are able induce the expression of REST in neuronal cultures, and that the increase of neuronal 
REST levels induces the expression of stress response genes (Lu et al., 2014). Finally, the 
repressive activity of REST is accompanied by a recruitment of histone deacetylases and 
chromatin-remodelling enzymes, which are also known to be altered in major depression 
(Schroeder, Lin, Crusio, & Akbarian, 2007; Tsankova et al., 2006). 
A recent study on patients with major depressive and bipolar disorder showed that 
REST mRNA levels were decreased, whereas CRH, adenylate cyclase 5, and the tumor 
necrosis factor mRNA were increased in peripheral blood cells of patients (Otsuki et al., 
2010). Interestingly, this reduction of REST mRNA and increases of CRH, adenylate cyclase 
5, and the tumor necrosis factor mRNA were found in patients in a current depressive, but not 
a remissive state, suggesting that these alterations are state-dependent and could be associated 
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with depression pathophysiology (Otsuki et al., 2010). To our knowledge, the only study 
investigating brain REST expression in an animal model of depression was conducted by 
Uchida and colleagues (Uchida et al., 2010). These researchers reported that rats subjected to 
early-life stress and restraint stress in adulthood showed increased expression of REST4 (a 
splice variant of REST) in medial PFC (mPFC). Interestingly, REST4 overexpression in the 
mPFC of neonatal mice, but not adult mice, increased behavioral vulnerability to repeated 
restraint stress (Uchida et al., 2010). Collectively, these reports suggest that REST could play 
an important role in the regulation of stress vulnerability, neurogenesis, and the pathogenesis 
of mood disorders.  Therefore, further investigation of how REST is altered in recurrent 
depression would help elucidate potential mechanisms of depression episode relapse and 
open new avenues for novel pharmacological intervention.  
 
1.12. Inflammation, Stress, and Depression 
 
Growing evidence implicates immune system activation in the etiology and 
pathophysiology of depression. Clinical studies and meta-analyses repeatedly report that 
patients with major depression have elevated concentrations of cytokines in the plasma and 
cerebrospinal fluid, in the absence of any physical illness or infection (Alesci et al., 2005; 
Dahl et al., 2014; Dantzer, O’Connor, Freund, Johnson, & Kelley, 2008; Kern et al., 2014; 
Dowlati et al., 2010; Howren, Lamkin, & Suls, 2009). Moreover, a reduction of IL-1 and IL-
6 levels was associated with alleviation of depressive symptoms in response to antidepressant 
treatment in depressed patients (Hannestad, DellaGioia, & Bloch, 2011). In addition, several 
depressive symptoms, such as guilt and suicidal ideation, are strongly associated with plasma 
IL-6 levels (Alesci et al., 2005; O’Donovan et al., 2013). Interestingly, cancer patients treated 
with therapy involving cytokines exhibit depressive symptoms that can be relieved with 
antidepressant medication (Capuron et al., 2002). 
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Preclinical research supports clinical observations and has revealed increased 
cytokine content in both brain and plasma of animals with depression-like behavior 
(Golovatscka, Ennes, Mayer, & Bradesi, 2012; Grippo, Francis, Beltz, Felder, & Johnson, 
2005; Yirmiya & Goshen, 2011; You et al., 2011). Systemic and central treatment with 
proinflammatory cytokines, such as IL-1 or tumour necrosis factor-alpha (TNF-alpha) and 
lipopolysaccharide (LPS) were found to induce sickness behavior and/or depression-like 
behavior in animals dose-dependently (Dantzer, 2004; Dunn & Swiergiel, 2005; Henry et al., 
2008; Laugeray et al., 2011). For example, mice administered with IL-1beta (100, 300 and 
1,000 ng/mouse) and subsequently tested in the tail suspension test (TST) and forced swim 
test (FST) showed dose-dependent increases in the time spent immobile in both TST and 
FST, statistically significant increases were found with higher doses only (Dunn & Swiergiel, 
2005). Interestingly, knockout mice lacking cytokines or cytokine receptors (e.g., interleukin-
6 (IL-6) or interleukin-1 (IL-1) type 1 receptor) do not show stress-induced depression-like 
behavior (Chourbaji et al., 2006). In addition, it has been demonstrated that acute and chronic 
stress (inescapable shock, restraint), as well as glucocorticoid administration, can increase 
cytokine mRNA and protein levels in the brain and plasma (Blandino et al., 2009; Bowers, 
Bilbo, Dhabhar, & Nelson, 2008; Deak et al., 2005; Porterfield, Gabella, Simmons, & 
Johnson, 2012; Sorrells, Caso, Munhoz, & Sapolsky, 2009).  
It is important to note that glucocorticoids are conventionally known to produce anti-
inflammatory effects. For example, glucocorticoids are used pharmacologically to control 
post-surgery inflammation, as well as to treat asthma, allergies, and autoimmune diseases 
(Hockey, Leslie, & Williams, 2009), as they reliably reduce the expression of 
proinflammatory cytokines including IL-1beta, IL-6, and TNF-alpha and increase levels of 
anti-inflammatory mediators including IL-10 and transforming growth factor-beta (TGF-b) 
(Correale, Arias, & Gilmore, 1998; Gayo et al., 1998). An activated HPA axis can exert 
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robust immunosuppressing effects by inhibiting the activity of the key inflammatory 
transcription factor, nuclear light chain kappa (NF-kB) (Lee et al., 1988; Silverman & 
Sternberg, 2012; Zuckerman, Shellhaas, & Butler, 1989). In contrast, as discussed earlier, 
major depression is strongly associated with significant elevations of both cortisol and 
proinflammatory cytokines, presenting a paradox of simultaneous overactivity of the immune 
and endocrine systems. Two theories have been put forward to explain this paradox: one 
theory postulates that the immune system becomes overactive as a result of a developed 
glucocorticoid resistance characterized by reduced glucocorticoid signaling, and the second 
theory discusses both pro- and anti-inflammatory effects of glucocorticoids under specific 
circumstances (Horowitz & Zunszain, 2015). Under the first theory, the initial exposure to 
CORT may desensitize or reduce the number of glucocorticoid receptors resulting in a 
decrease in intracellular glucocorticoid signaling and a subsequent decrease in the ability of 
glucocorticoids to inhibit the immune system. This hypothesis has found support from both 
clinical and preclinical research demonstrating glucocorticoid resistance (less transcriptional 
signaling for each cortisol molecule) co-occurring with elevations in pro-inflammatory 
cytokines in depressed individuals (Bauer et al., 2003; Carvalho et al., 2008; Fitzgerald et al., 
2006; Humphreys, Schlesinger, Lopez, & Araya, 2006; Landmann, Schaub, Link, & Wacker, 
1997; Maes, Scharpé, Meltzer, & Cosyns, 1993) and in stress-induced models of depression 
(Avitsur, Powell, Padgett, & Sheridan, 2009; Sheridan, Stark, Avitsur, & Padgett, 2000). The 
second proposed theory emphasizes that glucocorticoids are not invariably anti-
inflammatory, but rather that they can be both pro- and anti-inflammatory under certain 
conditions (Frank, Watkins, & Maier, 2013; Sorrells et al., 2009). In particular, preclinical 
studies report that exposure to glucocorticoids (or stress) after an inflammatory event results 
in immunosuppression (Goujon et al., 1995). In contrast, exposure to glucocorticoids (or 
stress) before an inflammatory insult enhances the immune system response (de Pablos et al., 
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2006; Espinosa-Oliva et al., 2011; Frank, Miguel, Watkins, & Maier, 2010; Johnson et al., 
2002; Munhoz et al., 2006; Munhoz, Sorrells, Caso, Scavone, & Sapolsky, 2010). Similarly, 
preliminary studies demonstrated that administration of hydrocortisone simultaneously with 
LPS stimulation in healthy humans abolished the elevation of TNF-alpha, whereas 
hydrocortisone administered 12 to 144 hours before LPS resulted in significant increases in 
IL-6 and TNF-alpha (Barber et al., 1993). Finally, in vitro studies provide further support for 
pro-inflammatory effects of glucocorticoids by reporting enhanced activity and cytokine 
release of rodent macrophages in response to inflammatory stimulation after glucocorticoid 
pre-treatment (Smyth et al., 2004). Collectively, these data emphasize the complex 
relationship between the endocrine and immune systems; therefore further research focused 
on depression models integrating both systems would help clarify the mechanisms of 
depression pathogenesis. 
 
1.13. Microglia 
 
Microglia are immune cells that belong to the mononuclear phagocyte system 
(Walker, Nilsson, & Jones, 2013a). Newborn microglial cells have an amoeboid shape and no 
processes; however as the cells mature, microglia change their morphological phenotype, so 
that they become characterized by a small soma and numerous fine ramifications (Butovsky 
et al., 2014; Erblich, Zhu, Etgen, Dobrenis, & Pollard, 2011; Kierdorf et al., 2013; Smith et 
al., 2013). Microglia are a major source of centrally released cytokines and other 
inflammatory mediators, however they are known to play an important role not only in the 
innate immune response but also in brain development, maintenance and repair (Michell-
Robinson et al., 2015). 
Depending on the circumstances, microglial cells have a very dynamic morphology 
and function (see Figure 1-3). In the absence of pathological conditions, microglia are in a  
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Figure 1-3. Dynamic morphological changes in a microglia cell. Panels A-C: 
photomicrographs showing examples of microglia classified into four different phenotypes: 
ramified, intermediate, and amoeboid. Figure adapted from (Thored et al., 2009) under 
copyright license agreement #4007161322200.  
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quiescent or “resting” state, constantly gauging the surrounding environment by spreading 
and retracting their motile branches. In doing this, microglia are able to communicate with  
surrounding cells, survey their territory, identify signals that demand a response, and 
maintain homeostasis (Davalos et al., 2005; Hanisch & Kettenmann, 2007; Kettenmann, 
Hanisch, Noda, & Verkhratsky, 2011; Lull & Block, 2010; Nimmerjahn, Kirchhoff, & 
Helmchen, 2005). Upon detection of potentially harmful signals (e.g., neuronal damage), 
microglia can rapidly acquire a reactive profile, which typically involves changes to the de-
ramified morphological form. Such activated microglia also exhibit changes in cell surface 
markers (e.g., upregulated cluster of differentiation molecule 68 (CD68) and major 
histocompatibility complex II proteins), and they can proliferate, migrate to sites of damage, 
release pro-inflammatory cytokines, recruit and activate other cells, and phagocytose  
(Davalos et al., 2005; Johnson et al., 2002; Lynch, 2009; Streit & Kreutzberg, 1987). The 
morphological changes of activated microglia are characterized by a swollen cell body, 
thickened and shortened ramifications, and ultimately, in the phagocytic stage, an amoeboid-
resembling shape (Kettenmann et al., 2011). 
Microglial cells seem to be most densely populated in neurogenic niches such as the 
hippocampus (Lawson, Perry, Dri, & Gordon, 1990). Importantly, emerging evidence 
suggests that microglia can play an important role in hippocampal neurogenesis (Butovsky et 
al., 2014; Sierra et al., 2010), neural plasticity (Butovsky et al., 2014; Rogers et al., 2011), 
and synaptic maturation (Paolicelli et al., 2011; Zhan et al., 2014). In addition, microglia are 
involved in producing a number of growth factors, such as insulin-like growth factor 1 (IGF-
1) and BDNF, which are important for neurogenesis as well (Butovsky et al., 2006; Coull et 
al., 2005; Sierra et al., 2010; Zhang et al., 2014). Finally, findings from several studies show 
that microglia are capable of making frequent contacts with neurons at presynaptic boutons, 
postsynaptic spines, and the synaptic cleft, and by doing this they participate in synapse 
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pruning, and therefore may contribute to the organization of neural circuitry (Paolicelli et al., 
2011; Tremblay, Lowery, & Majewska, 2010; Wake, Moorhouse, Jinno, Kohsaka, & 
Nabekura, 2009). 
 
1.14. Microglia, Stress, and Depression 
 
A growing body of evidence indicates that neuroinflammatory processes are triggered 
not only in response to immune challenges but also in response to psychological and 
physiological stress that is not associated with injuries and infection (Blandino et al., 2009; 
Bowers et al., 2008; Deak et al., 2005; Porterfield et al., 2012; Sorrells et al., 2009). 
Glucocorticoid and mineralocorticoid receptors are highly expressed by microglial cells 
(Tanaka et al., 1997), and activation of microglia has been implicated in modulating the 
effects of stress (Inbal Goshen & Yirmiya, 2009). For example, exposure to acute stressful 
stimuli was found to induce microglial morphological (i.e., enlarged soma and thick short 
processes) (Sugama, Fujita, Hashimoto, & Conti, 2007) and functional activation (Frank, 
Baratta, Sprunger, Watkins, & Maier, 2007), whereas the microglial inhibitor minocycline 
was shown to abolish stress-induced hypothalamic IL-1 release (Blandino et al., 2009). 
Studies using repeated stress or glucocorticoid administration have revealed conflicting 
findings, suggesting that glucocorticoids can have both inhibitory and stimulatory effects on 
microglia (Walker, Nilsson, & Jones, 2013b). For instance, anti-glucocorticoid agents (e.g., 
RU486, metyrapone) or adrenalectomy both inhibit stress-induced microglial proliferation 
(Frank et al., 2007; Nair & Bonneau, 2006). Furthermore, it was shown that dexamethasone 
administration reduced ionized calcium-binding adapter molecule-1 (Iba-1) expression 
(Zhang, Zhang, Artelt, Burnet, & Schluesener, 2007), decreased CD68 expression 
(Hinkerohe et al., 2010) and reduced nitric oxide and pro-inflammatory cytokine production 
by microglial cell culture after LPS stimulation (Graber, Hickey, Stommel, & Harris, 2012). 
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In contrast, repeated stress in rodents was reported to increase the number of 
microglia, induce Iba-1 immunoreactivity in several stress-responsive brain regions (Nair & 
Bonneau, 2006; Tynan et al., 2010a), and alter microglial morphology (Wohleb et al., 2011). 
The ability of CORT itself to produce both stimulatory and suppressive effects on microglia 
has been investigated in a study, which found that when exogenous CORT treatment 
preceded LPS stimulation, the subsequent microglial immune response was enhanced. 
However, when CORT was delivered one hour after the LPS challenge, the pro-inflammatory 
response of microglia was inhibited (Frank et al., 2010). Collectively, these findings further 
emphasize the complex temporal relationship between glucocorticoids and immune 
responses, and they also highlight the critical need for integral investigation of these systems 
in the search for the mechanisms underlying psychiatric disorders, such as depression.  
In addition to microglial involvement in stress, several lines of evidence suggest that 
microglia may play a significant role in depression. First, activation of microglia was 
reported in some depressed and suicidal individuals (Bayer, Buslei, Havas, & Falkai, 1999; 
Steiner et al., 2008). Second, as earlier discussed, depressed patients exhibit elevated CSF 
levels of pro-inflammatory cytokines, which are thought to be released by brain microglia 
(Dowlati et al., 2010; Howren et al., 2009). Third, depression is comorbid with several 
neurodegenerative and neurological diseases, such as Alzheimer’s (Cameron & Landreth, 
2010; Evans et al., 2005), which are characterized by profound microglial alterations 
(Kettenmann et al., 2011). Fourth, cancer and hepatitis C patients receiving interferon-α 
immunotherapy, as well as healthy individuals experimentally treated with LPS, develop 
depressive symptoms (Krabbe et al., 2005; Raison, Capuron, & Miller, 2006). Finally, 
antidepressant medications are known to regulate hippocampal neurogenesis and microglial 
activity (Hashioka et al., 2007; Malberg et al., 2000; Santarelli et al., 2003; Tynan et al., 
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2012) and microglia, in turn, are important regulators of neurogenesis (Ekdahl, Kokaia, & 
Lindvall, 2009; Ekdahl, Claasen, Bonde, Kokaia, & Lindvall, 2003).  
Several methods are available for visualizing microglial reactivity in a brain. For 
example, in depressed individuals, in vivo positron emission tomography (PET) technique is 
commonly used. The translocator protein density, which is elevated in reactive microglia, can 
be measured using PET distribution volume. Depressed individuals were found to have 
higher translocator protein density in the PFC, anterior cingulate cortex, and insula (Setiawan 
et al., 2015). In the animal models of depression, analysis of microglia cell surface markers is 
more feasible. In the activated microglia, upregulation of several markers is observed, such as 
antigen presentation molecules (CD68, CD80, CD86, and CD40) and major 
histocompatibility complex II proteins (Davalos et al., 2005; Johnson et al., 2002). In 
addition, often microglial morphology is examined to confirm dynamic changes in cells and 
to detect a potential “primed” state of microglia (susceptible to a secondary inflammatory 
insult). Such analyses warrant the use of markers that are constitutively expressed in 
microglia, i.e. CD11b, Iba-1, which are commonly used in depression preclinical 
research (Kreisel et al., 2014; Lehmann, Cooper, Maric, & Herkenham, 2016; Pan, Chen, 
Zhang, & Kong, 2014; Wohleb et al., 2012). 
 Taken together, this evidence strongly supports the involvement of microglia in the 
pathogenesis of depression, and suggests that further examination into microglial alterations 
affecting immune and stress responses may be of importance for understanding and treating 
disorders characterized by dysregulations of both endocrine and immune systems. 
	
1.15. Goals and objectives 
 
 The general aim of the research presented in this dissertation is to develop and 
examine an animal model of recurrent depression using repeated and cyclic administration of 
glucocorticoids. Specifically, I have tested how pre-exposure to exogenous CORT affects rat 
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behavioral vulnerability to subsequent CORT re-exposures. These effects were examined 
using repeated and non-repeated behavioral testing strategies. Further, I have investigated 
how repeated and cyclic glucocorticoid treatment impacts adult neurogenesis and REST 
expression within the rat hippocampus. Finally, I have done a preliminary examination into 
the role of repeated and cyclic stress on microglia morphology and activation in the 
hippocampus. 
Experiment 1. Repeated CORT administration is known to increase depression-like 
behavior in one of the most commonly used tests of rodent helplessness behavior, the FST 
(Nestler, Gould, et al., 2002). However, the majority of previous research has examined the 
behavioral changes after only one cycle (e.g. three weeks) of repeated exposure to stress. 
Taking into consideration the recurrent nature of depressive disorders (Hollon et al., 2006; 
Solomon et al., 2000), it is highly important to incorporate the depression disease course into 
stress-induced animal models of depression. To address this gap in the preclinical research, I 
examined the effects of two cycles of daily CORT injections (21 days), each followed by 
injection-free recovery periods (21 days), in male rats using repeated FST behavior testing in 
the middle (day 10) and in the end (day 22) of each stress cycle, and at the end of each 
recovery period. 
Hypothesis: The effects of repeated and cyclic CORT injections were expected to be 
more pronounced during the second CORT cycle. In particular, I predicted that it would 
require fewer CORT injections (10 days) in treatment cycle 2 to produce increases in 
depression-like behavior in rats that were pre-exposed to CORT and allowed to recover.    
Experiment 2. After identifying that repeated and cyclic CORT treatment produced 
progressively larger changes in rodent depression-like behavior, it was important to 
reproduce these effects in a model using naïve rats and a non-repeated behavioral testing 
strategy. This model would control for potential confounding effects of repetitive FST task 
	 37	
learning in the previous experiment. Additionally, it would be critical to investigate whether 
the aggravating effects of multiple CORT cycles extend to other behaviors associated with a 
depressive phenotype (i.e. anhedonia). Furthermore, our laboratory has previously shown that 
one cycle of repeated CORT treatment decreases neurogenesis and dentate granule cell 
maturation (Lussier et al., 2009). Clinical evidence suggests that depression could be a 
progressive disorder, as hippocampal volumetric reductions were found to be strongly 
associated with the number and duration of depressive episodes (Bremner et al., 2000; 
Sheline, Sanghavi, Mintun, & Gado, 1999; Sheline, Gado, & Kraemer, 2003). However, it is 
not known how multiple cycles of glucocorticoid exposure impact hippocampal plasticity, 
such as neurogenesis and neuronal maturation. Finally, considering the emerging evidence of 
aberrant brain transcriptional regulation in depression and other psychiatric disorders, 
examination of hippocampal REST protein expression alterations after one or several CORT 
exposures was of great interest. 
Hypotheses: I expected that the findings of behavioral sensitization during CORT re-
exposure in Experiment 1 would be replicated in Experiment 2 using non-repeated behavioral 
testing of naïve rats. Specifically, I hypothesized that rats pre-treated with CORT injections 
would display greater depression-like and anhedonia behaviors than rats exposed to CORT 
only once. I also predicted that shorter periods of CORT injections would increase 
depression-like and anhedonia behaviors in rats that experienced previous cycles of CORT 
exposure. In contrast, I expected no changes in general exploratory behavior in the open field 
test between groups, as CORT is known to have few effects of rat locomotion (Marks et al., 
2009). Additionally, with every subsequent re-exposure to CORT, I expected that rats would 
have accumulative deficits in rates of neurogenesis and dentate granule cell maturation 
paralleled with progressive worsening of depression-like behaviors. Finally, previous reports 
suggest that REST plays critical roles in neurogenesis, stress, and depression (Ballas et al., 
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2005; Otsuki et al., 2010; Uchida et al., 2010; Westbrook et al., 2008), therefore I 
hypothesized a progressive loss of hippocampal REST levels with multiple cycles of CORT 
treatment. 
Experiment 3. A wealth of research demonstrates a substantial involvement of 
neuroinflammatory processes in depression. Considering the existing complex relationship 
between the endocrine and immune systems, as well as emerging evidence of significant 
impact of microglial cells on both brain immune response and hippocampal neurogenesis, I 
examined changes in hippocampal microglia in the CORT model of recurrent depression. To 
address this question, I analyzed changes in microglial immunoreactivity and morphology 
after one or three cycles of CORT exposure. Combining two existing hypotheses of 
depression (inflammatory and neurogenesis theories) allows for a more integrated approach 
and closer examination of underlying mechanisms that promote the development and 
progression of depression over time.  
Hypothesis: I expected that one cycle of CORT would result in activation of 
microglial cells demonstrating a reactive phenotype of cell morphology: enlarged soma; 
fewer, thicker, and shorter processes.  Moreover, I hypothesized that with additional cycles of 
CORT treatment, microglia cells would show potentiated effects in these morphological 
changes. 
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Abstract 
Stress is a significant risk factor for depression. Many animal models of depression with 
stress exposure have been developed. However, almost without exception, stress-induced 
models of depression focus on reproducing single incidences of depression endophenotypes 
(e.g., anhedonia, negative mood bias) and therefore, they do not provide any means to 
understand the typical cycling of mood observed in most patients with depression. In the 
current study, we attempted to recapitulate the cyclical disease course of depression in a 
rodent model. Rats were treated with 20 or 40 mg/kg corticosterone (CORT), or vehicle for 
two cycles (21 days each), followed by a 21-day recovery period. Depression-like behavior 
was assessed via repeated forced swim tests (FSTs) in the middle and at the end of each 
CORT treatment and at the end of each recovery period.  Our results demonstrate that 
repeated treatment with CORT for two cycles produced increasingly greater effects on 
depression-like behavior. In the 1st cycle, CORT increased the time spent immobile and 
decreased the time spent swimming in the FST after 21 days of treatment. These behaviors 
then normalized after the recovery. In the 2nd cycle, however, we observed an early 
manifestation of depression-like behavior after only ten days of CORT treatment, as well as 
diminished recovery with each subsequent cycle of treatment, suggesting sensitization of the 
depression-like symptoms in rats. Potential confounding effects of aging, body weight, and 
repetitive behavioral testing should be considered in the interpretation of sensitization of rat 
depressive-like behavior. The proposed model of recurrent depression provides stronger face 
validity as it mimics several aspects of human depression, including the phenomenon of 
episode recurrence seen in more than 70% of patients with depression.   
	 41	
2.1. Introduction 
 
Depression is a serious psychiatric disorder and a profound public health concern. The 
complex structure of human depression and the subjective nature of its symptoms have made 
the development of animal models extremely challenging.  
Exposure to stress has a strong impact on the manifestation of depression. A large 
body of experimental and clinical data suggests that stress is a major risk factor in the 
development of depression (Kendler et al., 1999; Mazure, 1998). For example, the initial 
depressive episodes are often preceded by stressful or traumatic life events (Keller, Schatzberg, & 
Maj, 2007). One of the key endocrine changes in depressed individuals is a dysregulation of 
the HPA axis (Nestler, Barrot, et al., 2002). Patients with depression often exhibit cortisol 
hypersecretion and disrupted cortisol rhythmicity (Burke et al., 2005; Sachar & Baron, 1979), 
which can be normalized with antidepressant treatment (Holsboer, 2001). Also, patients with 
Cushing's disease, a disorder characterized by chronically high levels of cortisol, show 
unusually high rates of depression (Sonino & Fava, 2001). Interestingly, preclinical research 
reveals similar trends: high levels of glucocorticoids have been shown to increase depression-
like behaviors in rodents (i.e. increased immobility time in forced swim and tail suspension 
tests, and decreased sucrose preference). In addition, repeated exposure to glucocorticoids 
has been demonstrated to have deleterious effects on neurochemistry and neuroanatomy that 
are associated with depressive disorders. Many of behavioral and neurobiological changes 
produced by repeated glucocorticoid administration in animals are reversed by antidepressant 
treatment (Ago et al., 2008; David et al., 2009). 
Major depression is a highly recurrent disorder, as it is frequently characterized by 
repeated episodes over the life course. Some evidence estimates that 60% of individuals who 
have had one depressive episode will have another, 70% of depressed individuals with two 
episodes will have a third, and finally, 90% of depressed individuals with three episodes will 
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have a fourth episode (Hollon et al., 2006; Monroe & Harkness, 2005; Pettit, Lewinsohn, & 
Joiner, 2006).  The probability of recurrence increases with the earlier age of onset of the 
initial episode, the severity of the episode, and with poor quality of recovery from the episode 
(Judd et al., 2000; Pettit et al., 2006). However, current animal models of depression fail to 
provide any means to understand the typical cycling of episode re-establishment across time 
that occurs in most depressed patients. Accordingly, in the current study, we aimed to 
recapitulate the cyclical disease course of depression in the animal model and test the 
hypothesis of sensitization of stress-induced depression-like behavior over two cycles of 
CORT treatment. This question was addressed by comparing effects of repeated and cyclic 
CORT treatment on depressive-like behaviors in rats. 
 
2.2. Materials and Methods 
2.2.1. Subjects 
	
Male Long-Evans rats (n = 30) were purchased from Charles River Laboratories, 
Montreal, QC, Canada. At the time of arrival, the rats weighed approximately 200-250 
grams. The rats were individually housed in standard polypropylene cages with Purina rat 
chow and water available ad libitum. The colony room was maintained at a temperature of 
21°C with a 12 h :12 h light/dark cycle (lights on at 7:00 a.m.). All experimental procedures 
were conducted during the light phase of the light/dark cycle and in accordance with the 
Canadian Council on Animal Care and the University of Saskatchewan Committee on 
Animal Care.  
 
2.2.2. Treatment with CORT  
	
The rats were handled for seven days in the colony room prior to any experimental 
manipulations. At the end of handling, the rats were weight matched and assigned to one of 
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three different treatment groups: 20 mg/kg CORT (n = 10), 40 mg/kg CORT (n = 10), or 
vehicle (n = 10). CORT or vehicle was delivered once per day via subcutaneous injection 
between 09:00 and 11:00 h. CORT (Steraloids, Inc., Newport, RI) was suspended in 0.9 
(w/v) physiological saline with 2% (v/v) polyoxyethylene glycol sorbitan monooleate 
(Tween-80, Sigma-Aldrich, St. Louis, MO). Each cycle of injections comprised 21 
consecutive days, followed by 21 days of injection-free recovery. During recovery periods 
the rats were left untouched in their home cages. The experimental design is depicted in 
Figure 2-1. 
 
2.2.3. Body Weight 
	
All rats were weighed on a daily basis during CORT treatment periods and once at the 
end of each recovery period. Body weights were recorded for later analyses. 
 
2.2.4. Behavioral Testing 
	
A modified one-day version of FST was used to assess depression-like behavior, as 
described previously (Gregus et al., 2005). No pre-test session was conducted; each rat was 
tested in the swim tank only once to evaluate “helplessness” induced by prior exposure to 
CORT injections. The modified one-day version of a FST was chosen because previous 
research in our laboratory has shown comparable behavioral results with both a one-day and 
a two-day version of the FST. Furthermore, a one-day FST protocol seems to be appropriate 
to assess depression-like behavior in experiments with prior exposures to stress by 
eliminating potential confounding effects of memory from the first day of FST exposure on 
behavior during the second “testing” day (Marks et al., 2009).  
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Figure 2-1.  A schematic of the experimental design. Two groups of corticosterone (CORT)-
treated rats and one group of vehicle-treated rats were exposed to two cycles of treatments 
and recovery periods. Behavioral testing was repeatedly administered in the middle and in the 
end of each treatment, and in the end of each recovery period. 
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The FST was conducted in a rectangular Plexiglas swim tank (25 cm long×25 cm 
wide×60 cm high), filled with 27±2 °C water to a depth of 30 cm. Rats were transported from 
the colony room into an adjacent behavioral testing room. Each rat was placed individually	
into swim tank for 10 minutes. Behavior in the swim tank was video recorded with a camera 
mounted on a tripod horizontal to the swim tank. After 10 min, the rat was removed from the 
tank, towel dried and placed back in its home cage to dry under a heat lamp for 
approximately 20 min. The water in the swim tank was changed in between rats. Time spent 
immobile, swimming and climbing, as well as the latency to become immobile in the FST has 
been assessed as measures of depression-like behavior.   
 The rats were repeatedly tested during the course of the experiment. The FSTs were 
conducted in the middle (day 10) and at the end (day 22) of each period of CORT treatment, 
and at the end of each recovery period (Figure 2-1). The within-subject research paradigm 
was chosen because it was used in a previous study in which naïve rats treated with 
antidepressants showed a significant decrease in immobility rates over several repetitive 
FSTs, indicating a decrease in depression-like behavior with each consecutive behavioral test 
(Mezadri, Batista, Portes, Marino-Neto, & Lino-de-Oliveira, 2011). 
 
2.2.5. Statistical Analyses 
	
The data were analyzed using the statistical package for social sciences (SPSS) 
software program (v. 18). Repeated measures analysis of variance (ANOVA) was conducted 
to measure main effects and interactions, with treatment as the between-subjects factor and 
time as the within-subjects factor. The significance level was set at p = 0.05 for all statistical 
comparisons. In addition, separate one-way ANOVA’s were used to compare the effect of 
treatment on dependent variables at each experimental time point. This was followed by the 
Fisher’s least significant difference (LSD) post hoc t-tests when appropriate.  
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2.3. Results 
2.3.1. Body Weight 
	
	 Mauchly’s test indicated that the assumption of sphericity was violated, X2 (14) = 
102.02, p = 0.001, therefore the degrees of freedom were corrected using Greenhouse-Geisser 
sphericity estimates. One-way repeated measures ANOVA revealed a significant main effect 
of time on body weight [F(1.9, 49.9) = 350.7, p = 0.001], as well as a significant interaction 
of treatment by time [F(3.8, 49.9) = 4.042, p = 0.007]. There was no significant main effect 
of treatment on body weight (p = 0.156). 
 Group differences at each time point of the experiment were investigated using 
planned comparisons of separate one-way ANOVAs. Figure 2-2 shows the mean body 
weights for the rats in each group during the two-cycles of CORT treatment. In the first 
cycle, the CORT rats gained dramatically less weight than did the vehicle rats. The statistical 
analysis demonstrated a significant main effect of group on injection day 10, [F(2,27)  = 
5.405, p = 0.011], and injection day 21, [F(2,27) = 3.266, p = 0.05]. Post hoc tests (LSD) 
revealed that the rats treated with 40 mg/kg CORT weighed significantly less than the vehicle 
rats after ten days of injections (p = 0.003), and continued to do so until day 21 of CORT 
treatment (p = 0.018). No significant differences in body weight among all groups of rats 
were detected after the recovery in cycle 1 (p = 0.941). 
In the second cycle, the rats treated with CORT weighted less than the vehicle rats by 
injection day 10, but the difference between groups missed statistical significance (p = 
0.098). However, the differences between the groups in body weight were significant by day 
21 [F(2,27) = 4.845, p = 0.016]. Post hoc (LSD) analyses revealed that the 40 mg/kg CORT 
group was significantly different from the vehicle group on day 21 (p = 0.004). After the 
final recovery period, no differences in body weight between groups were observed (p = 
0.419). 
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Figure 2-2.  The effect of one and two cycles of repeated corticosterone (CORT) injections 
on rat body weight. Rats treated with CORT displayed decreased body weight throughout the 
two cycles of treatment, with the exception of recovery periods and early CORT re-exposure. 
Asterisks indicate significant differences between groups (p < 0.05) at specific time points. 
Error bars denote the standard error of the mean (SEM). 
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2.3.2. Forced Swim Tests 
	
2.3.2.1. Immobility  
	
Mauchly’s test indicated that the assumption of sphericity was violated, X (14) = 
30.6, p = 0.006, therefore the degrees of freedom were corrected using Greenhouse-Geisser 
sphericity estimates. One-way repeated measures ANOVA revealed a significant main effect 
of time on immobility [F(3.7, 94.96) = 19.61, p = 0.001], but no significant interaction of 
treatment by time (p = 0.09). There was also a significant main effect of treatment on 
immobility [F(2, 26) = 3.28, p = 0.05]. Post hoc (LSD) analyses confirmed that the difference 
occurred between the 40 mg/kg CORT group and the vehicle group (p = 0.023). 
 Group differences at each time point of the experiment were investigated using 
planned comparisons of separate one-way ANOVAs. The results of all FSTs conducted in the 
experiment are shown in Figure 2-3. CORT treatment had no significant effect on immobility 
behavior in the FST 1, after 10 days of injections (p = 0.187). There was a significant 
increase in time spent immobile in CORT-treated groups in FST-2, after 21 days of injections 
[F(2,27) = 3.788, p = 0.035]. The post hoc (LSD) analyses revealed that the difference lies 
between the 40 mg/kg CORT group and the vehicle group (p = 0.024), as well as between the 
20 mg/kg CORT group and the vehicle group (p = 0.025). No difference (p = 0.906) between 
groups was found in FST-3, which occurred after recovery.  
  In the second cycle, CORT treatment had a significant effect on immobility time 
during both FST-4 [F(2,27) = 6.597, p = 0.005] and FST-5 [F(2,27) = 6.272, p = 0.006] 
testing, after 10 and 21 days of injections, respectively. The post hoc (LSD) tests confirmed 
that the 40 mg/kg CORT group showed more immobility than the vehicle group [p = 0.004 in 
FST-4 and p = 0.004 in FST-5], and that the 20 mg/kg group also showed more immobility 
than the vehicle group [p = 0.005, in FST-4 and p = 0.006, in FST 5]. There were no 
significant differences among the groups in immobility behavior after recovery (p = 0.283). 
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A B 
 
C D 
 
Figure 2-3.  The effect of one and two cycles of repeated corticosterone (CORT) injections 
on behavior in the forced swim test. Panel (A) shows the mean time spent immobile, panel 
(B) - the mean latency to immobility, panel (C) - the mean time spent climbing, and panel (D) 
- the mean time spent swimming. Rats treated with CORT spent significantly more time 
immobile and less time swimming and climbing at the end of the 1st treatment cycle. 
Following CORT re-exposure in the second cycle, the CORT rats showed a sensitized 
increase in depression-like behavior after only ten days of treatment. The asterisk indicates a 
significant difference between groups at specific time points (p < 0.05). Error bars denote the 
standard error of the mean (SEM). 
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2.3.2.2. Latency to Immobility 
	
Mauchly’s test indicated that the assumption of sphericity was violated, X (14) = 
32.18, p = 0.004, therefore the degrees of freedom were corrected using Greenhouse-Geisser 
sphericity estimates. Repeated measures ANOVA revealed a significant main effect of time 
on latency to immobility [F(3.1, 74.6) = 13.03, p = 0.001], but no significant interaction of 
treatment by time (p = 0.31). There was also a significant main effect of treatment on latency 
to immobility [F(2, 24) = 3.28, p = 0.036]. Post hoc (LSD) analyses confirmed significant 
differences between the 40 mg/kg CORT group and the vehicle group (p = 0.018), as well as 
between the 20 mg/kg CORT group and the vehicle group (p = 0.03). 
Group differences at each time point of the experiment were investigated using 
planned comparisons of separate one-way ANOVAs. Figure 2-3B shows the mean latency to 
immobility in each group for the FSTs conducted during cycle 1 and cycle 2.  In cycle 1, no 
significant group differences in latency to immobility were seen during any of the FSTs (all 
p’s > 0.05).  
In cycle 2, there was a significant decrease in the latency to immobility in both groups 
of CORT-injected rats after ten days of treatment, [F(2,27) = 4.261, p = 0.025]. That is, both 
the 40 mg/kg CORT rats (p = 0.016) and the 20 mg/kg CORT rats (p = 0.019) had a shorter 
latency to immobility compared to the vehicle rats. A similar effect of CORT was seen 
during FST-5, after 21 days of treatment, there was a significant difference among the groups 
[F(2,27) = 3.524, p = 0.045], and post hoc (LSD) analyses revealed that the 40 mg/kg CORT 
group had a shorter latency to immobility than the vehicle group (p = 0.015). There were no 
significant group differences in latency to immobility during FST-6, after recovery (p > 
0.05). 
 
2.3.2.3. Climbing 
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Mauchly’s test indicated that the assumption of sphericity was violated, X (14) = 
47.06, p = 0.001, therefore the degrees of freedom were corrected using Greenhouse-Geisser 
sphericity estimates. One-way repeated measures ANOVA revealed a significant main effect 
of time on climbing [F(3.07, 79.82) = 16.45, p = 0.001], as well as a significant interaction of 
treatment by time [F(6.14, 79.82) = 2.29, p = 0.042]. There was no significant main effect of 
treatment on climbing (p = 0.144). 
 Group differences at each time point of the experiment were investigated using 
planned comparisons of separate one-way ANOVAs. There were no significant group 
differences in climbing behavior during any of the FSTs in cycle 1 (all p’s > 0.05). However, 
CORT had a significant effect on climbing behavior in cycle 2. In FST 4, there was a 
significant group difference in climbing after 10 days of treatment [F(2,27) = 5.040, p = 
0.014], and post hoc (LSD) analyses revealed that the 40 mg/kg CORT rats (p = 0.006) and 
20 mg/kg CORT rats (p = 0.023) both showed less climbing behavior than the vehicle rats. In 
FST-5, after 21 days of treatment, there was also a significant group difference in climbing 
[F(2,27) = 4.330, p = 0.023], and this time only the 40 mg/kg CORT rats showed less 
climbing than the vehicle rats (p = 0.007). There were no significant group differences in 
climbing on FST-6, after recovery (p > 0.05). 
 
2.3.2.4. Swimming 
	
Mauchly’s test indicated that the assumption of sphericity was violated, X (14) = 
35.43, p = 0.001, therefore the degrees of freedom were corrected using Greenhouse-Geisser 
sphericity estimates. Repeated measures ANOVA revealed a significant main effect of time 
on swimming behavior [F(3.36, 87.43) = 11.17, p = 0.001], but no significant interaction of 
treatment by time (p = 0.22). There was also a significant main effect of treatment on latency 
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to immobility [F(2, 26) = 3.18, p = 0.05]. Post hoc (LSD) analyses confirmed a significant 
difference between the 40 mg/kg CORT group and the vehicle group (p = 0.024). 
Group differences at each time point of the experiment were analyzed using planned 
comparisons of separate one-way ANOVAs. CORT treatment had significant effects on 
swimming behavior during both cycles. In cycle 1, although there were no group differences 
in swimming in FST-1, the groups did differ on this measure in FST-2 [F(2,27) = 3.385, p= 
0.049]. Post hoc (LSD) analyses showed that the 40 mg/kg CORT rats (p = 0.025) and the 20 
mg/kg CORT rats (p = 0.045) both showed less swimming than did the vehicle rats. No 
significant group differences were found in FST-3, after recovery (p > 0.05).  
In cycle 2, there was a significant main effect of treatment on time spent swimming in 
FST-4, after 10 days of treatment, [F(2,27)  = 4.782, p = 0.017]. Post hoc (LSD) analyses 
revealed that both the 40 mg/kg CORT rats (p = 0.014) and the 20 mg/kg CORT rats (p = 
0.011) swam less than the vehicle rats. The same pattern of results was seen in FST-5, after 
21 days of treatment. That is, there was an overall main effect of treatment on swimming 
during this test [F(2,27)  = 6.272, p = 0.006], and post hoc (LSD) analyses showed that both 
the 40 mg/kg CORT (p = 0.01) and 20 mg/kg CORT rats (p = 0.005) swam less than the 
vehicle rats. There were no group differences in swimming groups in FST-6, after recovery 
(p > 0.05). 
 
2.3.3. FST Behaviors Controlled for Body Weight 
	
 To account for the influence of body weight increases on FST behaviors, ratio scores 
were created: T/BW = ratio score, where T is time the subject spent engaging in FST 
behaviors (immobility, climbing, etc.) in seconds, and BW is subject’s body weight in grams 
at the time of testing. Figure 2-4 shows the mean ratio scores in each treatment group for the 
FSTs conducted during cycle 1 and cycle 2.   
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2.3.3.1. Immobility to Body Weight (IBW) Ratio  
Mauchly’s test indicated that the assumption of sphericity was violated, X (14) = 
31.82, p = 0.004, therefore the degrees of freedom were corrected using Greenhouse-Geisser 
sphericity estimates. Repeated measures ANOVA revealed a significant main effect of time 
on immobility to body weight (IBW) ratios [F(3.62, 94.086) = 13.55, p = 0.001], as well as a 
significant interaction of treatment by time [F(7.23, 94.086) = 3.14, p = 0.005]. There was 
also a significant main effect of treatment on IBW ratios [F(2, 26) = 7.32, p = 0.003]. Post 
hoc (LSD) analyses confirmed significant differences between the 40 mg/kg CORT group 
and the vehicle group (p = 0.001), as well as between the 20 mg/kg CORT group and the 
vehicle group (p = 0.027). 
Group differences at each time point of the experiment were analyzed using planned 
comparisons with separate one-way ANOVAs. CORT treatment had significant effects on the 
immobility/body weight (IBW) ratio during both cycles. In cycle 1, the treatment groups 
differed on this measure in both FST-1 [F(2,27) = 4.44, p = 0.022] and FST-2 [F(2,27) = 
6.84, p = 0.004]. Post hoc (LSD) analyses revealed that the 40 mg/kg CORT rats (p = 0.009 
and p = 0.002) and 20 mg/kg CORT rats (p = 0.034 and p = 0.01) both showed smaller ratio 
scores than did the vehicle rats in FST-1 and FST-2, respectively. No significant group 
differences were found after recovery on FST-3 (p = 0.701).  
In cycle 2, there was a significant main effect of treatment on IBW ratios after 10 
days of treatment on FST-4 [F(2,27)  = 11.27, p = 0.001]. Post hoc (LSD) analyses revealed 
that both the 40 mg/kg CORT rats (p = 0.001) and the 20 mg/kg CORT rats (p = 0.002) had 
lower IBW ratio scores than the vehicle rats. The same pattern of results was seen in FST-5, 
after 21 days of treatment. That is, there was an overall main effect of treatment on IBW ratio 
scores during this test [F(2,27)  = 13.95, p = 0.001], and post hoc (LSD) tests showed that 
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Figure 2-4.  The effect of one and two cycles of repeated corticosterone (CORT) injections 
on the forced swim test (FST) behavior plotted by body weight. Panel (A) shows the 
immobility time to body weight ratio, panel (B) shows the latency to immobility to body 
weight (IBW) ratio, panel (C) shows the climbing time to body weight ratio, and panel (D) 
shows the time spent swimming to body weight ratio. Rats treated with CORT higher IBW 
ratio scores at the end of treatment cycle one. Following CORT re-exposure in the second 
cycle, the CORT rats showed a sensitized increase in IBW scores after only ten days of 
treatment. It was also noted that CORT rats showed worsened recovery of IBW scores at the 
end of the second recovery period. Asterisks indicate significant differences between groups 
at specific time points (p < 0.05). Error bars denote the standard error of the mean (SEM). 
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both the 40 mg/kg CORT (p = 0.001) and 20 mg/kg CORT rats (p = 0.001) had lower ratio 
scores than the vehicle rats. Additionally, a significant main effect of treatment on IBW ratios 
was found in FST-6, after recovery [F(2,27)  = 3.37, p = 0.05]. The post hoc (LSD) analyses 
indicated that the difference occurred between the 40 mg/kg CORT and the vehicle rats (p = 
0.02). 
 
2.3.3.2. Latency to Immobility to Body Weight (LIBW) Ratio  
Mauchly’s test indicated that the assumption of sphericity was violated, X (14) = 
57.26, p = 0.001, therefore the degrees of freedom were corrected using Greenhouse-Geisser 
sphericity estimates. Repeated measures ANOVA revealed a significant main effect of time 
on latency to immobility/body weight (LIBW) ratios [F(2.5, 59.82) = 24.55, p = 0.001]. 
There was no significant main effect of treatment on LIBW ratios (p = 0.42), and no 
significant interaction of treatment by time (p = 0.116). 
Our a priori predictions led us to investigate group differences at each time point of 
the experiment using planned comparisons with separate one-way ANOVAs. In cycle 1, no 
significant group differences in LIBW ratios were seen during any of the FSTs (all p’s > 
0.05). In cycle 2, there was a significant decrease in the LIWB ratio scores in both groups of 
CORT-injected rats after 10 days of treatment, [F(2,27) = 3.34, p = 0.05]. That is, both the 40 
mg/kg CORT rats (p = 0.032) and the 20 mg/kg CORT rats (p = 0.035) had lower LIBW 
scores compared to the vehicle rats. There were no significant group differences in LIBW 
ratio scores during FST-5 and FST-6 (p > 0.05). 
 
2.3.3.3. Climbing to Body Weight (CBW) Ratio  
Mauchly’s test indicated that the assumption of sphericity was violated, X (14) = 
42.9, p = 0.001, therefore the degrees of freedom were corrected using Greenhouse-Geisser 
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sphericity estimates. Repeated measures ANOVA revealed a significant main effect of time 
on climbing/body weight (CBW) ratios [F(3.43, 89.22) = 38.19, p = 0.001], as well as a 
significant interaction of treatment by time [F(6.86, 89.22) = 2.9, p = 0.009]. There was no 
significant main effect of treatment on CBW (p = 0.409). 
Group differences at each time point of the experiment were investigated using 
planned comparisons of separate one-way ANOVAs. In cycle 1, we found no significant 
group differences in CBW ratios during the FST1-3 (all p’s > 0.05). In cycle 2, there was a 
significant main effect of treatment on CWB ratio scores in FST-4 [F(2,27) = 3.9, p = 0.032] 
after 10 days of treatment, and in FST-5 after 21 days of treatment [F(2,27) = 3.32, p = 0.05]. 
That is, both the 40 mg/kg CORT rats (p = 0.013) and the 20 mg/kg CORT rats (p = 0.05) 
had lower CBW scores compared to the vehicle rats in FST-4. And only the 40 mg/kg CORT 
rats (p = 0.013) had lower CBW ratio scores than the vehicle group in FST-5. There was no 
significant group difference in CBW ratio scores during FST-6 after recovery (p = 0.201). 
 
2.3.3.4. Swimming to Body Weight (SBW) Ratio  
Mauchly’s test indicated that the assumption of sphericity was violated, X (14) = 
40.33, p = 0.001, therefore the degrees of freedom were corrected using Greenhouse-Geisser 
sphericity estimates. Repeated measures ANOVA revealed a significant main effect of time 
on swimming/body weight (SBW) ratios [F(3.7, 84.99) = 25.82, p = 0.001]. There was no 
significant main effect of treatment on SBW ratios (p = 0.41), and no significant interaction 
of treatment by time (p = 0.187). 
Our a priori predictions led us to investigate group differences at each time point of 
the experiment using planned comparisons with separate one-way ANOVAs. In cycle 1, no 
significant group differences in SBW ratios were found during the FST1-3 (all p’s > 0.05). In 
cycle 2, no significant group differences in SBW ratios were found during the FST-4, after 10 
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days of injections (p > 0.078). There was a significant decrease in the SWB ratio scores in 
both groups of CORT-injected rats after 21 days of treatment [F(2,27) = 3.61, p = 0.041]. 
That is, both the 40 mg/kg CORT rats (p = 0.043) and the 20 mg/kg CORT rats (p = 0.019) 
had lower SBW scores compared to the vehicle rats. There were no significant group 
differences in SBW ratio scores during FST-6, after recovery (p = 0.09). 
 
2.3.4. Changes in Recovery of Immobility Behavior Across Two Cycles of Treatment 
	
To evaluate the changes in the quality of recovery across two cycles of CORT 
treatment, the percent change in immobility time and IBW ratio in the 20 mg/kg and 40 
mg/kg CORT rats were calculated. For each rat, we calculated the difference in FST scores 
on day 22 and after recovery and then divided that amount by the day 22 FST score and 
multiplied by 100. We then averaged the obtained values for rats in each group to get a group 
mean.  
The results are presented in Table 2-1. Repeated measures ANOVA revealed no 
significant main effect of time on percent change in immobility (p = 0.72) in either the  
CORT 20 and CORT 40 mg/kg groups. However, there was a significant main effect of time 
on percent change of IBW ratio scores [F(1,17) = 13.06, p = 0.002]. The post hoc (LSD) 
analyses confirmed that the difference occurred between percent change in cycle 1 and cycle 
2 in the 40 mg/kg CORT rats (p = 0.002). 
 
2.4. Discussion 
 
The purpose of this experiment was to determine whether the effects of CORT on 
depression-like behavior can be sensitized with multiple cycles of exposure. Our results 
support this idea. There were no significant differences between the vehicle and CORT-  
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Table 2-1. Changes in recovery over two cycles of corticosterone (CORT) treatment. The 
values listed are the percent change in immobility time and immobility time corrected for 
body weight (IBW) ratio in the 20 mg/kg and 40 mg/kg CORT groups. Asterisks (*) 
represent statistically significant difference between the labeled values. For details, see the 
text. 
 
 
 
 Immobility Time,  
% change 
Immobility to Body Weight Ratio,  
% change 
CORT- 
20 mg/kg 
CORT- 
40 mg/kg 
CORT- 
20 mg/kg 
CORT- 
40 mg/kg 
Recovery, cycle 
one 
 
13.6 ± 5.5% 
 
8.5 ± 5.2% 
 
53.1 ± 44.7% 
 
42.3 ± 16.9% * 
Recovery, cycle 
two 
 
19.9 ± 6.0% 
 
5.1 ± 5.6% 
 
29.7 ± 20.7% 
 
19.2 ± 9.3% * 
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Figure 2-5.  Scatter plots of changes in immobility and immobility to body weight (IBW) 
ratio scores in individual rats. Panels (A) and (C) show immobility time and IBW ratio scores 
in the 20 mg/kg corticosterone (CORT) rats; panels (B) and (D) and show immobility time 
and IBW ratio scores in the 40 mg/kg CORT rats. CORT rats exhibit high variability in the 
recovery rate of immobility time and IBW ratio scores during the first recovery period, and 
less individual variability during the second recovery period. 
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treated rats in FST behaviors (immobility, climbing, swimming, and latency to immobility 
onset) after only ten days of injections in cycle 1. As previously reported (Brotto, Gorzalka, 
& Barr, 2001; Mitra & Sapolsky, 2008), ten days of daily CORT injections are not sufficient 
to produce significant increases in depression-like behavior in rats. However, CORT did 
significantly alter immobility and swimming behavior after 21 days of injections. Rats treated 
with 40 mg/kg or 20 mg/kg CORT spent significantly more time immobile and less time 
swimming compared to control rats. This result supports previous findings from our 
laboratory (Johnson et al., 2006; Lussier et al., 2013; Marks et al., 2009) and others 
(Brummelte & Galea, 2010; Waters & McCormick, 2011; Workman, Brummelte, & Galea, 
2013; Zhao, Ma, et al., 2008). Specifically, rats injected with 40 mg/kg CORT for 21 
consecutive days reliably display an increase in immobility in the FST, which typically 
reflects a depressive phenotype in rodents (Cryan, Valentino, & Lucki, 2005). 
A novel aspect of this experiment was providing rats with a recovery period and then 
administering CORT for one additional cycle. Our data revealed that 21 days of recovery was 
sufficient for both behavior and body weight to normalize, as seen in FST-3: CORT-treated 
rats showed a substantial decrease in time spent immobile and restored body weight gain to 
the levels of the control group. However, when the rats were re-exposed to CORT for the 
second time, we found greater immobility and reduced swimming and climbing in the FST. 
For example, we observed an early re-establishment of depression-like behavior after only 
ten days of CORT injections. Specifically, rats re-exposed to the second cycle of CORT spent 
significantly more time immobile and less time climbing and swimming compared to the 
vehicle-injected rats. This effect was seen with both doses of CORT. These findings suggest 
that only half of the initial duration of CORT treatment in the second cycle was sufficient to 
trigger significant increases in depression-like symptoms in rats that were pre-exposed to 
CORT treatment and allowed to recover.  
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Similar to our observations with immobility behavior, the latency to immobility 
measure also seemed to decrease over two cycles in CORT-treated rats. Specifically, there 
were no group differences in latency to immobility in cycle 1, but in cycle 2, both groups of 
CORT rats had a shorter latency to immobility on days 10 and 22 compared to the vehicle 
rats.  
In addition to these behavioral changes, exposure to repeated CORT injections 
produced physiological alterations indicative of depression. Rats treated with 40 mg/kg and 
20 mg/kg CORT had significant decreases in body weight gain in during both cycles of 
treatment. During the recovery periods, their body weight recuperated, and the CORT rats 
were no longer different from the vehicle rats. Several mechanisms described in the literature 
could explain the effect of CORT treatment on body weight loss. There is a curvilinear 
relationship between CORT and body weight: relatively low levels of CORT result in weight 
gain, whereas chronically high levels of CORT (or glucocorticoid receptor agonists) lead to 
body weight loss (Devenport, Knehans, Sundstrom, & Thomas, 1989; Santana et al., 1995). 
Chronic glucocorticoid exposure increases hepatic gluconeogenesis and glycogenlysis, 
antagonizes insulin utilization in skeletal muscles and white adipose tissue, and modulates 
insulin and glucagon secretion from pancreatic β and α cells. Collectively, these effects result 
in insulin resistance, hyperglycemia, and consequent losses of urinary glucose (loss of 
kilocalories) (Andews & Walker, 1999; Di Dalmazi, Pagotto, Pasquali, & Vicennati, 2012; 
Kuo, Harris, & Wang, 2013). Additionally, glucose concentrated urine leads to polyuria 
(increases in urination frequency) and may result in dehydration and rapid weight loss 
(Harris, 2015). Finally, chronic and high levels of CORT inhibit protein synthesis promoting 
the breakdown of muscles, and increase lipolysis, eventually leading to a reduction in adipose 
tissue, muscle atrophy, and body weight loss (Tempel & Leibowitz, 1994; Tomas, Munro, & 
Young, 1979). However, in human depression, both body weight gain (atypical subtype) and 
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body weight loss (melancholic subtype) have been observed (American Psychiatric 
Association, 2013), which can be explained by different mechanisms, such as increased 
appetite, emotional eating, or, in contrast, reduced food intake due to anhedonia or 
socioeconomic factors (Konttinen, Männistö, Sarlio-Lähteenkorva, Silventoinen, & 
Haukkala, 2010; van Strien, Konttinen, Homberg, Engels, & Winkens, 2016; van Strien, van 
der Zwaluw, & Engels, 2010). 
Several biological factors, such as strain, body weight, age, and sex, are known to 
influence rodent behavior in various behavioral tests, including the FST (Bogdanova, 
Kanekar, D ’anci, & Renshaw, 2013). The mechanisms by which these factors affect rodent 
performance in behavioral tests are not well understood. Aging significantly impacts multiple 
body systems. Changes in the peripheral nervous system (neuromuscular junction) are known 
to cause a decline in motor control in older humans (Faulkner, Larkin, Claflin, & Brooks, 
2007). Additionally, central brain changes (atrophy of the motor cortex and corpus callosum, 
degeneration of dopaminergic neurotransmitter system) may contribute to age-related motor 
declines (Carlsson & Winblad, 1976; Inoue et al., 2001; van Dyck et al., 2002). However, not 
all age-related changes in behavior can be explained by reduced motor ability. For example, 
Turner et al. (2012) demonstrated that older rats (18-20 months old) showed reduced 
exploration of the open arms in the elevated plus maze and greater immobility time in the 
FST compared with young adult rats (3-4 months old), whereas on the Rotarod and total 
locomotor activity assessment, all groups behaved similarly (Turner et al., 2012).  There are 
striking changes in HPA axis function associated with older age, such as dramatic increases 
in basal cortisol levels (Van Cauter, Leproult, & Kupfer, 1996), diminished circadian rhythm 
amplitude of cortisol fluctuations (Ferrari et al., 2001; Van Cauter et al., 1996), and 
dysregulated HPA negative feedback (Otte et al., 2005). It is important to note that these 
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changes in the HPA function resemble those seen in depressed individuals irrespective of age 
(Gobinath, Mahmoud, & Galea, 2015). 
The longitudinal design of the present experiment has allowed for potential 
confounding effects of age-related body weight gain on FST behavior. Therefore, we 
attempted to account for these effects by creating and analyzing ratio scores, where each FST 
behavior was converted to a ratio according to each rat’s weight at the time of testing. 
Interestingly, the IBW ratio of the vehicle rats eliminated the nonspecific increase in 
immobility in these rats that was seen over the course of two cycles of testing. In contrast, the 
calculation of IBW ratios for both 40 mg/kg and 20 mg/kg CORT rats had no effect on our 
expected changes in immobility with 10 and 21 days of CORT treatment, and our expected 
decreases in immobility after CORT-free recovery periods.  
Finally, our data provide some evidence to suggest a progressive worsening of 
recovery in CORT-treated rats, which is dependent on the dose of CORT being used. 
Specifically, the 40 mg/kg CORT rats showed a 8.5% reduction of immobility time and a 
42.3% reduction in IBW after the recovery period in cycle 1. However, after the recovery 
period in cycle 2, this group showed only a 5.9% reduction in immobility time and a 19.2% 
reduction of IBW ratio (Table 2-1, Figure 2-5). Similarly, but to a smaller degree, the 20 
mg/kg CORT rats showed a 13.6% reduction of immobility time and a 53.1% IBW ratio 
reduction after recovery in cycle 1, and a 19.9% reduction in immobility time and 29.7% 
IBW ratio reduction after recovery in cycle 2 (Figures 2-3A, 2-4A, 2-5, and Table 2-1). In the 
clinical literature, this phenomenon is described as “partial remission” or remission with 
residual symptoms (Fava, Ruini, & Belaise, 2007). Several clinical studies showed that more 
than 80% of responders to antidepressant medication displayed residual symptoms (Gastó, 
Navarro, Catalán, Portella, & Marcos, 2003; Nierenberg et al., 1999). Also, residual 
symptoms were found in depressed patients treated with psychotherapy (Karp et al., 2004; 
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Ogrodniczuk, Piper, & Joyce, 2004; Simons, Murphy, Levine, & Wetzel, 1986; Thase et al., 
1992). Moreover, 30-88% of patients who were successfully treated with antidepressants and 
categorized as “remitted”, also had residual symptoms of depression (Paykel, 1985; Paykel et 
al., 1995). Importantly, the residual symptoms were repeatedly reported as strong predictors 
of subsequent relapses into depression, and therefore are considered to be an important 
problem in therapeutic interventions (Fava & Visani, 2008; Paykel, 1998; Petersen et al., 
2004). Along with increased depression severity over time (Kessing, 2008), smaller inter-
episode duration, and increased number of episodes (Kendler et al., 2001; Kessing, 1998), 
partial remission could be a major contributor to the progression of depression (i.e., 
progressive structural and functional brain changes produced by recurring depressive 
episodes) (Moylan, Maes, Wray, & Berk, 2012). 
 The newly presented model mimics the periodic change of behavior into and out of 
depression that is observed in patients with depressive disorders (Belmaker & Agam, 2008).  
Episode recurrence has been shown as one of the hallmarks of major depression disease 
course (Kennedy, Abbott, & Paykel, 2003; Monroe & Harkness, 2005). Furthermore, 
increasing evidence in human research (Liu & Alloy, 2010) supports the role of stress 
generation (sequence of dependent stress) in depression pathogenesis.  Our results provide 
evidence for the kindling hypothesis of depression, which suggests that due to lasting 
neurobiological changes that occur with each bout of depression, progressively less stress is 
required to trigger subsequent depression episodes (Monroe & Harkness, 2005; Post, 1992). 
The research focused on the development of novel antidepressants has had limited 
success, partly due to the lack of adequate animal models of depression. More than half of 
patients that recover from major depressive episodes experience a relapse (Hollon et al., 
2006; Pettit et al., 2006). The absence of treatments that prevent the recurrence of depression 
can be explained, in part, by the absence of animal models showing spontaneous episodes of 
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depression. The development of new animal models with recurrent depressive-like episodes 
is, therefore, essential in this regard. Our model provides stronger construct and face validity 
compared with other existing animal models of depression. This animal model imitates the 
cyclical disease course of major depression over and above its ability to produce 
depressogenic effects on behavior (inhibited grooming and sexual behavior, increased 
helplessness), as well as physiological changes indicative of depression (weight loss, 
dysregulated HPA axis function) and finally, neurobiological alterations associated with 
depression disorders, such as hippocampal dendritic atrophy and decreased neurogenesis 
(Sterner & Kalynchuk, 2010).  
Some of the limitations of this model of recurrent depression are potential 
confounding effects of repetitive FST exposure, aging, and body weight changes in the rats. 
Therefore, the interpretation of sensitization of depression-like behavior in the FST should be 
made with caution. One improvement that will be addressed in my next experiment is having 
separate groups of rats for each time point of FST, thus eliminating any repeated testing of 
the same rat.  
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Abstract 
Exposure to chronic stress (or glucocorticoids) is a significant risk factor for depressive 
disorders. However, the mechanism by which stress might lead to depression is still 
unknown. Several hypotheses have suggested one such mechanism could involve stress-
induced decreases in adult neurogenesis. The purpose of this experiment was to determine the 
effects of repeated and cyclic CORT administration on depression-like behavior, 
hippocampal neurogenesis, and its transcriptional regulation. Rats were given CORT 
injections or vehicle injections once per day for one, two, or three cycles (21 days each), 
followed by recovery periods. Rat behavior was measured in the forced swim, sucrose 
preference and open field tests to assess depressive symptoms and general locomotion at 
specific time points after CORT treatment or recovery. After behavioral testing, the rats were 
sacrificed for immunohistochemical analyses of adult hippocampal neurogenesis (immature 
neuron number, dendritic complexity), and the repressor element-1 silencing transcription 
factor (REST) expression in hippocampus. Our results demonstrate that repeated and cyclic 
exposure to high levels of CORT results in greater increases in depression-like behaviors, 
including higher immobility and lower swimming in the FST, and lower sucrose preference 
scores, but not in general locomotor behaviors. These changes in depression-like behaviors 
are paralleled by accumulated decreases in neurogenesis, specifically the number and 
dendritic complexity of doublecortin positive cells in dentate gyrus. Furthermore, we found a 
precise and time-dependent bi-directional regulation of REST levels within the hippocampus, 
which correlated with changes in depression-like behavior.  
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3.1. Introduction  
 
Depression has an increasing prevalence worldwide, affecting over 350 million people 
in both developed and developing countries. The World Health Organization estimates that 
depression will be the leading cause of global disease burden by 2030 (World Health 
Organization, 2012).  
In seeking a better understanding of the neurobiological mechanisms of depression, 
much of the current research has suggested that hippocampal dysfunction may be 
contributing to the etiology and treatment of this disease (Nestler, Gould, et al., 2002; 
Nestler, Barrot, et al., 2002). Numerous neuroimaging and post-mortem studies have reported 
hippocampal volume loss and abnormal cell morphology in depressed patients (MacQueen et 
al., 2003; Sheline, Wang, Gado, Csernansky, & Vannier, 1996; Sheline, Sanghavi, Mintun, & 
Gado, 1999; Sheline, Gado, & Kraemer, 2003). Aberrant adult hippocampal neurogenesis is 
hypothesized to be one of the reasons for the observed hippocampal pathology in major 
depression (Fournier & Duman, 2012; Sahay & Hen, 2007). Interestingly, preclinical studies 
of depression have demonstrated that various forms of chronic stress, including 
glucocorticoid administration, reduce the proliferation, survival, and differentiation of 
newborn hippocampal neurons in adult animals (Bambico & Belzung, 2013; Banasr & 
Duman, 2007). In addition, both clinical and preclinical data show that nearly all forms of 
antidepressant treatment, as well as exercise, enriched environments and other manipulations 
that lead to antidepressant-like behavioral effects promote adult neurogenesis (Boldrini et al., 
2009; Fournier & Duman, 2012).  
Adult neurogenesis is continuously controlled by multiple signalling pathways (Ables 
et al., 2010; Lie et al., 2005; Mira et al., 2010, Beckervordersandforth et al., 2015) and 
neurotransmitter systems (Deisseroth et al., 2004; Ge et al., 2006; Tozuka, Fukuda, Namba, 
Seki, & Hisatsune, 2005). Recent work has identified zinc finger protein REST (RE1-
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silencing transcription factor, also known as NRSF) as a master factor for both differentiating 
precursor cells and adult neurons as well (Baldelli & Meldolesi, 2015). Initially, REST was 
known as a repressor of neuronal genes during embryonic development that was down-
regulated once terminal neuronal differentiation has occurred (Ballas et al., 2005; Chong et 
al., 1995; Schoenherr & Anderson, 1995). However, growing evidence indicates that REST 
induction in mature neurons is subject to plasticity, for example, adult hippocampal granule 
cells and pyramidal neurons express high levels of REST (Calderone et al., 2003; Kuwabara 
et al., 2004; Palm et al., 1998; Sun et al., 2005), and adult neurons upregulate REST and 
specific target genes in response to ischemia or seizures (Calderone et al., 2003; Jessberger et 
al., 2007; Palm et al., 1998). An increase in REST was reported in normal aging in human 
cortical and hippocampal neurons, but a loss of hippocampal REST was found in patients 
with Alzheimer’s disease, dementia and mild cognitive impairment (Lu et al., 2014). To my 
knowledge, the effects of repeated stress and depression on REST levels on the brain are 
largely unknown. 
A longer course of depression is associated with more pronounced neurobiological 
changes, including atrophy of hippocampal volume (Bremner et al., 2000; Sheline et al., 
1999; Sheline et al., 2003). Additionally, research in our laboratory shows that CORT-treated 
rats demonstrate gradual increases in depression-like behavior with 7, 14 and 21 days of 
treatment.  These behavioral effects were accompanied by similarly gradual decreases in 
reelin expression in the dentate SGZ and decreases in the number and maturation rate of 
immature neurons in dentate gyrus (Lussier et al., 2013).  These observations suggest that 
depression may be a progressive disease, with increasingly larger neurobiological 
perturbations leading to progressively severe symptoms and episode relapse. However, little 
is known about how the hippocampus is affected after multiple stress-induced depression-like 
episodes. 
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The specific aims of this experiment were: (1) to examine the effect of three cycles of 
CORT treatment with recovery between cycles on depression-like behavior, (2) to determine 
whether the progressive development of depression-like behavior in CORT-treated rats is 
paralleled by decreases in immature granule cell number and maturation, and (3) to examine 
changes in hippocampal REST protein immunoreactivity after one and three cycles of CORT 
treatment. Our results indicate that CORT does indeed produce greater effects on rat 
depression-like behavior (including higher immobility and less swimming in the FST, and 
lower sucrose preference scores) in cycles two and three compared to cycle one. These 
behavioral changes were paralleled by accumulated decreases in dentate gyrus immature 
neuron number and cell complexity. In addition, hippocampal REST levels displayed bi-
directional changes depending on the number of CORT exposures. 
 
3.2. Materials and Methods 
3.2.1. Subjects 
	
We used 183 male Long-Evans rats in this study (Charles River Laboratories, 
Canada). The rats weighed approximately 225-250 grams upon arrival to our facility. They 
were individually housed in standard polypropylene cages with water and food available ad 
libitum (unless otherwise indicated). The temperature of the colony room was maintained at 
21°C and all experimental procedures were conducted during the light phase of the light/dark 
cycle (lights on at 8 a.m.). All experimental procedures were carried out according to a 
protocol approved by the University of Saskatchewan Committee on Animal Care and 
Supply. 
 
3.2.2. Experimental Procedures   
	
The rats were handled once per day for 7 days before the experimental procedures 
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were started. The rats were weight-matched and randomly assigned to one of the two 
treatment groups: repeated and cyclic CORT injections: 20 mg/kg, CORT (N = 91) or vehicle 
injections (N = 92). Both CORT and vehicle groups were divided into subgroups so that a 
different group of rats was evaluated at each time point: (1) 10 days of cycle one, (2) 21 days 
of cycle one, (3) recovery of cycle one, (4) 10 days of cycle two, (5) 21 days of cycle two, (6) 
recovery of cycle two, (7) 10 days of cycle three, (8) 21 days of cycle three, and (9) recovery 
of cycle 3. Each subgroup consisted of 20-22 rats (CORT and vehicle). These subgroups 
were employed to avoid the use of repeated exposure to the FST.  
All injections were administered once per day for three cycles. Each cycle comprised 
21 consecutive days of injections, followed by a 21-day injection-free recovery period 
(Figure 3-1). The injections were administered subcutaneously, between 9 and 11 a.m. CORT 
(Steraloids) was suspended in 0.9% (w/v) physiological saline with 2% (v/v) Tween-80 
(Sigma Aldrich) and given in a volume of 1 ml/kg. The body weight of rats was recorded on 
each day of CORT treatment, and in the end of each recovery period. 
 
3.2.3. Behavioral Testing 
	
The behavioral testing was carried out in a different procedure room from the one 
used for the injections. We used the FST to assess depression-like behavior, the sucrose 
preference test (SPT) to assess anhedonia, and the open field test (OFT) to assess general 
locomotor behavior. All behavioral tests were administered in the middle (day 11) and in the 
end (day 22) of each cycle of CORT administration, and in the end of each recovery period.  
As mentioned above, we used rats that were naïve to behavioral testing at each time 
point (Figure 3-1). 
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Figure 3-1.  A schematic of the experimental design. Separate groups of corticosterone 
(CORT)- and vehicle-treated rats were exposed to varying durations of treatment and 
recovery. Behavioral testing was administered as shown in the diagram. At each time point, 
behavioral testing was followed by perfusions and brain tissue collection the next day. 
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3.2.3.1. Forced Swim Test 
A modified version of the FST test protocol was used (Gregus et al., 2005). We chose 
to use a modified one-day version of the FST because previous research in our laboratory has 
shown comparable behavioral results with both a one-day and two-day versions of this test. 
Furthermore, a one-day FST protocol is appropriate to measure depression-like behavior in 
experiments with prior exposure to a repeated stress because it removes the possible 
confounding effects of memory from the first day of FST exposure on behavior during the 
second “testing” day (Marks et al., 2009). Briefly, rats were individually placed into a 
Plexiglas tank (25 cm W x 25 cm L x 60 cm H, 30 cm D) with 27 ±2 °C water, for a duration 
of 10 minutes. The standard FST behaviors were scored: time spent immobile, time spent 
swimming, time spent climbing, and the latency to the first bout of immobility. Depression-
like behavior was inferred from increases in time spent immobile and decreases in active FST 
behaviors (Gregus et al., 2005; Porsolt et al., 1978). 
 
3.2.3.2. Sucrose Preference Test  
	
Prior to any experimental procedures, all rats were given a 48-hour habituation to a 
two-bottle SPT procedure. During this time, the rats were presented with two 100 ml plastic 
bottles with 1% sucrose solution and allowed to drink freely. After this habituation, the rats 
were given their regular water until the SPT was conducted. The SPTs were conducted on the 
days following the FSTs. During the testing, the rats were provided with one bottle filled with 
1% sucrose solution and another bottle filled with regular distilled water. The bottles were 
available for approximately 15 hours (overnight). The following morning the sucrose and 
water intake was measured and recorded.   
 
3.2.3.3. Open Field Test  
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The OFTs were conducted following the SPTs. The open field apparatus (70 cm W × 
70 cm L × 60 cm H) was a black wooden box with a transparent Plexiglas bottom and no top. 
The floor of the apparatus was divided into 36 equal squares by tape attached underneath the 
floor. Rats were individually placed in the corner of the open field and allowed to explore for 
five minutes. A video camera mounted on a tripod above the open field recorded the rats' 
activity. Total OFT activity, which included the number of lines crossed and the number of 
rears during the 5-minute session, was recorded. A rat was credited with one line cross when 
the center of rat’s back moved over from one square and into the next square of the open 
field. A rat was credited with one rear each time it was standing on its rear limbs (Marks et 
al., 2009).  
 
3.2.4. Perfusions and Tissue Preparation  
	
After behavioral testing at each experimental time point, the rats were anesthetized 
with an overdose of intraperitoneal sodium pentobarbital and perfused transcardially with 0.1 
M phosphate buffer (PB, pH 7.4) followed by 4% (w/v) paraformaldehyde in 0.1 M 
phosphate buffer (PB, pH 7.4). The brains were removed and postfixed in 4% (w/v) 
paraformaldehyde for 48 h at 4°C. Tissue was then sectioned at 50 μm using a vibratome 
(Vibratome 3000, Vibratome Company, St. Louis, MO, USA) and stored at -20°C in a 
cryoprotectant solution containing 30% (v/v) ethylene glycol, 1% (w/v) 
polyvinylpyrrolidone, and 30% (w/v) sucrose in 0.1 M PBS (pH = 7.4). 
 
3.2.5. Immunohistochemical Procedures and Analyses 
	
A subset of rats from each group (n = 4-5) was randomly selected for 
immunohistochemical analyses. Every 12th section of the hippocampus (from approximately 
-2.40 mm to -3.94 mm from bregma) was used for immunostaining. All immunostaining 
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procedures were done in 6-well tissue culture plates. For each immunohistochemical 
preparation, hippocampal slices from each treatment group were counterbalanced across all 
6-well culture plates to ensure consistency in the immunohistochemical processing. Finally, 
to confirm the specificity of antibodies used in immunostaining, one well with brain sections 
served as a control and was subjected to immunohistochemical procedures in the absence of 
the primary antibody. We did not observe any immunoreactivity in the absence of the 
primary antibodies. 
 
3.2.5.1. Doublecortin (DCX) 
	
 To visualize immature neurons, DCX immunohistochemistry was done according to 
our previously published methods (Fournier et al., 2010). Briefly, free-floating tissue sections 
were rinsed in 0.1 M Tris-buffered saline (TBS, pH 7.4). Following rinsing, the sections were 
subjected to a heat-induced antigen retrieval in a sodium citrate buffer (pH 6.0) at 95 °C for 
30 min. Sections were then blocked with 5% (v/v) normal goat serum (NGS), 1% (w/v) BSA, 
and 0.5% (v/v) Triton X-100 in 0.1 M TBS, and incubated with a rabbit anti-DCX 
monoclonal primary antibody (1:1000; Cell Signaling Technology, MA, USA); diluted in 
block solution) for 48 hours at 4°C. Then, the tissue was incubated in 5% (v/v) H2O2 for 30 
min to block endogenous peroxidase activity, followed by incubation with a biotinylated 
secondary antibody (goat anti-rabbit; 1:500; Vector Laboratories, USA; diluted in 5% NHS 
and TBSx) for 2 hours at RT, then ABC for 1 hour (1:500, Vector Laboratories, USA). 
Immunolabelling was visualized with 0.025% (w/v) 30-diaminobenzidine (DAB, Sigma 
Aldrich, St. Louis, MO), 4.167% (w/v) nickel ammonium sulphate, and 0.002% (v/v) H2O2 
diluted in 0.175M sodium acetate. After approximately 5 minutes, the sections were rinsed in 
0.175 M sodium acetate to stop the DAB reaction. The sections were then mounted onto glass 
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slides, dehydrated, and coverslipped using Entellan resin (Millipore, USA) for light 
microscopic examination. 
DCX cell counts and maturation analysis. We assessed the total number of DCX 
positive cells using the unbiased optical fractionator method. Five tissue sections per rat were 
quantified. We visualized the brain sections at 400X magnification on a Nikon E800 
microscope with a motorized stage and a stereology system software (Stereo Investigator, 
MicroBrightField). DCX positive cells were counted in the SGZ and GCL in the dentate 
gyrus (from approximately -2.40 mm to -3.94 mm from bregma). Counting parameters 
included a dissector height of 15 m, a sampling area of 90x90 m, and a counting frame of 
50x54 m. A guard zone of 5 m was used to avoid the artifacts of sectioning. The total 
number of DCX positive cells was estimated using the formula: N(total): ΣQ- × 1/ssf × \A(x,y 
step)/ a(frame) × t/h; where ΣQ is the number of counted cells; ssf is the section sampling 
fraction; A(x, y step) is the area associated with each x, y movement; a(frame) is the area of 
the counting frame; t is the section thickness-weighted average, and h is the dissector height.  
The dendritic morphology of immature granule neurons was quantified by 
categorizing a dendritic tree in a subset of DCX positive neurons from rats according to 
previously described methods (Lussier et al., 2013; Plümpe et al., 2006). A stereology system 
was used to randomly select at least a 100 cells per rat. The cells were placed into one of six 
categories depending on the presence and amount of the apical dendrites (see Figure 3-6, 
Panel B). Briefly, categories one and two cells had either no processes (category one) or very 
short processes (category two), and were considered as cells at the early proliferative stage of 
cell development. Category three cells had medium size processes that extended to the 
granular cell layer. Category four cells had a medium size process that extended to the 
molecular layer. Categories five and six cells were at more mature stages of development, 
with one major dendrite branching in the molecular layer (category five) or a well-defined 
	 77	
dendritic tree with several branches in the GCL (category six). The percentage of cells under 
each of these categories was determined for each rat.  
 
3.2.5.2. REST 
	
 To visualize REST positive cells, free-floating tissue sections were first rinsed in 0.1 
M TBS (pH 7.4). Following rinsing, the sections were subjected to heat-induced antigen 
retrieval in a sodium citrate buffer (pH 6.0) at 85 °C for 30 min. The sections were then 
blocked in a 0.5% (v/v) Triton X-100 TBS buffer containing 5% (v/v) normal goat serum 
(NHS) and 1% (w/v) bovine serum albumin (BSA; Sigma, USA) for 30 min at 37 °C, 
followed by incubation with a rabbit anti-REST polyclonal antibody (1:1500; generous gift 
from Dr. Jenny Hsieh, UT Southwestern Medical Center, USA) for 48 hours at 4 °C. Then, 
the sections were incubated in 1% H2O2 for 20 min to block endogenous peroxidase activity, 
followed by incubation with a biotinylated secondary antibody (goat anti-rabbit; 1:500; 
Sigma-Aldrich, USA) for 1.5 hours at 37 °C, and incubation in avidin-biotin complex (1:500, 
Vector Laboratories, USA) for 1.5 hours at 37 °C. Immunolabelling was visualized with 
0.033% (w/v) DAB and 0.0078% (v/v) H2O2 diluted in TBS. After approximately 4 minutes, 
the sections were rinsed in TBS to stop the DAB reaction. The sections were then mounted 
onto glass slides, dehydrated, and coverslipped using Entellan resin (Millipore, USA) for 
light microscopic examination. 
REST cell counts and optical density. The number of REST positive cells was 
quantified using a computerized image analysis program (Stereo Investigator, version 8.0, 
MicroBrightField Inc.) attached to a Nikon Eclipse E800 microscope. The following regions 
were quantified: hilus, CA3 strata oriens and radiatum, and CA1 strata oriens and radiatum, 
strata lacunosum. An experimenter who was blind to the treatment conditions manually 
counted cells using a profile counting method, which involved using a meander scan setting 
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to sample non-overlapping fields from each brain region. Five sections per brain were 
analyzed (from −2.40 mm from bregma to approximately −3.94 mm from bregma) in both 
right and left hemispheres. According to Schiffer et al. (2014), REST labelling is mainly 
cytoplasmic in neurons and nuclear in glial cells. Therefore, only large cells with dark, 
uniformly stained cytoplasm and well-defined cell bodies were counted as REST positive. 
The number of cells counted for each brain region, within the traced contours (in μm). The 
values were re-expressed as cells per mm2. Data are presented as the average number of 
REST+ cells per mm2 within a defined contour within each region. 
Optical density (OD) analysis was used to assess REST immunostaining in 
hippocampal subregions, where cells are normally tightly packed. This included the GCL, 
CA3 strata pyramidale and CA1 strata pyramidale. The dense aggregation of immunostained 
cells in these areas made accurate cell counting impossible, therefore OD analysis was 
conducted. Monochrome images of brain sections were collected at 200X magnification 
using a Nikon E800 microscope. Optical densities from 3 brain sections (both hemispheres) 
were determined using the Image J software program (v1.43u, National Institutes of Health). 
The OD was corrected according to the background staining measured in the corpus callosum 
of each individual section. The resulting average OD in each brain area was taken as a 
measure of REST immunoreactivity. 
 
3.2.6. Statistical Analysis  
	
Main effects and interactions were first analyzed using a two-way univariate 
ANOVA, with time and treatment as independent variables. Separate independent sample t-
tests (one-tailed or two-tailed, as appropriate) were used to analyze treatment effect at 
specific experimental time points as per our a priori hypotheses. All data were analyzed 
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using Statistical Package for the Social Sciences (Chicago, IL, version 18.0). The criterion for 
statistical significance of between-group differences was set at p < 0.05.  
Bivariate Pearson's correlations were used to examine the statistical relation between 
measures of depression-like behavior and neurobiological changes in CORT and vehicle 
groups of rats in treatment cycles one and three. The criterion for statistical significance of 
these correlational analyses was set at p < 0.05.  
 
3.3. Results 
3.3.1. Effects of Repeated and Cyclic CORT Treatment on Body Weight 
	
Figure 3-2 illustrates the mean body weight for the rats in both groups at different 
time points throughout the experiment. The two-way ANOVA revealed a significant main 
effect of time [F(8, 166) = 61.657, p < 0.001] and treatment [F(1, 166) = 37.92, p < 0.001] on 
body weight. There was no significant interaction of treatment by time (p = 0.521). 
In cycle 1, the CORT rats weighed significantly less than the vehicle rats at all time 
points: after 10 days of treatment, after 21 days of treatment, and after recovery [t(18) = 
3.299, p < 0.0001; t(19) = 1.864, p = 0.039; t(19) = 2.01, p = 0.029, respectively]. Similarly, 
in cycle 2, the CORT rats also weighed significantly less than the vehicle rats after 10 and 21 
days of treatment [t(19) = 2.028, p = 0.029; t(18) = 2.84, p = 0.002, respectively], but after 
recovery the difference between the CORT rats and vehicle rats narrowly missed statistical 
significance [t(18)= 1.547, p = 0.069]. Cycle 3 looked very much like cycle 1, with the 
CORT rats weighing significantly less than the vehicle rats at all time points [day 11: t(18) = 
1.935, p = 0.035; day 22: t(17) = 2.543, p = 0.011; recovery: t(20) = 1.749, p = 0.048]. 
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Figure 3-2.  The effect of one, two, and three cycles of repeated corticosterone (CORT) 
injections on body weight. The CORT rats weighed less than the vehicle rats at all time 
points of the experiment. Asterisks (*) indicate significant differences between CORT and 
vehicle groups at specific time points (p < 0.05). Error bars denote the standard error of the 
mean (SEM). 
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3.3.2. Effects of Repeated and Cyclic CORT Treatment on Forced Swim Test Behaviors 
	
 Figure 3-3 shows the effects of cyclical CORT treatment on FST behaviors 
throughout the three cycles of treatment.  
 
3.3.2.1. Immobility 
The two-way ANOVA revealed a significant main effect of time [F(8, 162) = 9.577, p 
< 0.001] and treatment [F(1, 162) = 20.304, p < 0.001] on immobility. There was no 
significant interaction of treatment by time (p = 0.174). 
In cycle 1, we found no significant difference between CORT and vehicle rats in the 
amount of time spent immobile after 10 days of treatment [t(18) = 1.245, p = 0.115]. 
However, after 21 days of treatment, the CORT rats spent significantly more time immobile 
than the vehicle rats [t(19) = 2.249, p = 0.019]. After the recovery period, the CORT and 
vehicle rats did not differ in the amount of time spent immobile [t(19) = 0.136, p = 0.297]. 
In cycle 2, the CORT rats spent significantly more time immobile than the vehicle rats 
after 10 days of treatment [t(18) = 1.902, p = 0.037], and continued to do so after 21 days of 
treatment [t(18) = 2.946, p = 0.005]. No statistical difference was found in immobility time 
between groups after the recovery period [t(20) = 1.009, p = 0.163]. 
Similarly, in cycle 3, the CORT rats spent significantly more time immobile 
compared to the vehicle rats after 10 days of treatment [t(18) = 3.984, p = 0.0005], and 
continued to do so after 21 days of treatment [t(18) = 2.946, p = 0.005]. No statistical 
difference was found in immobility between the groups after the recovery period [t(20) = 
1.009, p = 0.163].  
 
3.3.2.2. Latency to immobility 
The two-way ANOVA revealed a significant main effect of time [F(8, 162) = 5.368, p  
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Figure 3-3. The effect of one, two, and three cycles of repeated corticosterone (CORT) 
exposure on behavior in the forced swim test (FST): immobility - panel (A), latency to 
immobility - panel (B), climbing - panel (C), and swimming - panel (D). CORT produced 
increases in immobility behavior and decreases in swimming behavior in all three treatment 
cycles. Rats treated with CORT spent significantly more time immobile and less time 
swimming and climbing at the end of treatment cycle one. Following CORT re-exposure in 
the second and third cycles, the CORT rats showed a sensitized increase in immobility and 
decrease in swimming after only ten days of treatment. Asterisks (*) indicate significant 
differences between CORT and vehicle groups at specific time points (p < 0.05). Error bars 
represent the standard error of the mean (SEM). 
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< 0.001] and treatment [F(1, 162) = 6.335, p = 0.013] on latency to immobility. There was no 
significant interaction of treatment by time (p = 0.916). 
In general, there were few significant group differences in latency to immobility. All 
group differences were nonsignificant, except for two time points – recovery after cycle 2 
[t(14.27) = 2.027, p = 0.03] and after 10 days of treatment in cycle 3 [t(18) = 3.984, p = 
0.042]. In both of these cases, the CORT rats had a shorter latency to immobility than the 
vehicle rats.  All other group differences were nonsignificant (all p values > 0.21).  
 
3.3.2.3. Climbing 
The two-way ANOVA revealed a significant main effect of time [F(8, 162) = 6.964, p 
< 0.001] on climbing. There was no significant main effect of treatment (p = 0.166) or 
interaction of treatment by time (p = 0.773). 
No statistical differences between the groups were observed in climbing at any time 
point of the experiment (all p values > 0.18), with exception of cycle 3 (after 10 days of 
treatment) [t(14.27) = 2.535, p = 0.01]. 
 
3.3.2.4. Swimming 
The two-way ANOVA revealed a significant main effect of time [F(8, 162) = 2.477, p 
= 0.015] and treatment [F(1, 162) = 39.355, p < 0.001] on swimming. Additionally, there was 
a significant interaction of treatment by time [F(8, 162) = 2.216, p = 0.007]. 
In cycle 1, we found no significant difference between the CORT and vehicle rats 
after 10 days of treatment (p > 0.05). However, after 21 days of treatment, the CORT rats 
showed significantly less swimming than did the vehicle rats [t(13.75) = 4.00, p = 0.001]. 
After the recovery	period, CORT and vehicle rats did not differ in the amount of time spent 
swimming (p = 0.209). 
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 In cycle 2, the CORT rats swam significantly less than vehicle rats after ten days of 
treatment [t(15.605) = 3.157, p = 0.003], and continued to do so after 21 days of treatment 
[t(14.107) = 3.539, p = 0.001]. No statistical difference between the groups was found after 
the recovery period (p = 0.78). 
 Similarly, in cycle 3, the CORT rats swam significantly less than the vehicle rats after 
10 days of treatment [t(18) = 4.796, p = 0.001], and continued to do so after 21 days of 
treatment [t(14) = 3.917, p = 0.001]. No statistical group difference was found in swimming 
after the recovery period (p = 0.608).  
 
3.3.3. Effects of Repeated and Cyclic CORT Treatment FST Behaviors Controlled for 
Body Weight 
 To account for the influence of body weight increases on FST behaviors, ratio scores 
were calculated and statistically analyzed. T/BW = ratio score, where T is the ime the subject 
spent engaging in FST behaviors (immobility, climbing, etc.) in seconds, and BW is rat’s 
body weight in grams at the time of testing. Figure 3-4 shows the mean ratio scores in each 
treatment group for the FSTs conducted during cycle 1 through 3.   
 
3.3.3.1. Immobility to Body Weight (IBW) Ratio 
	
The two-way ANOVA revealed a significant main effect of time [F(8, 162) = 9.141, p 
< 0.001] and treatment [F(1, 162) = 51.652, p < 0.001] on immobility/body weight (IBW) 
ratio. Additionally, there was a significant interaction of treatment by time [F(8, 162) = 
1.953, p = 0.05]. 
CORT treatment had significant effects on the IBW ratio during all three cycles. In 
cycle 1, 20 mg/kg CORT rats showed smaller ratio scores than did the vehicle rats in both 
FST-1  [t(18) = 2.04, p = 0.05] and FST-2 [t(19) = 2.4, p = 0.027], after 10 and 21 days of 
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Figure 3-4.  The effect of repeated and cyclic corticosterone (CORT) on the forced swim test 
(FST) behavior plotted by body weight. Panel (A) shows the immobility time to body weight 
ratio, panel (B) shows the latency to immobility to body weight (IBW) ratio, panel (C) shows 
the climbing time to body weight ratio, and panel (D) shows the time spent swimming to 
body weight (SBW) ratio. Rats treated with CORT exhibited larger IBW ratio and lower 
SBW scores at the end of treatment cycle one. Following CORT re-exposure in the second 
and third cycles, the CORT rats showed a sensitized increase in the IBW scores and 
decreases in SBW scores after only ten days of treatment. Asterisks indicate significant 
differences between groups at specific time points (p < 0.05). Error bars denote the standard 
error of the mean (SEM).  
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treatment, respectively. No significant group differences were found after recovery on FST-3 
(p = 0.409).  
Similarly, in cycle 2, 20 mg/kg CORT rats had lower IBW ratio scores than the 
vehicle rats after 10 days of treatment on FST-4 [t(18) = 2.85, p = 0.011], and after 21 days 
of treatment on FST-5 [t(18)  = 5.94, p < 0.001]. No significant group differences were found 
after recovery on FST-6 (p = 0.656).  
In cycle 3, 20 mg/kg CORT rats showed lower IBW ratio scores than did the vehicle 
rats after 10 days and 21 days of treatment on FST-7 [t(18) = 4.6, p < 0.001] and on FST-8 
[t(14)  = 3.085, p = 0.008]. Additionally, a significant difference between groups on IBW 
ratios was found in FST-9, after the recovery [t(20)  = 2.43, p = 0.024].  
 
3.3.3.2. Latency to Immobility to Body Weight (LIBW) Ratio 
	
The two-way ANOVA revealed a significant main effect of time [F(8, 162) = 15.395, 
p < 0.001] on latency to immobility/body weight (LIBW) ratio. There was no main effect of 
treatment (p = 0.518), or interaction of treatment by time (p = 0.982). 
No statistical differences between the groups were observed in LIBW ratios at any 
time point of the experiment (all p values > 0.138). 
	
3.3.3.3. Climbing to Body Weight (CBW) Ratio 
	
The two-way ANOVA revealed a significant main effect of time [F(8, 162) = 15.701, 
p < 0.001] on climbing/body weight (CBW) ratio. There was no main effect of treatment (p = 
0.984), or interaction of treatment by time (p = 0.949). 
No statistical differences between the groups were observed in CBW ratios at any 
time point of the experiment (all p values > 0.19).	
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3.3.3.4. Swimming to Body Weight (SBW) Ratio 
	
The two-way ANOVA revealed a significant main effect of time [F(8, 162) = 9.686, p 
< 0.001] and treatment [F(1, 162) = 23.742, p < 0.001] on swimming/body weight (SBW) 
ratio. Additionally, there was a significant interaction of treatment by time [F(8, 162) = 
2.127, p = 0.012]. 
In cycle 1, we found no significant difference between the CORT and vehicle rats 
after ten days of treatment (p = 0.629). However, after 21 days of treatment, the CORT rats 
had significantly lower SBW ratios than did the vehicle rats [t(15.9) = 3.67, p = 0.002]. After 
the recovery	period, CORT and vehicle rats did not differ in SBW ratios (p = 0.321). 
 In cycle 2, the CORT rats showed significantly lower SBW ratios than did vehicle rats 
after 10 days of treatment [t(18) = 2.78, p = 0.012], and continued to do so after 21 days of 
treatment [t(18) = 2.79, p = 0.012]. No statistical difference between the groups was found 
after the recovery period (p = 0.92). 
 Similarly, in cycle 3, the CORT rats had significantly smaller SBW ratios than the 
vehicle rats after 10 days of treatment [t(18) = 3.48, p = 0.003], as well as after 21 days of 
treatment [t(14) = 3.63, p = 0.003]. No statistical group difference was found in SBW ratios 
after the recovery period (p = 0.395). 
	
3.3.4. Assesment of Recovery of Immobility Behavior Across Three Cycles of CORT 
Treatment 
To evaluate the quality of recovery across three cycles of CORT treatment, the 
percent change in immobility time and IBW ratio in the CORT rats were calculated. In the 
present experiment, obtaining the individual values of the percent recovery is not possible 
due to the non-repeated measures design (no pairwise comparisons). Thereore,  for 
calculations, we obtained the difference in the group mean scores in the FST on day 22 and 
after recovery, and then divided that amount by the day 22 FST mean score, and multiplied 
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by 100. The analogous calculations were carried out for cycles two and three. The results are 
listed in Table 3-1. 
	
3.3.5. Effects of Repeated and Cyclic CORT Treatment on Open Field Test Behavior 
Figure 3-5A shows the effect of CORT on behavior in the OFT. The two-way 
ANOVA revealed a significant main effect of time [F(8, 166) = 5.149, p < 0.001] on total 
OFT activity (the number of total lines crossed and rearing counts). There was no main effect 
of treatment (p = 0.204) or interaction of treatment by time (p = 0.861). 
The separate t-test analyses confirmed no significant differences between the groups 
in total OFT activity at any time point of the experiment (all p values > 0.094). 
 
3.3.6. Effects of Repeated and Cyclic CORT Treatment on Sucrose Preference Test 
Behavior 
Figure 3-5B illustrates the effect of CORT on behavior in the SPT throughout the 
three cycles of treatment and recovery. The two-way ANOVA revealed a significant main 
effect of time [F(8, 154) = 1.993, p = 0.05] and treatment [F(1, 154) = 10.117, p = 0.002] on 
sucrose preference. There was no significant interaction of treatment by time (p = 0.231). 
 In cycle 1, we found no significant difference between the CORT and vehicle rats in 
sucrose preference at 10 or 21 days of treatment. Similarly, no difference in sucrose 
preference was observed after the recovery period [all p values > 0.25]. 
 In cycle 2, no statistically significant group difference was observed in sucrose 
preference after 10 days of treatment [t(17) = 1.094, p = 0.145]. After 21 days however, the 
CORT rats had a significantly reduced preference for sucrose [t(17) = 2.525, p = 0.015]. 
After recovery, sucrose preference was similar in both groups [t(16) = 0.744, p = 0.234].  
Similarly, in cycle 3, no statistically significant group difference was observed in sucrose  
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Table 3-1. Changes in recovery over three cycles of corticosterone (CORT) treatment. The 
listed values are the percent change in the group mean immobility time and IBW ratio in the 
20 mg/kg CORT group. For details see the text. 
	
	
 Immobility Time,  
% change 
Immobility to Body 
Weight Ratio,  
% change 
Recovery, Cycle 1  
4.4% 
 
25.1% 
 
Recovery, Cycle 2  
17.2% 
 
 
31.5% 
 
Recovery, Cycle 3  
11.7% 
 
 
22.7% 
 
  
	 90	
A B 
Figure 3-5. The effect of one, two, and three cycles of repeated corticosterone (CORT) 
exposure on behavior in the open field (A) and in the sucrose preference test (B). CORT 
produced significant decreases in sucrose preference after 21 days of treatment in cycles two 
and three, but not in cycle one. There were no group differences in general locomotor 
behavior. Asterisks (*) denote a significant difference between the CORT and vehicle groups 
at specific time points (p < 0.05). Error bars represent the standard error of the mean (SEM). 
Arb. units, arbitrary units; OFT, open field test.  
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preference after 10 days of treatment [t(15) = 1.253, p = 0.118], but after 21 days, the CORT 
rats had a reduced preference for sucrose [t(16) = 1.883, p = 0.039]. Again, sucrose 
preference was similar in both groups after recovery [t(18) = 0.409, p = 0.334].	
	
3.3.7. Effects of Repeated and Cyclic CORT Treatment on the total DCX+ cell number 
in SGZ and GCL  
Figure 3-6 shows the effect of CORT on the number of immature granule neurons in 
the SGZ and GCL. The two-way ANOVA revealed a significant main effect of time [F(8, 73) 
= 33.87, p < 0.001] and treatment [F(1, 73) = 32.092, p < 0.001] on the number of DCX+ 
cells in SGZ and GCL. There was no significant interaction of treatment by time (p = 0.26). 
In cycle 1, the CORT had fewer DCX positive cells in the SGZ and GCL on days 11 
and 22 compared to the vehicle rats, but these differences narrowly missed statistical 
significance [all p values > 0.07]. After the recovery period, the CORT rats did have 
significantly fewer DCX positive cells than did the vehicle rats [t(9) = 3.471, p = 0.004].  
In cycle 2, no significant differences were observed between CORT and vehicle rats 
in the number of DCX positive cells after ten days of treatment [t(8) = 1.459, p = 0.092]. 
However, after 21 days of treatment, the CORT rats had significantly fewer DCX positive 
cells compared to the vehicle rats [t(8) = 2.739, p = 0.013]. This trend continued after 
recovery, but the group differences narrowly missed statistical significance [t(8) = 1.659, p = 
0.068]. 
In cycle 3, no differences were observed between the CORT and vehicle rats in the 
number of DCX positive cells after 10 days of treatment [t(8) = 1.457, p = 0.092]. After 21 
days of treatment, the CORT rats had significantly fewer DCX positive cells compared to the 
vehicle rats [t(8) =2.76, p = 0.013]. After recovery, no statistical difference was found 
between groups [t(8) = 0.515, p = 0.621]. 
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A 
 
  
B Vehicle, 1 cycle Vehicle, 2 cycles Vehicle, 3 cycles 
CORT, 1 cycle CORT, 2 cycles CORT, 3 cycles 
 
 
Figure 3-6.  The effect of one, two, and three cycles of repeated corticosterone (CORT) 
treatment on the number of doublecortin (DCX)-positive cells in the subgranular zone (SGZ) 
and granule cell layer (GCL): Panel (A) shows the number of DCX-positive cells in the 
CORT and vehicle groups at different points of CORT exposure and recovery. Panel (B) 
shows representative micrographs of DCX immunoreactivity at the end of each cycle of 
CORT treatment. CORT treatment produced accumulative decreases in the number of DCX-
positive cells in SGZ and GCL. Error bars represent the standard error of the mean (SEM). 
Asterisks (*) denote statistical significance between groups at specific time points (p < 0.05).  
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3.3.7.1. Effects of Repeated and Cyclic CORT Treatment on Maturation of DCX+ 
neurons in the Subgranular Zone and Granule Cell Layer 
To assess the effect of CORT on the maturation rate of newborn granule cells, we 
examined dendritic complexity in a subset of DCX positive cells in rats treated for one cycle 
(CORT and vehicle) and rats treated for three cycles (CORT and vehicle). Each DCX 
positive cell was placed into a category based on the presence and extent of dendritic 
branching (Figure 3-7B). The results of this analysis are shown in Figure 3-7A.  The two-way 
ANOVA analyses revealed no main effect of time on the percentage of category one, two, 
three, five, and six DCX+ cells (all p values > 0.09), however there was a significant main 
effect of time on the percentage of category four DCX+ cells [F(1,15) = 4.647, p = 0.048]. 
No main effect of treatment was found on the percentage of category one DCX+ cells (p = 
0.411), however the significant main effects of treatment were observed on the percentage of 
category two [F(1,15) = 8.187, p = 0.012], category three [F(1,15) = 9.551, p = 0.007], 
category four [F(1,15) = 8.758, p = 0.010], category five [F(1,15) = 38.922, p < 0.001], and 
category six DCX+ cells [F(1,15) = 16.174, p = 0.001]. No significant interactions of time by 
treatment were found (all p values > 0.233). 
Separate t-test analyses at specific time points revealed, in cycle 1, CORT rats had a 
significantly larger percentage of category three and four cells compared to the vehicle rats 
[t(8) = 1.967, p = 0.043; t(8) = 2.878, p = 0.019, respectively]. However, the CORT rats had 
significantly fewer category five and six DCX positive cells [t(8) = 3.531, p = 0.007; t(8) = 
3.268, p = 0.012]. In cycle 3, the CORT rats had a significantly higher percentage of category 
two DCX positive cells [t(7) = 4.823, p = 0.001], and significantly lower percentage of 
category five cells [t(7) = 4.596, p = 0.001] and category six cells [t(4.85) = 3.326, p = 0.022] 
compared to the vehicle rats. 
 
 
	 94	
A   
  
  
B   
 
 
Figure 3-7.  The effect of one and three cycles of repeated corticosterone (CORT) treatment 
on the maturation of doublecortin (DCX)-positive cells in the subgranular zone (SGZ) and 
granule cell layer (GCL): Panel (A) shows the percentage of cells placed into each category 
in the CORT and vehicle groups, treated for one or three cycles. Panel (B) provides an 
example the six categories of neuron maturation stages used in this analysis (image adapted 
from Lussier et al., 2013). CORT treatment affected the percentage of cells in categories two, 
five, and six, with a total increase in the percentage of category two DCX-positive cells 
(immature stage of development) and a total decrease in the percentage of category five and 
six cells (more mature stages of development). Error bars denote the standard error of the 
mean (SEM). Asterisks (*) indicate overall significant differences between CORT and 
vehicle groups; letters (a) and (b) indicate significant differences between two vehicle groups 
(treated with one and three cycles) and CORT groups (treated with one and three cycles), 
respectively (p < 0.05). 
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3.3.8. Effects of Repeated and Cyclic CORT Treatment on REST Levels in the 
Hippocampus 
3.3.8.1 REST Expression Levels in CA Pyramidal and Granule Cell Layers  
	
Figure 3-8 illustrates the effect of CORT on REST immunoreactivity in several 
hippocampal regions in cycles one and three. The two-way ANOVA analyses revealed a 
significant main effect of time on REST optical density in CA1 and CA3 pyramidal cell 
layers [F(1,14) = 5.278, p = 0.038 and F(1,14) = 7.779, p = 0.014, respectively], but not in 
the GCL (p = 0.084). No significant main effects of treatment were found on REST optical 
density in CA1, CA3 pyramidal cell layers, or GCL (all p values > 0.361). There was a 
significant interaction of time by treatment on REST optical density in GCL [F(1,14) = 
5.377, p = 0.036]. 
The treatment effects at specific time points of the experiment were analyzed using 
separate t-tests. In cycle 1, the CORT rats had a small increase in REST expression in the 
CA1 and CA3 pyramidal layers and the GCL compared to the vehicle rats, but the difference 
did not reach statistical significance (all p values > 0.414). In cycle 3, the CORT rats had 
decreased REST expression in the CA3 pyramidal layer [t(7) = 2.562, p = 0.037] and GCL 
[t(7) = 3.860, p = 0.006] compared to the vehicle rats. There were no group differences in the 
CA1 pyramidal layer (p = 0.365). 
Within the control rats, vehicle rats treated for three cycles had a significant increase 
in REST expression in the GCL, CA1 and CA3 pyramidal layers [t(8) = 3.359, p = 0.01; t(8) 
= 3.906, p = 0.005; t(5.14) = 3.452, p = 0.017, respectively]. No significant differences in 
these hippocampal subregions were found between CORT rats treated for one and three 
cycles  (all p values > 0.541). 
	
3.3.8.2. REST+ Cell Counts in Hippocampal Subregions 
	
Figure 3-9 illustrates the effect of CORT on the number of REST positive cells in  
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Figure 3-8. The effect of one and three cycles of repeated corticosterone (CORT) treatment 
on RE-1 Silencing Transcription factor (REST) protein density in several hippocampal 
regions: Panel (A) shows quantified REST levels in the hippocampal CA1 pyramidal cell 
layer, Panel (B) – in the CA3 pyramidal cell layer, and Panel (C) in the granule cell layer 
(GCL). Representative photomicrographs of REST protein density in the CA1 and CA3 
(Panel (D) pyramidal cell layers, and GCL (Panel (E) in CORT and vehicle rats for one or 
three cycles. REST optical density was decreased in CORT rats compared to vehicle rats in 
the CA3 pyramidal cell layer and GCL in cycle three. Error bars denote the standard error of 
the mean (SEM). Letter (a) denotes significant differences between CORT and vehicle 
groups treated for three cycles; letter (b) denotes differences between two vehicle groups 
(treated for one and three cycles) (p < 0.05).  
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Figure 3-9. The effect of one and three cycles of repeated corticosterone (CORT) treatment 
on the number of RE-1 Silencing Transcription factor (REST)-positive cells in several 
hippocampal regions: Panel (A) the stratum lacunosum, Panel (B) the hilus, Panel (C) the 
CA1 stratum oriens (SO), Panel (D) the CA1 stratum radiatum (SR), Panel (E) the CA3 
stratum oriens (SO), and Panel (F) the CA3 stratum radiatum (SR). Panel (G) shows 
representative photomicrographs of REST immunohistochemistry in these hippocampal 
regions from CORT and vehicle rats treated for one and three cycles. Bi-directional changes 
in REST expression were observed in several hippocampal subregions, with overall increases 
in REST+ cell counts after one cycle of CORT treatment and overall decreases after three 
cycles of CORT treatment. Error bars denote the standard error of the mean (SEM). Letters 
(a), and (b) represent significant differences between CORT and vehicle groups treated for 
three cycles and one cycle, respectively (p < 0.05).    
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several hippocampal subregions in cycles one and three. The two-way ANOVA analyses 
revealed no significant main effects of time or treatment on the total number of REST+ cells 
in hilus, stratum lacunosum, CA1 strata radiatum and oriens, and CA3 strata radiatum and 
oriens (all p values > 0.116). However, significant interactions of time by treatment were 
observed on the number of REST+ cells in hilus [F(1,15) = 8.479, p = 0.011], stratum 
lacunosum [F(1,15) = 8.715, p = 0.01], CA1 stratum oriens [F(1,15) = 8.421, p = 0.011], 
CA1 stratum radiatum [F(1,15) = 16.625, p = 0.001], and CA3 stratum oriens [F(1,15) = 
12.531, p = 0.003]. 
The treatment effects at specific time points of the experiment were analyzed using 
separate t-tests. In cycle 1, the CORT rats had a significant increase in the number of REST 
positive cells in the CA1 stratum radiatum [t(8) = 3.126, p = 0.014] and CA3 stratum 
radiatum [t(8) = 4.101, p = 0.003] compared to the vehicle rats. A similar increase was 
observed in other quantified regions of hippocampus, but the group differences did not reach 
statistical significance (all p values > 0.07). 
 In contrast to the results for cycle 1, in cycle 3 the CORT rats had fewer REST 
positive cells than the vehicle rats in the hilus [t(7) = 4.317, p = 0.003], the stratum 
lacunosum [t(7) = 2.979, p =  0.021], the CA1 stratum radiatum [t(7) = 2.662, p = 0.032], 
and the CA3 stratum oriens [t(7) = 4.175, p = 0.004].  
	
3.3.9. Analyses of Correlations 
	
Figure 3-10 depicts a number of correlations between measures of depression-like 
behavior and neurobiological changes in the CORT and vehicle rats in cycles one and three.  
	
3.3.9.1. Correlations between Behavioral Measures and DCX+ Cell Counts and 
Maturation Rate 
Pearson’s correlation analyses revealed that the time spent immobile was strongly and  
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Figure 3-10. Correlations between measures of depression-like behavior and neurobiological 
changes in the corticosterone (CORT) and vehicle rats in cycles one and three. Correlation of 
immobility behavior with the total number of doublecortin (DCX)-positive cells in the 
granule cell layer (GCL) and subgranular zone (SGZ), (r = −0.705, p = 0.001) (A), with the 
percentage of DCX-positive category three cells (r = 0.577, p = 0.012) (B), and with the 
percentage of DCX-positive category six cells (r = −0.596, p = 0.009) (C). Correlation of 
immobility behavior with the number of RE-1 Silencing Transcription factor (REST)-positive 
cells in the stratum lacunosum, in cycle one (r = 0.730, p < 0.05) (D). Correlation of the total 
number of DCX-positive cells in GCL and SGZ with REST optical density in the GCL in 
cycle three (r = 0.853, p < 0.05) (E). Correlation of immobility behavior with the number of 
REST-positive cells in the CA1 stratum radiatum in cycle one (r = 0.733, p < 0.05) (F), with 
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the number of REST-positive cells in the CA1 stratum radiatum in cycle three (r = 0.532, p < 
0.05) (G). Correlation of the number of REST-positive cells in the hilus with swimming in 
cycle three (H). Correlation of sucrose preference with REST optical density in the GCL in 
cycle one (I) and with REST optical density in the hilus in cycle three (r = 0.931, p < 0.001) 
(J). Correlation of the number of REST-positive cells in the CA1 stratum radiatum with the 
percentage of DCX-positive category six cells in cycle one (r = −0.740, p < 0.05) (K). 
Correlation of REST optical density in the GCL with the percentage of DCX-positive 
category five cells in cycle three (r = 0.827, p < 0.05) (L).  
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inversely associated with the number of DCX+ cells in GCL and SGZ (Figure 3-10A; r = 
−0.705, p = 0.001, N = 18). Additionally, immobility was positively correlated with the 
percentage of category three DCX+ cells (Figure 3-10B; r = 0.577, p = 0.012, N = 18), and 
negatively correlated with the percentage of category six DCX+ cells (Figure 3-10C; r = 
−0.596, p = 0.009, N = 18). Swimming behavior and latency to immobility were positively 
correlated with the number of DCX+ cells in GCL and SGZ (r = 0.748 and r = 0.526, 
respectively; p = 0.001, N = 18). 
 
3.3.9.2. Correlations between REST (Cell Counts and Optical Density) and DCX+ Cell 
Counts and Maturation Rate 
Due to bi-directional changes in REST, correlational analyses involving REST were 
conducted separately for treatment cycle 1 and cycle 3. In cycle 3, REST protein optical 
density in the GCL (Figure 3-10E), CA3 and CA1 pyramidal cell layers was positively 
correlated with the number of DCX+ cells (r = 0.853, r = 0.835, and r = 0.962, p < 0.05, N = 
6, respectively). Additionally, the number of DCX+ cells in the stratum lacunosum was 
correlated with the number of DCX+ cells (r = 0.969, p = 0.001, N = 7). 
With regard to neuronal maturation, in cycle 1 there was a significant positive 
correlation between the number of REST+ cells in the CA1 stratum oriens and the percentage 
of category three cells in the GCL and SGZ (r = 0.763, p < 0.05, N = 8). In contrast, the 
percentage of category six DCX+ cells in the GCL and SGZ was inversely correlated with the 
number of REST+ cells in CA1 stratum radiatum (Figure 3-10K) and CA3 stratum radiatum 
(r = −0.740, and r = −0.760, p < 0.05, N = 8, respectively). In cycle 3, the percentage of 
category five DCX+ cells was positively correlated with REST optical density in the GCL 
(Figure 3-10L; r = 0.827, p < 0.05, N = 7).  
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3.3.9.3. Correlations between REST (Cell Counts and Optical Density) and Behavioral 
Measures 
Sucrose preference was positively correlated with REST optical density in the GCL 
(Figure 3-10I) and with the number of REST+ cells in the hilus (Figure 3-10J) in cycle 3 only 
(r = 0.698, and r = 0.706, p < 0.05, N = 9, respectively). Finally, the time spent immobile was 
positively correlated with the number of REST+ cells in cycle 1 (Table 3-1), and inversely 
correlated with the number of REST+ cells in cycle 3 (Table 3-2). Conversely, time spent 
swimming was positively correlated with the number of REST+ cells in hilus, in cycle 3 
(Figure 3-10H; r = 0.931, p < 0.001, N = 9). 
 
3.4. Discussion 
 
The results of this experiment can be summarized as follows. We found that 3 cycles 
of repeated CORT administration produced time-dependent increases in depression-like 
behavior and decreases in neurogenesis that are consistent with the results of previous 
experiments (Lussier et al., 2013; review in Sterner & Kalynchuk, 2010). In addition, CORT 
had significant effects on dendritic complexity in newborn dentate granule neurons, 
indicating that cell maturation is dysregulated in rats exposed to repeated treatment with 
glucocorticoids. Finally, CORT altered REST protein immunoreactivity in various regions of 
the hippocampus, providing evidence of altered transcriptional regulation. These findings are 
discussed in more detail in the following paragraphs.  
	
3.4.1 Repeated and Cyclic Treatment with CORT Resulted in Progressively Larger 
Changes in FST Behaviors 
In cycle 1, the CORT rats exhibited more immobility and less swimming in the FST 
after 21 days of treatment, but not after 10 days of treatment, which is consistent with 
previous reports (Brotto et al., 2001; Mitra & Sapolsky, 2008), and with the results of our  
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Table 3-2.  Correlations between immobility in the forced swim test (FST) and RE-1 
silencing transcription factor (REST) immunoreactivity in different subfields of 
hippocampus: hilus, stratum lacunosum, CA1.SO and CA3.SO (stratum oriens), CA1.SR and 
CA3.SR (stratum radiatum), in cycle 1. Asterisks (*) denote significant correlations (p < 
0.05, N = 9). 
 
Pearson’s r Hilus Stratum 
Lacunosum 
CA1.SO CA1.SR CA3.SO CA3.SR 
Immobility 0.627 0.730* 0.679* 0.733* 0.412 0.576 
 
Table 3-3. Correlations between immobility in the forced swim test (FST) and RE-1 
silencing transcription factor (REST) immunoreactivity in different subfields of 
hippocampus: hilus, stratum lacunosum, CA1.SO and CA3.SO (stratum oriens), CA1.SR and 
CA3.SR (stratum radiatum), in cycle 3. Asterisks (*) denote significant correlations (p < 
0.05, N = 9). 
 
Pearson’s r Hilus Stratum 
Lacunosum 
CA1.SO CA1.SR CA3.SO CA3.SR 
Immobility 0.890* 0.594 0.339 0.532* 0.811* 0.174 
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first experiment (Chapter 2). After 21 days of injection-free recovery, a decrease in 
immobility and increases in swimming and latency to immobility were observed. Finally, 
during the re-exposure to CORT treatment in cycle 2, a significant increase in depression-like 
behavior was re- established after only ten days of CORT administration, indicating that only 
half of the initial CORT exposure (10 days) was sufficient to produce depression-like 
behaviors in CORT rats in cycle 2.  Similarly, following the second recovery period, the third 
re-exposure to CORT resulted in a pronounced increase in immobility, and decreases in 
swimming and climbing after ten days of CORT injections. The re-establishment of the 
depression-like behavior following shorter periods of glucocorticoid exposure suggests that 
the rats may have become sensitized to the deleterious effects of CORT over successive 
cycles of exposure. These results support previous studies showing sensitization of 
depression-like behavior in adult rats exposed to one week of variable stress and re-exposed 
to 90 min of restraint stress (Zurita et al., 2000). Additionally, it has been shown that 
chronically-stressed animals subjected to novel acute stressors show a sensitized release of 
stress hormones (Konarska, Stewart, & McCarty, 1989; Pardon, Ma, & Morilak, 2003) and 
neurotransmitters (Nisenbaum, Zigmond, Sved, & Abercrombie, 1991).  
Importantly, the vehicle rats again have exhibited gradual increases in immobility 
from treatment cycle 1 to treatment cycle 2, similar to the results observed in Experiment 1 
(Chapter 2) of this dissertation. In Chapter 2, we hypothesized that repetitive behavioral 
testing or task learning could have accounted for the slow increase in immobility seen in 
control conditions. The results observed here go against that hypothesis, as the non-repeated 
FST method used in this experiment produced analogous results, suggesting that other factors 
could be confounding the results of the FST behavior in rats, including aging, body weight 
changes, mild stress from daily subcutaneous saline injections, or stress from isolated single-
housing of rats. Interestingly, the time spent immobile plateaus from cycle 2 to cycle 3 in the 
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vehicle rats, indicating that the potential effects of confounding factors are diminished at later 
stages of the experiment. Given the results of these experiments, the interpretation of 
sensitization of CORT-induced effects in the FST should be made with caution. It is possible 
that the sensitization could be inferred from the behavior in cycle 3 only, considering that the 
immobility behavior of vehicle rats stabilizes at these time points. Similar to Experiment 1, 
we have created and analyzed ratio scores in the attempt to account for the potential effect of 
body weight increases on the FST behaviors. Again, the IBW ratio of the vehicle rats 
eliminated the nonspecific increase in immobility in these rats that was seen over the course 
of three cycles of testing, whereas the CORT rats exhibited the expected cycling in 
immobility behavior throughout treatment with and recovery from CORT exposure.  
Data from this experiment further provide some support for recovery worsening in 
CORT-treated rats (observed in the original Experiment in Chapter 2) across three cycles of 
treatment (Table 3-1). Interestingly, CORT rats have showed not only a lower rate of 
recovery in cycle three compared to cycle two, but also their IBW ratio during recovery in 
cycle three was significantly different from the vehicle rats’ IBW ratio. This finding indicates 
that IBW ratio of CORT rats no longer normalized to the levels of control rats after three 
cycles of treatment. The observed worsening of recovery may be analogous to the 
phenomenon of “partial remission” in treated depressed patients (Fava et al. 2007) and is 
considered an important contributor to the relapse of depression episodes (Moylan et al., 
2012). 
 
3.4.2. Possible Sensitization of the Effect of CORT on Sucrose Preference Across Cycles 
of Treatment 
The effects of CORT on sucrose preference were different across cycles of exposure. 
Specifically, no significant changes in sucrose preference were observed in cycle 1 of CORT 
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treatment, however, after 21 days of the 2nd CORT re-exposure, the CORT rats showed a 
significant decrease in sucrose preference. Finally, after 21 days of the 3rd re-exposure to 
CORT, anhedonia-like behavior was observed again in CORT rats. These results suggest that 
CORT had greater effects on sucrose preference in cycles two and three than in cycle one, 
which again points to a possible sensitization of the depressogenic effects of CORT across 
cycles of exposure. Our findings of behavioral sensitization associated with stress re-
exposure and recurrent depression-like episodes in rats are supported by a paper that reported 
similar, but more pronounced effects of stress on rodent sucrose consumption (Remus et al., 
2013). Specifically, the researchers reported that when rats were exposed to 35 days of CMS 
and 20 days of recovery, and then were re-exposed to CMS for 15 days, they exhibited a 
more rapid decline in sucrose consumption compared with non-stressed control rats. Our 
results also suggest anhedonia sensitization, but at a later time point of stress re-exposure. 
Therefore, it appears that sensitization of stress can occur with other stress paradigms in 
addition to CORT administration, but the exact timing of the sensitization can vary 
depending on differences in experimental protocols such as length and severity of stress 
exposure and the type of behavioral testing that is employed.  
 
3.4.3. CORT- and Vehicle-Treated Rats did not Differ in General Locomotor Behavior 
We found no significant differences in OFT behavior between CORT or vehicle rats 
exposed to one, two or three cycles of treatment. This finding suggests that prolonged 
treatment with CORT does not alter nonspecific locomotor activity. These results are 
consistent with previous findings in our laboratory (Marks et al., 2009), which showed that 
rats treated with CORT for 3 weeks were not different from control rats in the OFT 
locomotor activity and muscle strength in the wire suspension test, suggesting that the effects 
of CORT on depression-like behavior were not accounted for by the general metabolic effect 
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produced by glucocorticoids. Low to moderate levels of CORT are known to have anabolic 
effects, however, at chronically high levels CORT has a catabolic effect on muscle tissue 
(Tempel & Leibowitz, 1994). In the present experiment, we found that the CORT rats 
showed a significant decrease in body weight gain after ten days of treatment, and continued 
to do so throughout the entire experiment. Therefore, it was important to confirm that 
potential catabolic effects of prolonged high CORT levels were not sufficient to affect 
general locomotor activity and cloud the interpretation of the FST behaviors. Studies from 
our laboratory as well as others have shown that CORT-treated rats exhibit similar muscle 
strength on the wire suspension test (Marks et al., 2009), swim the same distance as control 
rats in a Morris Water Maze (Sousa, Lukoyanov, Madeira, Almeida, & Paula-Barbosa, 2000) 
and engage in more lever pressing for electrical stimulation than control rats (Barr et al., 
2000). Taken together, we can conclude that in the present study, repeated and cyclic CORT 
administration produced a significant change in the forced swimming behavior of rats, which 
is indicative of the depression-like phenotype rather than a reduction in general locomotion. 
 
	
3.4.4. Repeated and Cyclic CORT Treatment Decreases the Number of DCX+ Cells and 
their Maturation Rate, in GCL and SGZ 
The present experiment examined whether the accumulative effects of CORT on 
behavior are paralleled by significant changes in hippocampal neurogenesis. Reduced 
neurogenesis is hypothesized to be involved in the pathophysiology of major depression. This 
hypothesis is largely supported by preclinical studies using chronic stress paradigms (Barha, 
Brummelte, Lieblich, & Galea, 2011; Brummelte & Galea, 2010; Duman et al., 2001; Gould 
et al., 1997; Pham et al., 2003; Snyder, Soumier, Brewer, Pickel, & Cameron, 2011). Work 
from our laboratory has shown that repeated administration of CORT produces time-
dependent (7, 14, and 21 days) and dose-dependent (5, 10, and 20 mg/kg) decreases in the 
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number of DCX+ cells and their morphology (Lussier et al., 2013; Lussier, Romay-Tallón, 
Kalynchuk, & Caruncho, 2011). In the present experiment, we discovered that repeated and 
cyclic CORT treatment exerted increasingly greater deleterious effects on the number and 
dendritic complexity of immature dentate granule cells over time. Specifically, we found a 
non-significant decrease in the number of DCX+ cells in the 1st cycle of CORT treatment, 
and significant decreases in the number of DCX+ cells at the end of the 2nd and 3rd CORT re-
exposures. Previous findings in our laboratory (Lussier et al., 2013) have shown that 21 days 
of 40 mg/kg CORT significantly decreases the number of DCX+ cells in the GCL. Here, 
CORT clearly decreased the number of DCX+ cells, but this effect just missed the statistical 
significance. This is likely due to the fact that we used a lower dose of CORT (i.e., 20 mg/kg) 
than the one used in the previous experiment.  
With the exception of the last recovery period, we did not find significant recovery (to 
the levels of control rats) of DCX cell populations after the cessation of CORT treatment, 
unlike the reversal of dendritic retraction of hippocampal neurons that had been reported 
previously (Conrad et al., 1999). This finding supports evidence from clinical studies 
demonstrating that repeated stress during recurrent episodes of major depression may result 
in growing hippocampal injury observed as total volume loss (Sheline et al., 1999). Our data 
are also consistent with reports from preclinical research showing the progressive impairment 
of proliferation and survival of new neurons in the rodent dentate gyrus following three and 
six weeks of restraint stress (Pham et al., 2003). In addition, elevated levels PSA-NCAM 
were reported after three weeks of stress and recovery, but not after six weeks of stress and 
recovery, which suggests that shorter durations of stress may induce adaptive structural 
plasticity, whereas prolonged chronic stress may result in more profound and permanent 
damage to the hippocampus (Pham et al., 2003). Finally, Sapolsky et al. (1985) also 
demonstrated that prolonged CORT injections (at the high physiological range) irreversibly 
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depletes glucocorticoid receptors and produces a significant loss of neurons expressing 
CORT receptors in CA3 subfield of rat hippocampus, closely resembling the characteristics 
of the aged hippocampus (Sapolsky, Krey, & McEwen, 1985).   
Importantly, in the present experiment, we found that vehicle rats also exhibited 
gradual decreases in the number of DCX+ cells over three cycles of injections. Neurogenesis 
is known to decline dramatically throughout adulthood and normal aging in rodents (Kuhn, 
Dickinson-Anson, & Gage, 1996) and humans (Manganas, Zhang, Li, & Hazel, 2007). 
Although the oldest rats in the experiment were approximately 6.5 months old and considered 
to be in the mature adulthood stage (Sengupta, 2013), in addition to potential aging effects it 
is plausible to suggest that daily subcutaneous vehicle injections could be a mild chronic 
stressor for control rats. This could explain the gradual decreases in DCX+ cell number and 
gradual increases in the immobility of our control rats. This is an interesting topic for further 
study because nonspecific alterations in behavior or neurobiological measures over time in 
control rats creates difficulties for the types of longitudinal studies that are needed to fully 
understand the deleterious effects of chronic stress. 
 We also found that DCX+ cells in CORT-treated rats were characterized by reduced 
dendritic complexity compared to vehicle-treated rats. CORT produced significant effects on 
neuronal maturation: CORT treatment was associated with more category two DCX cells (at 
the proliferative stage of development) and fewer category five or six cells (cells with defined 
dendritic branching). In general, a larger percentage of DCX+ cells from the CORT-injected 
rats had no or minimal dendritic branching compared to the vehicle-injected rats. Similarly, a 
smaller percentage of DCX+ cells from the CORT-injected rats had a well-developed 
dendritic tree. These results suggest that in addition to the glucocorticoid-induced cell loss in 
the hippocampus, the newborn cells that do survive show slower maturation that can impede 
their integration into the existing circuitry, and contribute to the impairment of hippocampal 
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plasticity and function. Our data revealed that some changes (percent of category five and six 
cells) in neuronal maturation were observed in cycle 1 and maintained through cycle 3, while 
other changes (percent of category two cells) became statistically significant only in cycle 3.  
Collectively, our findings provide some support to the idea that an exacerbation of 
neuropathological changes accumulating over several episodes of stress/depression may be 
an important factor in mood cycling and susceptibility to relapse.  
Finally, the analyses of correlations revealed that a larger number of DCX+ cells in 
the GCL and SGZ was associated with less time spent immobile in the FST. Furthermore, 
less time spent immobile was associated with a greater percentage of category six (more 
mature) DCX+ neurons and smaller percentage of category three (less mature) neurons. 
These findings further support the role of dysregulated neurogenesis in the development and 
expression of depression-like symptoms in rodents. 
 
3.4.5. Bi-Directional Changes in REST Immunoreactivity and the Number of REST+ 
Cells in Hippocampus of Rats Treated with One or Three Cycles of CORT 
 There is growing evidence that abnormal transcriptional regulation plays a significant 
role in the pathogenesis of many neuropsychiatric disorders, including mood disorders 
(Duman & Monteggia, 2006; Tsankova et al., 2007). REST is a transcription factor that binds 
to the DNA chromatin at the RE1 and other motifs, promoting the repression of various target 
genes, which are largely expressed in neurons (Chong et al., 1995; Schoenherr & Anderson, 
1995; Tapia-Ramírez et al., 1997). Many of those genes (e.g., CRH, BDNF, and 5-HT1A 
serotonin receptor) are altered in conditions of stress and depression (Cieślik et al., 2011; 
Francis, Diorio, Plotsky, & Meaney, 2002; Goodfellow et al., 2009; Kolasa et al., 2014). 
In the present study, we examined how REST protein levels were altered depending 
on the duration of CORT treatment. In the 1st cycle of treatment, we found that the number of 
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REST+ cells was upregulated in CORT-treated rats in several hippocampal subregions (i.e. 
CA1 and CA3 strata radiatum) compared to vehicle-treated rats. Similarly, a recent study 
reported increases in depression-like behavior and mPFC mRNA REST4 levels (a splicing 
variant of REST) in rats subjected to early life maternal separation (Uchida et al., 2010). In 
addition, upregulation and downregulation of a number of target genes within the RE1 site 
were also reported. Interestingly, overexpressing REST in the mPFC in neonatal mice 
resulted in their enhanced vulnerability to developing depression-like behavior and an 
enhanced expression of REST4 target genes. However, overexpressing mPFC REST in adult 
mice did not yield such results (Uchida et al., 2010). Additionally, a study by Mandel et al. 
(2011) reported that the sustained presence of REST (in utero overexpression) inhibited 
neuronal migration and differentiation, resulting in a subcortical band heterotopia-like 
phenotype, similar to the loss of DCX.  Our correlation analyses also demonstrate that higher 
levels of REST in CA3 were associated with lower numbers of DCX+ cells in the GCL and 
SGZ in rats exposed to one cycle of CORT. In addition, lower levels of DCX+ cells and 
higher levels of REST were strongly associated with higher immobility scores of rats in the 
FST.  
Intriguingly, the repressive activity of REST is accompanied by a recruitment of 
histone deacetylases and chromatin-remodelling enzymes, such as methyl CpG binding 
protein 2 (MeCP2) (Ballas et al., 2005), which is also known to be altered in major 
depression (Schroeder et al., 2007; Tsankova et al., 2007). For example, MeCP2-deficient 
hippocampal neurons have fewer dendritic spines and reduced dendritic branching, and 
exhibit impaired neuronal maturation (Smrt & Zhao, 2010; Zhou et al., 2006). Similarly, 
research in our laboratory showed that one cycle of CORT administration upregulated 
MeCP2 expression in the hippocampal SGZ (Fenton & Kalynchuk, unpublished data). 
Furthermore, growing evidence suggests that MeCP2 is directly associated with the 
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regulation of the reelin and BDNF genes (Martinowich et al., 2003; Matrisciano et al., 2013; 
Tsankova et al., 2006), both of which are decreased in depressed patients and in CORT-
treated rats, and are required for normal neurogenesis and neuronal maturation (Fatemi, 
Earle, & McMenomy, 2000; Karege et al., 2002; Lussier et al., 2009; Teixeira et al., 2012; 
Lussier et al., 2013). Together, these findings suggest that activation of REST-mediated 
pathways after the first exposure to CORT could be responsible for the generation of 
depression-like behaviors and dysregulated hippocampal function in rodents. 
In contrast, after three cycles of treatment, the CORT rats exhibited significant 
decreases in both the number of REST+ cells (i.e., in hilus, stratum lacunosum, CA1 stratum 
radiatum, CA3 stratum oriens) and the density of REST protein (i.e., in GCL and CA3 
pyramidal layers) relative to the vehicle rats. Our results demonstrate that CORT exerts bi-
directional changes in REST expression depending on the duration of the exposure. Our 
observation that REST is decreased after three cycles of CORT exposure is supported by a 
clinical study showing that patients with major depression and bipolar disorder have 
significant decreases in REST mRNA in peripheral blood cells while experiencing a 
depressive mood, but not during remission (Otsuki et al., 2010). Unfortunately, no 
information was provided on the number of depressive episodes experienced by the patients 
who participated in the study, therefore, no conclusions about the time-dependent changes of 
peripheral REST mRNA can be drawn. 
REST expression is sensitive to aging and age-related pathologies. Interestingly, a 
loss of REST in hippocampal and PFC neurons was found to be closely associated with 
Alzheimer’s pathology, increased pro-apoptotic gene expression and oxidative stress (Lu et 
al., 2014). And conversely, an increase of REST expression in these neurons during healthy 
aging was correlated to cognitive preservation and longevity in humans (Lu et al., 2014). 
Taking into consideration the high incidence of Alzheimer’s disease in depressed individuals 
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(Olin, Katz, Meyers, Schneider, & Lebowitz, 2002; Saczynski et al., 2010, for review see 
Diniz, Butters, Albert, Dew, & Reynolds, 2013), alterations in REST-mediated pathways 
could be a common underlying pathology of these comorbid disorders. Our results are 
consistent with the hypothesis that REST exerts neuroprotective effects in healthy aging. The 
control rats in our experiment showed significant increases in REST optical density from 
cycle 1 to cycle 3, whereas the CORT rats generally had either no change or less REST after 
cycle 3 than after cycle 1. The CORT-induced deficiency in REST immunoreactivity in GCL 
and CA3 and REST+ cells in several subregions of hippocampus could indicate a loss of 
neuroprotection as a result of multiple bouts of CORT exposure and aging. Additionally, our 
data indicates that in rats treated for three cycles, lower hippocampal REST expression was 
associated with fewer DCX+ neurons, a smaller percentage of category five (mature) dentate 
granule cells, greater immobility in the FST, and decreased sucrose preference. Finally, the 
important role of REST in neurogenesis was highlighted by a study reporting that REST 
impacts adult neurogenesis by restricting the neurogenic program in quiescent stem cells 
(Gao et al., 2011). Gao and colleagues showed that conditional knockout of REST from 
neural stem cells in mice leads to a transient increase in neurogenesis and, ultimately, to a 
depletion of the neural stem cell pool and fewer granule neurons. Taken together, these data 
suggest that altered REST protein expression in the hippocampus could be part of the 
mechanism by which CORT increases depression-like behavior and decreases adult 
hippocampal neurogenesis.  
In summary, the results of this experiment indicate that repeated and cyclic exposure 
to high levels of CORT results in increases in depression-like behaviors, including higher 
immobility and lower sucrose preference scores, but not in general locomotor behaviors. 
These behavioral changes are paralleled by decreases in neurogenesis, specifically the 
number and maturation rates of DCX+ immature neurons in the GCL and SGZ. Furthermore, 
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a precise and time-dependent regulation of REST levels in the hippocampus could play an 
important role in the initiation and progression of depression-like symptoms in rodents. 
Specifically, after the first exposure to CORT, increased REST expression could be a 
mechanism by which glucocorticoids facilitate alterations in the RE1-containing gene 
network that regulates adaptive cellular processes in the hippocampus. In contrast, the 
significant decrease in hippocampal REST levels after three cycles of CORT exposure could 
be a result of a dysregulated gene network mediating cell death and stress resistance (Lu et 
al., 2014). However, we did not test this assumption directly and, therefore, cannot make 
definitive conclusions about the affected genes that may be targeted by varying levels of 
REST expression in hippocampus. 
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Abstract 
Neuroinflammation has been associated with the development of a number 
neurodegenerative diseases and neuropsychiatric conditions, such as major depression. 
Microglia are resident brain immune cells that are known to exert their effects on multiple 
central nervous system functions, including neurogenesis and neuroinflammation. The 
current study sought to examine the influence of repeated and cyclic CORT administration on 
microglia cell morphology and activation in the rat hippocampus. Rats were treated with 
CORT injections or vehicle injections once per day for one, two, or three cycles (21 days 
each), each followed by a recovery period. Following treatment, the rats were sacrificed, and 
brain tissue was collected for immunohistochemical analyses of hippocampal microglia. We 
found significant decreases in microglial area fraction in GCL and hilus of the hippocampus 
in CORT rats treated for one and three cycles. Furthermore, microglial cell phenotype was 
found to be changed (decreased in the number of primary processes and ramifications) in the 
hilus of CORT rats treated for one cycle compared to vehicle rats, however, these decreases 
became statistically significant only in cycle three.  These data indicate that glucocorticoids 
could have a cumulative effect on brain immune cell activation. In addition, these measures 
of microglial activation were strongly correlated with the higher immobility scores in the FST 
and deficient granule neuron maturation reported in previous chapters of this dissertation, 
suggesting that microglial activation may be associated with paralleled decreases in 
neurogenesis and slowed immature neuron maturation. These results are consistent with the 
hypothesis that neuroinflammation plays a role in depression and suggests that specific 
neuroinflammation mediated by activated microglia could represent a common pathway of 
depressive symptom recurrence in major depressive disorder.   
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4.1. Introduction  
 
Growing data implicate immunological factors in the etiology and pathophysiology of 
depression, however, the mechanisms by which this occurs are unclear. Clinical studies 
report that individuals with major depression have increased cytokine levels in blood plasma 
and cerebrospinal fluid, which occur in the absence of the physical illness or infection (Alesci 
et al., 2005; Dahl et al., 2014; Dantzer et al., 2008; Kern et al., 2014). Meta-analysis studies 
also support the role of inflammation in depression by demonstrating consistent increases in 
TNF-alpha and IL-6 in plasma of depressed patients (Dowlati et al., 2010; Howren et al., 
2009), and a reduction of IL-1 and IL-6 along with depressive symptoms in response to 
antidepressant treatment (Hannestad et al., 2011). In addition, plasma IL-6 levels were found 
positively correlated with several depressive symptoms, such as guilt and suicidal ideation 
(Alesci et al., 2005; O’Donovan et al., 2013). 
Similarly, experimental research corroborates the clinical observations and reports 
elevated levels of cytokines in both plasma and brain tissue of animals with a depression-like 
phenotype (Golovatscka et al., 2012; Grippo et al., 2005; Yirmiya & Goshen, 2011; You et 
al., 2011). It has been demonstrated that acute and chronic stress, as well as glucocorticoid 
treatment, can increase cytokine mRNA and protein levels in the brain and leukocyte counts 
in plasma (Blandino et al., 2009; Bowers et al., 2008; Deak et al., 2005; Porterfield et al., 
2012; Sorrells et al., 2009). Systemic and central treatment with pro-inflammatory cytokines 
(IL-1 or TNF-alpha) induce sickness behavior and depression-like behaviors in a dose- and 
time-dependent manner (Dantzer, 2004; Dunn & Swiergiel, 2005; Laugeray et al., 2011). 
Likewise, patients treated with immunotherapy (IL-2 and IFN-α) display signs of severe 
neuropsychiatric changes, including major depressive disorders (Denicoff et al., 1987; 
Renault et al., 1987). 
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Microglia are brain immune cells and a major source of centrally released cytokines 
(Walker et al., 2013a). Microglia have a dynamic morphology that is closely associated with 
their function. Under basal conditions, microglia are quiescent (“resting”), constitutively 
express macrophage proteins CD11b and Iba-1, and have very motile ramifications for 
continuous surveillance of their territory and communication with surrounding cells (Davalos 
et al., 2005; Hanisch & Kettenmann, 2007; Kettenmann et al., 2011; Nimmerjahn et al., 
2005). However, under pathological conditions (e.g. neuronal damage), microglia can rapidly 
acquire a reactive profile, upregulate expression of antigen presentation molecules (CD80, 
CD86, CD40), generate reactive oxygen and nitrogen species, and release pro-inflammatory 
cytokines (Davalos et al., 2005; Johnson et al., 2002). In a reactive state, microglia are 
characterized by significant morphological transformations including a swollen cell body, 
thickened and shortened ramifications, and an amoeboid shape (Kettenmann et al., 2011).  
The hippocampus is one of the brain regions most densely populated with microglial 
cells (Lawson et al., 1990). Interestingly, there is evidence that microglia can play an 
important role in neurogenesis by producing a number of growth factors, such as IGF-1 and 
BDNF (Butovsky et al., 2006; Coull et al., 2005; Sierra et al., 2010; Zhang et al., 2014) that 
play important roles in regulating neurogenesis. Moreover, microglia make frequent brief 
contacts with neurons at presynaptic boutons, postsynaptic spines, and the synaptic cleft, and 
therefore may contribute to the organization of neural circuits (Paolicelli et al., 2011; 
Tremblay et al., 2010; Wake et al., 2009). 
Currently, it is not known if microglial reactivity is exacerbated by multiple cycles of 
CORT administration. Here we examined microglia activation in our animal model of 
recurrent depression and compared changes in microglia reactivity following one vs. three 
cycles of CORT treatment. We hypothesized a progressive, time-dependent increase in 
microglia activation, and that this activation would correlate with decreases in hippocampal 
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neurogenesis (number of DCX+ neurons). Furthermore, we expect that dynamic changes in 
microglial activation would be associated with depression-like behavior. Our findings 
indicate that CORT induced alterations in hippocampal microglial area fraction and cell 
morphology (decreased number of primary processes and ramifications), which are typical of 
microglial activation. Furthermore, we found that these measures of microglial activation 
were strongly correlated with higher immobility scores and slower rates granule cell 
maturation in the GCL and SGZ. 
 
4.2. Materials and Methods 
 
	 A subset of animals (n = 32) from Experiment 2 (Chapter 3) was used in the current 
Experiment. 
 
4.2.1. Subjects 
	
 Male Long-Evans rats (N = 183) were used in this study (Charles River Laboratories, 
Canada). The rats weighed 225-250 grams upon arrival to our animal holding facility. They 
were individually housed in standard polypropylene cages with water and food available ad 
libitum. The temperature of the colony room was maintained at 21 °C, and all experimental 
procedures were conducted during the light phase of the light/dark cycle (lights on at 8 a.m.). 
All experimental procedures were carried out according to a protocol approved by the 
University of Saskatchewan Committee on Animal Care and Supply. 
 
4.2.2. Experimental Procedures   
	
The rats were handled briefly once per day for seven days prior to the start of CORT 
injections. We then weight-matched the rats and randomly assigned them to one of the 
following two treatment groups: repeated and cyclic treatment with 20 mg/kg CORT (N = 
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91) or repeated and cyclic treatment with vehicle (N = 92). Both CORT and vehicle groups 
were divided into subgroups according to the duration of their treatment: (1) 10 days of cycle 
one, (2) 21 days of cycle one, (3) recovery of cycle one, (4) 10 days of cycle two, (5) 21 days 
of cycle two, (6) recovery of cycle two, (7) 10 days of cycle three, (8) 21 days of cycle three, 
and (9) recovery of cycle 3. Each subgroup comprised 20-21 rats (CORT and vehicle). A 
subset of rats from the CORT and vehicle groups treated for one cycle, and the CORT and 
vehicle groups treated for three cycles were used in this experiment. 
The CORT or vehicle injections were administered once per day for three cycles. 
Each cycle comprised 21 consecutive days, followed by a 21-day injection-free recovery 
period. All injections were administered between 9:00 and 11:00 a.m. CORT (Steraloids) was 
suspended in 0.9% (w/v) physiological saline with 2% (v/v) Tween-80 (Sigma Aldrich) and 
given in a volume of 1 ml/kg. 
 
4.2.3. Perfusions and Tissue Preparation  
	
Rats were anesthetised with an overdose of intraperitoneal sodium pentobarbital and 
perfused transcardially with 0.1 M phosphate buffer (PB, pH 7.4) followed by 4% (w/v) 
paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4). The brains were removed and 
postfixed in 4% (w/v) paraformaldehyde for 48 h at 4°C. Then the brain tissue was sectioned 
at 50 μm using a vibratome (Vibratome 3000, Vibratome Company, St. Louis, MO, USA) 
and stored at -20°C in a cryoprotectant solution with 30% (v/v) ethylene glycol, 1% (w/v) 
polyvinylpyrrolidone, and 30% (w/v) sucrose in 0.1 M PBS (pH 7.4). 
 
4.2.4. Immunohistochemical Procedures and Analyses 
	
A subset of rats from cycles one and three (CORT-cycle 1: n = 5-8; CORT-cycle 3: n 
= 5-8;, vehicle-cycle 1: n = 5-8; vehicle-cycle 3: n = 5-8) was used for the 
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immunohistochemical analyses in the current experiment. Every 12th section of the brain 
(from approximately -2.40 mm to -3.94 mm from bregma) was used for immunostaining. All 
immunostaining procedures were done in 6-well tissue culture plates. Brain sections from 
each treatment group were counterbalanced across all 6-well culture plates to ensure 
consistency in immunohistochemical processing. Finally, to confirm the specificity of the 
antibody used in immunostaining, one well with brain sections served as control and was 
subjected to immunohistochemical procedures in the absence of the primary antibody. We 
did not observe any immunoreactivity in the absence of the primary antibody. 
 
4.2.5. Immunohistochemical Procedures  
	
To visualize microglial cells, CD11b immunohistochemistry was conducted. Briefly, 
free-floating tissue sections were rinsed in 0.1 M TBS (pH 7.4) and incubated in 1% H2O2 
for 30 min to block endogenous peroxidase activity. Then the sections were blocked in a 
0.3% (v/v) Triton X-100 TBS buffer containing 5% (v/v) normal horse serum (NHS) for 1 
hour at RT, followed by incubation with a primary mouse anti-CD11b, clone OX-42, 
monoclonal antibody diluted in block solution (1:200; Millipore, USA) for 48 hours at RT. 
The tissue was then incubated with a biotinylated secondary antibody (horse anti-mouse; 
1:200; Sigma-Aldrich) for 2 hours at RT, and then in an avidin-biotin complex (1:500, Vector 
Laboratories, USA) for 30 min at RT. Immunolabelling was visualized with 0.05% (w/v) 
DAB, 4.167% (w/v) nickel ammonium sulphate, and 0.0078% (v/v) H2O2 diluted in 0.175 M 
sodium acetate. After approximately 8 minutes, the reaction was stopped by rinsing the 
sections in 0.175 M sodium acetate. The sections were then mounted onto glass slides, 
dehydrated, and coverslipped using Entellan resin (Millipore, USA) for light microscopic 
examination. 
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4.2.6. Analyses of Immunohistochemical Staining 
	
4.2.6.1. Quantitative Analysis of Microglial CD11b (OX-42) Structures in the 
Hippocampus  
The areas occupied by CD11b microglial elements (area fractions) were measured per 
unit area of the tissue in the GCL, hilus, CA1 strata oriens and radiatum, and CA3 strata 
oriens and radiatum subfields of the hippocampus. This quantification was accomplished 
through Image J. In brief, monochrome images of hippocampal regions (three tissue sections 
per rat) were collected at 200X magnification using a Nikon E800 microscope. In Image J, a 
binary image was created through selecting a threshold value that kept all CD11b 
immunostained elements but no background. The ROI was traced and the area occupied by 
the CD11b structures (area fractions) within the ROI was then measured using the “Analyze 
Particles” command in Image J (Kodali et al., 2015). 
 
4.2.6.2. Morphological Analyses of Microglia in Hilus 
	
The morphology of randomly selected microglia cells in the hilus was examined using 
a neuron tracing system (Neurolucida; Microbrightfield) linked to a Nikon microscope. Hilar 
microglia were chosen based on the results of the microglial area fraction analyses and due to 
their greater accessibility for unobstructed tracing. Five microglia cells per rat (five rats per 
group) were randomly selected and individually traced in their entirety on the live image 
using a 100X lens with oil immersion. The following criteria were used for selection: (1) 
location of the cell body in the hilus; (2) full staining of the cell body and its processes; (3) 
most microglial processes unobscured by background staining or by other cells. 
NeuroExplorer software (MicroBrightfield) was used for the quantification of somatic 
and process morphological parameters. Somatic metrics included cell body area and ferret 
maximum (the longest diameter of the soma). Total process length, the number of primary 
processes, the number of nodes and ends, and the average process diameter were quantified. 
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To compare branch architecture, a Sholl analysis was conducted in which the cell body was 
placed at the center of concentric circles (with diameters incrementing by 10 μm), and the 
number of intersections at all radial distances were quantified.  
 
4.2.7. Statistical Analyses 
	
Main effects and interactions were first analyzed using a two-way univariate 
ANOVA, with time and treatment as independent variables. Separate independent sample t-
tests (one-tailed or two-tailed, as appropriate) were used to analyze treatment effect at 
specific experimental time points as per our a priori hypotheses. All data were analyzed using 
Statistical Package for the Social Sciences (Chicago, IL, version 18.0). The criterion for 
statistical significance of between-group differences was set at p < 0.05.  
Bivariate Pearson's correlations were used to examine the statistical relation between 
measures of microglial activation, and the behavioral data and neurogenesis markers 
described in Chapter 3. The criterion for statistical significance of the correlational analyses 
was set at p < 0.05.  
 
4.3. Results 
4.3.1. Effect of Repeated and Cyclic CORT Treatment on Microglia Area Fraction 
Measures 
Figures 4-1 and 4-2 demonstrate the area fraction of CD11b microglial elements 
(soma and processes) in the hippocampus in CORT and vehicle rats in cycles one and three. 
The two-way ANOVA revealed significant main effects of time [F(1, 28) = 24.612, p < 
0.001; F(1, 28) = 15.568, p < 0.001] and treatment [F(1, 28) = 9.238, p = 0.005; F(1, 28) = 
9.865, p = 0.004] on microglia area fraction in the GCL and hilus. Similarly, there was a 
significant main effect of time [F(1, 28) = 10.206, p = 0.003; F(1, 28) = 7.063, p = 0.013] on 
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microglia area fraction in the CA1 stratum oriens and stratum radiatum, and a significant 
main effect of treatment on CA1 stratum oriens treatment [F(1, 28) = 4.111, p = 0.05], but 
not CA1 stratum radiatum (p values > 0.855).  Finally, there was a significant main effect of 
time [F(1, 28) = 5.33, p = 0.029; F(1, 28) = 5.94, p = 0.021] on microglia area fraction in the 
CA3 stratum oriens and stratum radiatum, and a significant effect of treatment on CA3 
stratum radiatum only [F(1, 28) = 4.21, p = 0.05]. There were no significant interactions of 
treatment by time on microglia area fraction of these hippocampal subregions (p values > 
0.843).   
In cycle 1, there was a significant decrease in area fraction in the hilus and GCL of 
CORT rats compared to the vehicle rats [t(14) = 2.131, p = 0.025, and t(14) = 2.001, p = 
0.033, respectively]. Similarly, the CORT rats had a decrease in area fraction in other 
hippocampal subfields (i.e., CA1 strata oriens and radiatum, CA3 strata oriens and radiatum) 
but these differences did not reach statistical significance (all p values > 0.161).  
In cycle 3, the CORT rats also had a decrease in area fraction of microglial elements 
in the hilus and GCL [t(14) = 2.308, p = 0.019, and t(14) = 2.35, p = 0.019, respectively]. 
And again, although the CORT rats had a decrease in area fraction in other hippocampal 
subfields (i.e., CA1 strata oriens and radiatum, CA3 strata oriens and radiatum), these 
differences were not statistically significant (all p values > 0.171). 
Within the CORT groups, rats treated for three cycles of CORT had significantly 
lower microglial area fraction compared to rats treated for one cycle in GCL, hilus, CA1 
stratum oriens and stratum radiatum, and CA3 stratum oriens and stratum radiatum [t(14) = 
4.43, p = 0.001; t(14) = 3.22, p = 0.003, t(14) = 3.005, p = 0.005, t(14) = 2.174, p = 0.023; 
t(14) = 1.886, p = 0.04; t(14) = 1.93, p = 0.036, respectively]. Within the control groups, 
vehicle treated rats for three cycles showed significantly lower microglial area fraction 
A  
	 126	
  
  
 
B 
  
  
 
   
Figure 4-1.  The effect of one and three cycles of repeated corticosterone (CORT) treatment 
on microglial area fraction measures in the granule cell layer (GCL) and hilar subregions of 
the dentate gyrus. Panel (A) shows representative photomicrographs of CD11b-positive 
microglia cells in the GCL and hilus of vehicle and CORT rats treated for one and three 
cycles. Panel (B) shows the quantification of area fraction of CD11b-positive structural 
elements in these brain regions in all four treatment groups. CORT produced significant 
reductions in area fraction of CD11b-positive microglia in both regions. Asterisks (*) indicate 
overall significant differences between treatment groups, respectively p < 0.05. Letters (a), 
and (b) represent significant differences between CORT and vehicle groups treated for one 
cycle and three cycles, respectively; letters (c) and (d) denote differences between two CORT 
groups and between two vehicle groups, respectively p < 0.05. Error bars denote the standard 
error of the mean (SEM). 
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Figure 4-2.  The effect of one and three cycles of repeated corticosterone (CORT) treatment 
on microglial area fraction measures in CA1 and CA3 hippocampal subregions. Panel (A) 
shows representative photomicrographs of CD11b-positive microglia cells in the CA3 
subregion of the hippocampus in vehicle and CORT rats treated for one and three cycles. 
Panel (B) shows representative photomicrographs of CD11b-positive microglia cells in the 
CA1 subregion of the hippocampus in vehicle and CORT rats treated for one and three 
cycles. Panel (C) shows the quantification of area fraction of CD11b-positive structural 
elements in these regions in the four treatment groups Asterisks (*) indicate overall 
significant differences between treatment groups, letter (d) denotes differences between two 
CORT groups p < 0.05. Error bars denote the standard error of the mean (SEM). 
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compared to rats treated for one cycle in GCL, and hilus [t(14) = 2.95, p = 0.005; t(14) = 
2.45, p = 0.014].  
	
4.3.2. Effects of Repeated and Cyclic CORT Treatment on Microglia Morphology  
	
Figure 4-3 shows the results of the 3D reconstruction of individual microglia cells in 
the hilar region of the dentate gyrus in CORT and vehicle rats after cycles one and three. The 
two-way ANOVA revealed no significant main effects of time on microglial morphology 
measures: the soma area, total process length, the number of primary processes, the number 
of nodes or ends, the average process diameter, and the number of intersections (all p values 
> 0.273). However, there were significant main effects of treatment on the number of primary 
processes [F(1, 16) = 7.491, p = 0.015],  the number of process nodes [F(1, 16) = 5.142, p = 
0.038], the number of process ends [F(1, 16) = 4.892, p = 0.042], the total process length 
[F(1, 16) = 5.537, p = 0.032], the total number of process intersections [F(1, 16) = 5.174, p = 
0.037], as well as the number of intersections at 20 and 30 μm distance from the soma [F(1, 
16) = 4.515, p = 0.05; F(1, 16) = 6.044, p = 0.026]. There were no significant interactions of 
treatment by time on measures of microglial morphology (p values > 0.213).   
In cycle 1, no statistically significant group differences were found in microglial soma 
area, total process length, the number of primary processes, the number of nodes or ends, the 
average process diameter, and the number of intersections between CORT and vehicle rats 
(all p values > 0.146). 
In cycle 3, no statistically significant group differences were found in microglial soma 
area (p = 0.277). Compared to the CORT rats, the vehicle rats had significantly more primary 
processes [t(8) = 2.2, p = 0.03], a larger number of branching nodes [t(8) = 2.13, p = 0.045], a 
larger number of branch ends [t(8) = 2.14, p = 0.045], a larger total process length [t(8) = 2.1, 
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Figure 4-3. The effect of one and three cycles of repeated corticosterone (CORT) treatment 
on microglial cell morphology. Panel (A): quantification of microglia cell soma area; (B) 
quantification of microglial primary processes; (C): average microglial process diameter; (D) 
microglial total process length; (E) and (F): number of microglial process intersections in 
total and at different radial distances from soma; (G) and (H): numbers of microglial process 
nodes and ends; (I) representative micrographs of microglial cells in CORT and vehicle rats 
after one and three cycles, as well as a 3D reconstruction of one microglial cell created with 
Neurolucida software. CORT altered microglia cell morphology in cycle three but not cycle 
one. Microglia in CORT-treated rats displayed fewer and shorter processes, reduced 
ramification of processes (nodes and ends), and decreased number of intersections, implying 
a tendency towards conversion into activated or amoeboid microglia phenotype. No 
significant changes were observed in the average diameter of microglial processes, the size of 
the microglial cell body, or the soma size. Asterisks (*) indicate overall significant 
differences between treatment groups; letter (a) indicates significant differences between 
CORT and vehicle groups treated for three cycles, p < 0.05. Error bars denote the standard 
error of the mean (SEM). 
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p = 0.034], and a larger number of intersections [t(8) = 2.23, p = 0.028], specifically, at 
10,20, and 30 μm distance from the soma (p = 0.04, p = 0.035, and p = 0.02). No group 
differences were found in the average process diameter (p = 0.252). 
	
4.3.3. Correlation analyses 
	
Figure 4-4 illustrates selected correlations between measures of microglial activation, 
behavior, and neurogenesis in the CORT and vehicle rats from cycles one and three.  
 
4.3.3.1. Correlations between Microglia Area Fraction and Behavioral Measures 
Immobility scores were negatively correlated with microglia area fraction in the GCL 
(Figure 4-4A; r = −0.498, p < 0.01, n =32), hilus (Figure 4-4B; r = −0.458, p < 0.01, n =32), 
CA1 stratum oriens (r = −0.405, p < 0.01, n =32), CA1 stratum radiatum (r = −0.373, p < 
0.05, n =32), CA3 stratum oriens (r = −0.371, p < 0.05, n =32), and CA3 stratum radiatum (r 
= −0.408, p < 0.05, n =32). Time spent swimming was correlated with microglia area fraction 
of the hilus (r = 0.384, p < 0.05, n =32), CA1 stratum radiatum (r = 0.392, p < 0.05, n =32), 
and CA3 stratum radiatum (r = 0.360, p < 0.05, n =32). 
	
	
4.3.3.2. Correlations between Microglia Area Fraction and DCX+ Cell Maturation 
Measures 
The GCL microglia area fraction was negatively correlated with the percentage of 
DCX+ category two cells (Figure 4-4E; r = −0.588, p < 0.05, n = 17), and positively 
correlated with the percentage of DCX+ category five (Figure 4-4F) and category six cells (r 
= 0.643 and r = 0.611, respectively, p < 0.01, n = 17).  
The hilus microglia area fraction was negatively correlated with the percentage of 
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Figure 4-4. Correlations between measures of microglial activation and morphology, 
behavior, and neurogenesis in the corticosterone (CORT) and vehicle rats in cycles one and 
three. Correlation of immobility behavior with microglia area fraction in the granule cell 
layer (GCL, r = −0.498, p < 0.01) (A) and hilus (r = −0.458, p < 0.01) (B). Correlation of 
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microglia area fraction in the hilus with the percentage of DCX+ category two cells (r = 
−0.681, p < 0.05) (C) and category five cells (r = 0.690, p < 0.01) (D). Correlation of 
microglia area fraction in the GCL with the percentage of DCX-positive category two cells (r 
= −0.588, p < 0.05) (E) and category five cells (r = 0.643, p < 0.01) (F). Correlation of the 
number of microglial primary processes with the percentage of DCX-positive category two 
cells (r = −0.542, p < 0.05) (G) and category five cells (r = 0.708, p < 0.01) (H). Correlation 
of the number of microglial branch ends with the percentage of DCX-positive category two 
cells (r = −0.574, p < 0.05) (I) and category five cells (r = 0.577, p < 0.05) (J). For details, 
see the text. 
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DCX+ category two cells (Figure 4-4C; r = −0.681, p < 0.05, n = 17) and positively 
correlated with the percentage of DCX+ category five and category six cells (Figure 4-4D; r 
= 0.690 and r = 0.640, respectively, p < 0.01, n = 17).  The CA1 SO microglia area fraction 
was negatively correlated with the percentage of DCX+ category three cells (r = −0.511, p < 
0.05, n = 17) and positively correlated with the percentage of DCX+ category five and 
category six cells (r = 0.506 and r = 0.602, respectively, p < 0.05, n = 17).  
 The CA1 SR microglia area fraction was negatively correlated with the percentage of 
DCX+ category three cells (r = −0.484, p < 0.05, n = 17) and positively correlated with the 
percentage of DCX+ category six cells (r = 0.540, p < 0.05, n = 17).   
The percentage of DCX+ category two cells was inversely correlated with the CA3 
SR microglia area fraction (r = −0.504, p < 0.05, n = 17). 
 
4.3.3.3. Correlations between Microglial Cell Morphology and DCX+ Cell Maturation 
Measures 
The number of microglial primary processes was inversely correlated with the 
percentage of DCX+ category two (Figure 4-4G) and category four cells (r = −0.542 and r = 
−0.599, respectively, p < 0.05, n = 14) and positively correlated with the percentage of DCX+ 
category five cells (Figure 4-4H; r = 0.708, p < 0.01, n = 14). The number of microglial 
branch nodes was negatively correlated with the percentage of DCX+ category two and 
category four cells (r = −0.576 and r = −0.551, respectively, p < 0.05, n = 14) and positively 
correlated with the percentage of DCX+ category five cells (r = 0.570, p < 0.05, n = 14).  
The number of microglial branch ends was negatively correlated with the percentage 
of DCX+ category two (Figure 4-4I) and DCX+ category four cells (r = −0.574 and r = 
−0.568, respectively, p < 0.05, n = 14) and positively correlated with the percentage of DCX+ 
category five cells (Figure 4-4J; r = 0.577, p < 0.05, n = 14).  
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4.4. Discussion 
 
 This experiment evaluated microglial activation following one and three cycles of 
repeated CORT treatment. Immunohistochemical characterization of CD11b (OX-42) 
suggested increased occurrence of reactive microglia exhibiting enlarged soma and fewer 
processes in CORT-treated rats, resulting in larger (white) spaces between microglial cells 
(Figure 4-1 and 4-2). In contrast, vehicle-treated rats displayed mostly ramified microglia 
(quiescent) with extensive fine branches. Using a thresholding technique, we quantified the 
area fraction of CD11b+ microglial elements (soma and processes) in several hippocampal 
subfields. This measurement revealed that after one cycle of treatment, there was an 
increased occurrence of ramified microglia (larger area fraction) in vehicle-treated rats 
compared to CORT-treated rats in the hilus and GCL regions of the dentate gyrus. 
Furthermore, after three cycles of treatment, this effect appeared to be potentiated, with 
CORT rats showing a smaller area fraction in the hilus and GCL, and therefore fewer 
microglial elements.  
Although thresholding is a simple method, the interpretation of results using this 
method is not straightforward, as there is no direct relationship between the amount of 
elements measured (area fraction) and microglial activation. Therefore, the difference in 
thresholded material (area fraction) could represent a change in microglial cell number, a 
change in cell morphology, or both. To confirm the reactive state of microglia further, we 
traced a subset of CD11b+ microglia and their processes in the hilus from both vehicle and 
CORT-treated rats using Neurolucida (Figure 4-2). Most of the microglia in CORT rats 
treated for one cycle displayed shorter processes and reduced ramification of processes 
(decreases in the number of branching nodes and ends), reduced number of primary 
processes, and a reduced number of process intersections, but these effects became 
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statistically significant only after three cycles of treatment. The microglial soma size was 
enlarged in rats treated with one and three cycles of CORT, however this effect did not reach 
statistical significance. Consistent with area fraction analysis, the results of this 
morphological analysis suggest a gradual transition of microglia from a resting into an 
activated phenotype.   
Overall, the findings from this experiment demonstrate evidence that repeated and 
cyclic treatment with CORT provoked significant alterations in the phenotype of 
hippocampal microglia through reductions in microglia cell ramifications. Microglial cell 
morphology is closely coupled with their functional properties (Stence, Waite, & Dailey, 
2001; Streit, Walter, & Pennell, 1999). The observed morphological changes are consistently 
described in the literature (i.e., soma enlargement, retraction and thickening of extant 
branches) all of which are indicative of microglial activation (Beynon & Walker, 2012). Such 
activated microglia are known to release increased levels of pro-inflammatory molecules, 
including pro-inflammatory cytokines such as TNF-alpha, and free radicals such as nitric 
oxide (Liu & Hong, 2003; Tansey, McCoy, & Frank-Cannon, 2007). To my knowledge, we 
are the first to show that multiple exposures to CORT (three cycles) induce cumulative 
changes in microglial activation compared to one cycle of CORT, suggesting that repeated 
and cyclic glucocorticoid treatment has a neuroinflammatory effect in hippocampus. 
Intriguingly, REST protein is known to target the TNF superfamily of genes (Otsuki et al., 
2010), and findings in Chapter 3 of this dissertation demonstrate significant decreases in 
hippocampal REST levels in rats treated for three cycles of CORT. These data further support 
the development of neuroinflammatory processes in these rats. Although our results are 
consistent with several studies reporting pro-inflammatory effects of chronic stress, it is 
important to note that they also contradict findings from another line of research. 
Glucocorticoids are traditionally known to have anti-inflammatory properties, because an 
	 137	
activated HPA axis can exert robust suppressing effects on the production of pro-
inflammatory cytokines by inhibiting the activity of nuclear light chain kappa beta (NF-kB), 
the key inflammatory transcription factor (Lee et al., 1988; Silverman & Sternberg, 2012; 
Zuckerman, Shellhaas, & Butler, 1989). Therefore, glucocorticoids have been reliably 
reported to reduce the expression of pro-inflammatory cytokines including IL-1, IL-6, and 
TNF-alpha and to increase anti-inflammatory mediators including IL-10 and TGF-b 
(Correale et al., 1998; Gayo et al., 1998). Moreover, the anti-inflammatory properties of 
glucocorticoids have been used pharmacologically to control post-surgical inflammation, as 
well as in cases of allergies, asthma, autoimmune diseases, etc. (Hockey et al., 2009). 
However, consistent with our results, several research studies showed that chronic stress 
resulted in an increase in microglia Iba-1 immunoreactivity and activation in several brain 
regions, including the hippocampus, PFC, and amygdala (Tynan et al., 2010a; Wohleb et al., 
2011, 2012). In addition, high levels of CORT in rats exposed to unpredictable mild stress 
increased the levels of LPS-induced inflammatory signalling mediator NF-KB in the 
hippocampus (Munhoz et al., 2006), whereas low concentrations of CORT inhibited the 
expression of pro-inflammatory cytokines mRNA IL-1 beta and TNF-alpha in rat 
hippocampus following the kainic acid stimulation (MacPherson, Dinkel, & Sapolsky, 2005).  
Furthermore, in humans psychological stress was found to initiate an acute catecholamine 
response with the release of pro-inflammatory cytokines from mononuclear cells in the 
periphery (Bierhaus et al., 2003). The ability of CORT to exert both pro-inflammatory and 
anti-inflammatory effects on microglia has been elegantly investigated in a research study by 
Frank and colleagues (Frank et al., 2010). In their study, the authors showed that when 
repeated stress is administered prior to the immune challenge (LPS), the subsequent 
inflammation is potentiated. In contrast, when CORT was administered to microglia of 
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stressed rats 1 hour after the LPS challenge, the pro-inflammatory response was inhibited, 
suggesting a temporal relationship between the endocrine and immune systems.  
As discussed earlier, major depressive disorder is frequently characterized by an 
elevation of both cortisol and pro-inflammatory cytokines, presenting a paradoxical 
overactivity of the immune and endocrine systems. Two theories have been proposed to 
resolve this paradox: one hypothesizes increased immunological activity as a result of 
developed glucocorticoid resistance, and the other theory highlights the evidence of both pro- 
and anti-inflammatory effects of glucocorticoids under specific conditions (Horowitz & 
Zunszain, 2015). Specifically, in the first theory, it is suggested that the initial exposure to 
CORT may desensitize or decrease the number of glucocorticoid receptors leading to a 
reduced intracellular glucocorticoid signalling that can no longer exert the same suppressive 
effects. This observation is supported by evidence from both clinical and preclinical literature 
demonstrating glucocorticoid resistance accompanied by high levels of pro-inflammatory 
cytokines in depressed patients (Bauer et al., 2003; Carvalho et al., 2008; Fitzgerald et al., 
2006; Humphreys et al., 2006; Landmann et al., 1997; Maes et al., 1993) and in chronically 
stressed animals in models of depression (Avitsur et al., 2009; Sheridan et al., 2000). The 
second proposed theory is focused on evidence that glucocorticoids can be both pro- and anti-
inflammatory under certain conditions (Frank et al., 2013; Sorrells et al., 2009). For example, 
animal studies demonstrated that exposure to glucocorticoids (or stress) after an 
inflammatory stimulus results in a suppression of cytokine release (Goujon et al., 1995). In 
contrast, exposure to glucocorticoids (or stress) before an inflammatory event heightens the 
inflammatory response (de Pablos et al., 2006; Espinosa-Oliva et al., 2011; Frank et al., 2010; 
Johnson et al., 2002; Munhoz et al., 2006, 2010). Similar results have been reported in 
preliminary studies in humans (Barber et al., 1993). Taken together, these data highlight the 
complex relationship between the stress and immune systems, suggesting that research 
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integrating both systems would help clarify the mechanisms involved in the etiology and 
pathogenesis of depression. 
In addition to inducing neuroinflammation, microglia play an important role in adult 
neurogenesis. Several mechanisms have been proposed to explain how microglia can effect 
neurogenic function. For example, quiescent (ramified) microglia can produce a number of 
growth factors, such IGF-1 and BDNF, which promote cell proliferation (Butovsky et al., 
2006; Coull et al., 2005; Sierra et al., 2010; Zhang et al., 2014). In addition, in vitro studies 
demonstrate that microglia have the ability to guide the differentiation of adult neural 
precursor cells toward a neuronal phenotype (Aarum, Sandberg, Haeberlein, & Persson, 
2003). Furthermore, microglia were reported to make frequent brief contacts with neurons at 
presynaptic boutons, postsynaptic spines, and the synaptic cleft, and likely may contribute to 
the maintenance of neural circuits (Paolicelli et al., 2011; Tremblay et al., 2010; Wake et al., 
2009). Finally, some of the well-known beneficial effects of environmental enrichment on 
neurogenesis may be mediated by microglia. Vukovic et al. (2012) demonstrated that when 
hippocampal microglia extracted from the runner mice were placed to the hippocampal 
neurosphere culture of sedentary mice, the number of NPCs in the culture of sedentary mice 
significantly increased, implying that microglia can be altered by enrichment to exert 
modulatory neurogenic effects. In fact, following an enriched experience, beneficial 
(ramified) microglia cell numbers increase, and this increase is accompanied by an increase 
in neurogenesis (Choi et al., 2008; Ziv et al., 2006). Interestingly, stem/progenitor cell 
proliferation was inversely correlated with the density of microglia expressing the Iba-1 
marker, which is expressed by activated microglia only (Gebara, Sultan, Kocher-Braissant, & 
Toni, 2013). Findings described in the previous chapter of this dissertation provide evidence 
of the cumulative loss of DCX positive neurons from the GCL and SGZ in rats treated with 
CORT for one to three cycles. Here we demonstrate a transition of microglial phenotype 
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(from resting to activated) in the same rats, moreover, the measures of microglial area 
fraction in multiple hippocampal subregions were strongly and inversely correlated with the 
percentage of category two and three neurons (less mature cells), while at the same time 
positively correlated with the percentage of category five cells (more mature cells). Similarly, 
several measures of microglial morphology (number of primary processes, the number of 
branch nodes and ends) were also correlated negatively with the percentage of category two 
and four cells, and positively correlated with the percentage of category five cells.  Finally, 
increased immobility behavior was associated with lower microglial area fraction (less 
ramification). Overall, these findings suggest that more activation (i.e. smaller area fraction, 
fewer processes, ends, and nodes) of microglia in the hilus, GCL, CA1 and CA3 is associated 
with increases in depression-like behavior and a slowed maturation rate of newborn dentate 
granule cells. Thus, it is possible that some of the anti-neurogenic effects of stress are 
regulated by microglial activation.  
The present experiment was a preliminary examination of how repeated and cyclic 
glucocorticoid exposure can influence the microglial morphology and thus microglial 
activation in the rat hippocampus. The progressive shift in microglial cell morphology in the 
hilus with more cycles of CORT treatment suggests that stress exerts cumulative effects on 
brain immune cell activation. Changes in microglial morphology co-occur with cumulative 
decreases in the number of DCX-positive cells and could represent a shared pathway in 
development and recurrence of major depressive episodes. Future work with this model of 
depression should examine whether these cells become primed and release increasing 
amounts of cytokine content to confirm an exacerbation of neuroinflammation.  In addition, it 
would be of interest to investigate whether the observed microglial activation is resolved 
during the stress-free recovery periods.   
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CHAPTER 5 
General Discussion 
5.1. Summary of the Main Findings 
 
The primary purpose of this dissertation was to develop an animal model of recurrent 
depression and to further advance our understanding of the neurobiological alterations 
associated with stress re-exposure and depression relapse. To accomplish this, I examined the 
effects of repeated and cyclic CORT injections on several measures of rat depression-like 
behaviors and associated changes in hippocampal neurogenesis, dendritic complexity, 
hippocampal REST protein expression levels, and hippocampal microglial activation.  
In Chapter 2, I examined the effect of repeated and cyclic CORT injections for two 
complete cycles (21 days each) on rat behavior in the FST. The behavior of rats was 
measured in a repeated fashion, where all rats were tested in the middle and at the end of each 
CORT treatment cycle, and at the end of each recovery period. CORT produced increasingly 
greater effects on depression-like behavior. Specifically, after developing a depression-like 
phenotype following the first cycle of CORT treatment, rats displayed sensitized increases in 
the time spent immobile and decreases in the time spent swimming, following a brief (ten 
days) CORT re-exposure. Additionally, a progressive worsening of recovery of immobility 
behavior was observed with more exposures to CORT. However, the potential confounding 
effects of repetitive behavioral testing, body weight, and aging need to be considered in the 
interpretation of these effects. Therefore, to address the issue of repetitive behavioral testing, 
further refining of the animal model was required. 
In Chapter 3, I examined the influence of repeated and cyclic CORT treatment on 
several measures of rat depression-like behavior, the number and maturation rate of immature 
dentate granule neurons, as well as changes in hippocampal REST protein expression. In this 
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experiment, all rats were naïve to behavioral testing, as all behavioral tests were conducted in 
distinct groups of rats. Consistent with results of the first experiment, CORT produced larger 
increases in depression-like behavior in cycles two and three, specifically, higher immobility, 
decreased swimming, and lower sucrose preference scores, but no changes in general 
locomotor or exploratory behaviors. Similar to Experiment 1, cyclic CORT treatment resulted 
in worsening of recovery of immobility behavior in cycle three. Exacerbation of depression-
like behaviors was paralleled by the accumulated decline in neurogenesis and dendritic 
complexity of immature granule neurons in the GCL and SGZ. Finally, I found that CORT 
also exerted its deleterious effects on transcriptional regulation of hippocampal function, 
which was characterized by measuring REST protein levels within the hippocampus. The 
finding of precise bi-directional regulation of hippocampal REST depending on the duration 
of CORT exposure was particularly important, as it may contribute to the mechanisms of 
depressive symptom recurrence, raising the possibility that novel antidepressant drugs could 
target REST-related deficits.   
 Chapter 4 included an examination of the effects of repeated and cyclic CORT 
exposure on hippocampal microglia. The goal of this project was to gain preliminary insight 
into microglial activation and its potential role in the function and plasticity of hippocampus 
under conditions of repeated stress. CORT produced cumulative changes in hippocampal 
microglia area fraction and microglial cell morphology, which are typically associated with 
neuroinflammatory processes. Additionally, these changes were strongly correlated with 
decreases in dentate granule neuron maturation rate and increases in depression-like 
behavior. These results suggested to me that the progressive activation of hippocampal 
microglia may be associated with exacerbation of depressive symptoms and paralleled 
decreases in the complexity of hippocampal immature neurons. Although these findings are 
correlational, further analyses of the complex relationship between the endocrine and 
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immune systems may elucidate common mechanisms underlying up-regulated levels of 
neuroinflammation, overactivity of the HPA axis, and the disruption of hippocampal function 
in major depressive disorders. 
The overall results of this dissertation demonstrate evidence that repeated and cyclic 
glucocorticoid treatment could be used as an animal model of recurrent depression, as it 
increasingly affects the severity of depression-like behavior and the quality of recovery in 
rats. The presented model provides stronger construct and face validities compared with other 
existing animal models of depression, and it provides an opportunity to investigate the 
neurobiological changes associated with depressive symptom relapse. Data presented in this 
dissertation suggest that accumulated decreases in neurogenesis and newborn cell dendritic 
complexity could be associated with increasingly severe depression-like symptoms. 
Furthermore, stress appears to have a critical influence on hippocampal REST levels and 
microglial phenotypes, both known to be highly involved in the regulation of hippocampal 
plasticity and function.  
 
5.2. Repeated and Cyclic Glucocorticoid Exposure as an Animal Model of Recurrent 
Depression 
Major depression is a chronic and highly recurrent disorder (Hollon et al., 2006; 
Kendler et al., 2000; Solomon et al., 2000). The recurrent aspect of this disorder, with 
relapses of depression episodes, significantly impact an individual patient and also put a 
strain on the public health system. Therefore, when we conduct research on depression, it is 
important to examine not only the onset of depression but also the mechanisms and risk 
factors of episode recurrence. The lack of efficacious antidepressant treatment specifically 
designed for preventing recurrent episodes is due, in part, to the absence of adequate animal 
models that recapitulate recurrent episodes of depression. As earlier discussed, to our 
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knowledge, only one study investigated the recovery of the depression-like behavior and a 
subsequent reinstatement of a depression-like episode (Remus et al., 2013). Although the 
authors demonstrated the sensitization of rat anhedonia-like behaviors following stress re-
exposure, the neurobiological mechanisms of this sensitization, as well as other depression-
like behaviors, were not studied.   
The results from my dissertation show that repeated and cyclic glucocorticoid 
administration produces cumulative increases in depression-like behaviors (immobility and 
sucrose preference) and cumulative worsening of behavioral recovery quality with every 
subsequent glucocorticoid re-exposure. Moreover, the depressogenic effects of CORT were 
not accounted for by changes in nonspecific locomotor activity, as CORT had no significant 
effects on rat behavior in the OFT. Importantly, the depressogenic effects of CORT on 
behavior were replicated in two separate experiments with repeated and non-repeated 
behavioral testing, further increasing the validity of the model. The observed re-establishment 
of the depression-like behavior following shorter periods of glucocorticoid re-exposure is 
indicative of the potential sensitization to stress and depression-like episodes in CORT-
treated rats. These results are consistent with previous research demonstrating sensitized 
depression-like behavior, as well as sensitized stress hormone release and neurotransmitter 
release, in rats exposed to the repeated stress and later re-exposed to an acute stressor 
(Konarska et al., 1989; Nisenbaum et al., 1991; Pardon et al., 2003; Zurita et al., 2000). 
Additionally, our finding of aggravation of anhedonia-like behaviors at the end of the 2nd and 
3rd CORT exposures is supported by a study that reported similar effects of stress on sucrose 
consumption in rats exposed to chronic CMS and then re-exposed to the shorter course of the 
same CMS procedure (Remus et al., 2013). 
Taken together, the overall findings of this dissertation and the literature suggest that 
repeated and cyclic treatment with stress or glucocorticoids produces greater depression-like 
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behavior in rats in response to smaller subsequent stress, reflective of a recurrent depression 
disease course. The proposed animal model provides stronger face and construct validities by 
recapitulating the depression disease course in addition to the core depressive symptoms (i.e. 
depressed mood and anhedonia). Importantly, this model can be used for researching the 
mechanisms of major depression recurrence, as well as investigating the potential therapeutic 
targets for preventing depression episode relapse. 
 
5.3. Neurogenesis and REST in Depression 
Decreased hippocampal neurogenesis has been implicated in the pathogenesis of 
depression since the 1990s. This hypothesis is widely supported by abundant preclinical 
evidence demonstrating that repeated stress (e.g., glucocorticoid administration, CMS, 
restraint stress, and others) inhibits the proliferation, differentiation, and survival of 
hippocampal neurons (Bambico & Belzung, 2013; Banasr & Duman, 2007). Clinical 
observations also indicate reduced hippocampal volumes in patients suffering from major 
depression (Sheline et al., 1996; Sheline et al., 2003). Further support for the neurogenesis 
hypothesis of depression comes from studies showing that antidepressant drugs increase the 
proliferation, maturation, and survival of new neurons within the hippocampus (Banasr & 
Duman, 2007). However, the precise nature of the relationship between neurogenesis and 
depression is far from being fully understood, as several lines of research report conflicting 
results. For example, post-mortem analyses of severely depressed patients’ brains did not 
reveal major cell loss (Reif et al., 2006). Additionally, although some research identified 
neurogenesis as a critical process in antidepressant action (Santarelli et al., 2003), others have 
found that efficacy of antidepressant medications are independent of neurogenesis (David et 
al., 2009), suggesting a potential contribution of other factors to the depressive 
symptomatology. Finally, there are conflicting reports on what stages of neurogenesis are 
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most affected by stress: Some research demonstrates suppressed hippocampal cell 
proliferation following stress (Brummelte & Galea, 2010; Duman et al., 2001; Gould et al., 
1997), whereas other studies reveal that stress majorly disrupts neuronal differentiation and 
maturation, but not proliferation (Mayatissa, Henningsen, West, & Wiborg, 2009; Jayatissa, 
Bisgaard, West, & Wiborg, 2008). Collectively, these results underline a complex association 
between neurogenesis, stress, depression, and antidepressants, and further suggest that 
studying this relationship in more longitudinal experimental paradigms (as such the type 
proposed in this dissertation) would allow for a more extensive investigation of the role of 
neurogenesis in mood disorders. 
Adult neurogenesis is strictly controlled by various signalling pathways, 
neurotransmitter systems, and transcriptional regulatory processes (Ables et al., 2010; Lie et 
al., 2005; Mira et al., 2010; Deisseroth et al., 2004; Ge et al., 2006; Tozuka et al., 2005). 
Recent work has identified zinc finger protein REST as a master factor for both 
differentiating precursor cells and adult neurons as well (Baldelli & Meldolesi, 2015). 
Moreover, growing evidence implicates REST in various neurological and psychiatric 
conditions, including depression. However, its role in the pathogenesis of mood disorders 
remains unclear. A recent study reported that REST targets several genes that are known to 
be involved in stress and depression, including CRH, the 5-HT1A receptor, BDNF, and the 
TNF superfamily (Otto et al., 2007; Otsuki et al., 2010). Additionally, REST was reported to 
regulate glucocorticoid synthesis (Somekawa et al., 2009), suggesting its important 
involvement in the stress response system. The current literature on the role of REST in 
depression revealed mixed reports. One study demonstrated increased expression of REST4 
in the mPFC of mice subjected to an early life stress. Interestingly, REST4 overexpression in 
the mPFC of neonatal mice, but not adult mice, potentiated depression-like behaviors in 
response to repeated restraint stress (Uchida et al., 2010). In contrast, a clinical study on 
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patients with major depressive and bipolar disorders showed that REST mRNA levels were 
decreased in peripheral blood cells of patients in a current depressive, but not a remissive 
state (Otsuki et al., 2010). The reduction of REST mRNA was accompanied by increases in 
CRH, adenylate cyclase 5, and the TNF superfamily mRNA. Intriguingly, the results from 
Chapter 3 may elucidate some of the discrepancies between the opposing findings of the 
above-mentioned research studies. Specifically, the results from Chapter 3 demonstrate that 
changes in brain levels of REST are highly dependent on the number/duration of 
glucocorticoid exposure: Increases in the number of REST+ cells within the hippocampus 
were found in CORT-treated rats after the 1st cycle of CORT administration, whereas 
profound decreases in the number of REST+ cells within the hippocampus were found in 
CORT-treated rats after the 3rd CORT cycle. These results suggest that biphasic changes in 
hippocampal REST could reflect the cumulative neurobiological damage associated with the 
progression of the depressive disorder, as well as potential mechanisms of depression 
recurrence. Also, these findings emphasize the importance of identifying which 
neurobiological changes in depression could be transient and adaptational, and which ones 
could be long lasting, accumulative, irreversible and potentially crucial for subsequent 
depression relapse. Additionally, the findings from Chapter 3 indicate that decreases in 
hippocampal REST expression were associated with decreased neurogenesis and a slowed 
maturation rate of immature neurons in hippocampus, as well as increased depression-like 
behaviors, further supporting the role of REST in neurogenesis and depressive 
symptomatology. 
Interestingly, similar decreases in hippocampal and PFC REST levels were revealed 
in the brains of patients with Alzheimer’s disease, along with increased pro-apoptotic gene 
expression and oxidative stress. And conversely, the increase in REST expression was found 
in individuals experiencing healthy aging, cognitive preservation, and longevity (Lu et al., 
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2014). Taking into consideration the high comorbidity between Alzheimer’s disease and 
depression (Olin et al., 2002; Saczynski et al., 2010, Diniz et al., 2013), as well as consistent 
reports of impaired hippocampal neurogenesis in Alzheimer’s genetic animal models 
(Demars, Hu, Gadadhar, & Lazarov, 2010; Donovan et al., 2006; Haughey et al., 2002; 
Zhang, McNeil, Dressler, & Siman, 2007), alterations in REST-mediated pathways could be 
a common underlying pathology of these both of these disorders. Collectively, these data 
strongly support a role for REST in the regulation of stress, neurogenesis, and the 
pathogenesis of mood disorders, therefore further investigation of REST in these disorders 
may allow for the development of novel targets for therapeutic intervention. 
 
5.4. Role of Microglia in Depression 
Mounting evidence suggests that chronic stress induces biological alterations in 
multiple interacting systems, particularly in the endocrine and immune systems, which result 
in an increased risk of disease, including major depression (Cohen, Janicki-Deverts, & 
Miller, 2007). For example, clinical and preclinical research consistently report elevated 
levels of pro-inflammatory cytokines in the plasma and cerebrospinal fluid of depressed 
individuals and the brains of animals exhibiting depression-like phenotypes (Alesci et al., 
2005; Dahl et al., 2014; Dantzer et al., 2008; Kern et al., 2014; Golovatscka et al., 2012; 
Yirmiya & Goshen, 2011). Decreases in cytokine levels were found in response to 
antidepressant treatment (Hannestad et al., 2011). Furthermore, both animals and humans 
treated with cytokine therapies display signs of depressive symptomatology (Dantzer, 2004; 
Dunn & Swiergiel, 2005; Laugeray et al., 2011; Renault et al., 1987). Microglia are the 
primary source of centrally released cytokines (Walker et al., 2013a). These cells have a very 
dynamic morphology and function, and, under pathological conditions, can rapidly turn into a 
reactive state by altering the morphological characteristics (swollen soma, deramified 
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processes), upregulating the expression of antigen presentation molecules, generating reactive 
oxygen and nitrogen species, and releasing pro-inflammatory cytokines (Davalos et al., 2005; 
Johnson et al., 2002; Kettenmann et al., 2011). Therefore, studying changes in microglial 
reactivity may provide insight into the neuroinflammatory correlates of stress and depression. 
Another potential implication for the microglial alterations in the brain is related to its 
effects on neurogenesis. For example, research has shown that pro-inflammatory cytokines 
produced by microglia impact neuronal functioning through apoptosis, disrupting synaptic 
plasticity, and neurogenesis (Hayley, Poulter, Merali, & Anisman, 2005; Michael Maes et al., 
2009; McAfoose & Baune, 2009). For example, IL-1b and TNF-alpha have been shown to 
impair long-term potentiation (Cunningham, Murray, O’Neill, Lynch, & O’Connor, 1996), 
neural progenitor cell proliferation (Goshen et al., 2008; Koo & Duman, 2008; Kuzumaki et 
al., 2010), and induce neuronal apoptosis by enhancing glutamatergic activity and 
potentiating excitotoxicity (Ben-Hur et al., 2003; Zou & Crews, 2005). In contrast, resting 
(surveilling) microglia are known to play an important role in neurogenesis by producing a 
number of growth factors, such as IGF-1 and BDNF (Butovsky et al., 2006; Coull et al., 
2005; Sierra et al., 2010; Zhang et al., 2014), facilitating synaptic pruning, and contributing 
to the organization of neural circuits (Paolicelli et al., 2011; Tremblay et al., 2010; Wake et 
al., 2009). Decreased hippocampal neurogenesis and a slowed maturation rate of newborn 
dentate granule cells were found after repeated and cyclic CORT exposure (Chapter 3), and 
these changes were accompanied by progressive changes in microglial morphology (i.e., 
deramification) (Chapter 4). Moreover, the depression-like symptoms of rats were found to 
be strongly associated with both disrupted neurogenic function and microglial activation 
(Chapters 3 and 4). Interestingly, neuroinflammation is frequently associated with normal 
aging and neurodegenerative diseases (Eikelenboom & Veerhuis, 1996), which are also 
characterized by increased basal cortisol levels (Csernansky et al., 2006; Davis et al., 1986; 
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Lupien et al., 1994; Rasmuson, Nasman, Carlstrom, & Olsson, 2002). Finally, the findings in 
Chapter 3 revealed substantial decreases in hippocampal levels of REST protein expression, 
which is known to target the TNF superfamily genes. Decreases in REST mRNA and 
increases in TNF-12,13 mRNA were reported in blood cells of depressed patients. These data 
further suggest the potentiation of neuroinflammatory processes in the brains of CORT-
treated rats, which could be mediated through microglial activation and REST signaling 
within the hippocampus.  
Taken together, research from this dissertation and other literature suggest that 
microglial activation could represent a putative mechanism by which glucocorticoids impair 
neurogenesis and the integration of new neurons into existing circuitry. Although microglial 
investigation in this dissertation provides preliminary correlational evidence that 
glucocorticoids may exert progressive effects on microglial activation in the hippocampus, 
more research is needed to determine how this process regulates neurogenesis and how it 
manifests in depression-like behaviors. 
 
5.5. Limitations 
5.5.1. Can Depression Be Modeled in Laboratory Rodents?  
	
Creating animal models of affective disorders is an extremely challenging task for a 
number of reasons. First, many of the symptoms used for depression diagnosis (DSM-V) are 
uniquely human (e.g., suicidal ideations, guilt, sadness) and cannot be convincingly 
recapitulated in animals. Second, some features of the human depressive syndrome, such as 
despair and anhedonia, which have been replicated in animals, are still considered 
approximate correlates of the human disorder (Nestler & Hyman, 2010). Third, the diagnosis 
of depression is established on a set of heterogeneous and vaguely defined clinical symptoms 
(weight gain/loss, increased/decreased appetite, irritable/sad mood) in the absence of 
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objective biomarkers or neuroimaging tests, creating additional difficulties for both clinical 
and preclinical research.   
 Despite these difficulties, several animal models of depression have been developed, 
replicating separate endophenotypes of the depressive syndrome. The experimental chapters 
of this dissertation were focused on the exogenous CORT administration model, which shares 
a common criticism of many stress-induced models of depression – unrealistic emulation of 
stress. High doses of CORT injections (20-40 mg/kg) are needed to produce robust and 
reliable effects on rat depression-like symptoms in this model (Chapters 2 and 3, Johnson et 
al., 2006), however, these doses are supraphysiological, as they exceed the highest plasma 
concentrations of glucocorticoids (5 mg/kg) produced in response to acute stressors in 
rodents (Sandi, 1996). However, the CORT model allows for better control over 
glucocorticoid levels in experimental subjects, avoiding the typical habituation effects seen 
with physical stressors such as restraint (Galea et al., 1997; Gregus et al., 2005; Grissom et 
al., 2007). Additionally, it gives an opportunity to investigate the direct impact of stress 
hormones on brain and behavior. Interestingly, the use of unnatural stressors is a typical 
limitation of stress-induced models of depression, with exception of CMS and social defeat 
stress models. CMS is known to utilize the most realistic imitation of the daily stressors. 
However, this model also faces criticisms in that it is the least reproducible and may cause 
heterogeneity in response to the perceived stimuli in different animals (Willner, 1997). 
Finally, the social defeat model, despite having strong ethological and ecologic validities, is 
not feasible for use with female rodents, who do not readily exhibit aggressive behaviors 
(Hollis & Kabbaj, 2014).  
This dissertation has taken the CORT administration model of depression a step 
further by incorporating the recurrent nature of major depression disorder. The improved face 
validity would allow for a more precise examination of the development of behavioral 
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vulnerability, as well as a better way to identify the mechanisms governing depressive 
episode relapse. 
 
5.5.2. Sex Differences in Depression 
	
 No female subjects were used in the experiments of this dissertation. Therefore, there 
are some limitations in extrapolating the results of these experiments to the human condition.  
Epidemiological reports consistently demonstrate a higher prevalence of depression in 
females, and these differences are seen in various cultures, suggesting a biological basis 
(Angst et al., 2002; Grigoriadis & Robinson, 2007; Weissman et al., 1993). For example, 
there is evidence that female rodents have higher resting circulating CORT levels, as well as 
higher CORT levels following stress exposure, compared to males (Seale, Wood, Atkinson, 
Bate, et al., 2004; Seale, Wood, Atkinson, Harbuz, & Lightman, 2004), suggesting potential 
sex differences in HPA function. Furthermore, previous research has shown that the immune 
system shows a marked sex-based dimorphism, observed in differing susceptibilities of 
women and men to some immunological diseases (Da Silva & Hall, 1992; Miller & Hunt, 
1996; Offner, Moore, & Biffl, 1999). Surprisingly, evidence from animal research 
investigating the behavioral and neurobiological effects of stress indicates that females are 
rather resistant to stress in preclinical models. For example, findings from our laboratory 
show that CORT administration for 3 weeks increases depression-like behavior in both male 
and female rats, but the effect was less pronounced in the females (Kalynchuk et al., 2004). 
Another study demonstrated that 20 days of CORT injections increased depression-like 
behaviors in the FST in males, but not in females (Hill et al., 2003). Similarly, CMS exerted 
more profound effects on depression-like behavior in male rats compared to females (Dalla et 
al., 2005; Kamper et al., 2009). Also, an acute stress was shown to enhance fear behaviors 
and learned helplessness in males, but to a lesser degree in females (Heinsbroek, Van Haaren, 
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Van de Poll, & Steenbergen, 1991; Steenbergen, Heinsbroek, van Hest, & van de Poll, 1990). 
Consistent with these behavioral observations, stress was shown to cause variable changes in 
the neurobiology of males and females. For instance, repeated CORT administration impairs 
neurogenesis in the dorsal and ventral hippocampus of male rats, and only in the ventral 
hippocampus of females (Brummelte & Galea, 2010). Additionally, repeated stress produced 
reversible atrophy of dendrites of pyramidal neurons in the hippocampus of males (Conrad et 
al., 1999), but this effect is not observed in female rats (Galea et al., 1997). Similar findings 
were demonstrated in a study comparing male and female primates exposed to repeated social 
stress (Uno, Tarara, Else, Suleman, & Sapolsky, 1989). Taken together, these data imply that 
female rodents, despite enhanced HPA axis activity, display a greater resilience to a wide 
variety of stress challenges.  
Fluctuations in gonadal hormones across the estrous cycle present a potential 
explanation for female stress resistance. For example, during proestrus (characterized by high 
estrogen levels), female rats exhibit fewer anxiety-like behaviors and depression-like 
behaviors compared to male rats and females during in diestrus (Frye & Walf, 2002). 
Similarly, in humans, women have greater risks of developing major depression during the 
postpartum period, when estradiol levels are low (Brummelte & Galea, 2010). In addition, 
higher estrogen levels have been associated with increased hippocampal cell proliferation and 
decreased cell death (Pawluski, Brummelte, Barha, Crozier, & Galea, 2009; Tanapat, 
Hastings, Reeves, & Gould, 1999). 
Interestingly, the innate brain immune system may also play a significant role in the 
sexual dimorphism of depression prevalence. Although male rats have more microglia in the 
developing brain (Lenz, Nugent, Haliyur, & McCarthy, 2013; Schwarz, Sholar, & Bilbo, 
2012), this difference is reversed in adulthood, when females have more microglia with 
activated morphology and greater levels of pro-inflammatory cytokines (Schwarz et al., 
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2012). Estrogen may exert anti-inflammatory effects in the brain (Członkowska, Ciesielska, 
Gromadzka, & Kurkowska-Jastrzebska, 2006), therefore the correlation between low 
estrogen levels in females and increased risk of mood disorders could be mediated by 
alterations in microglia and neuroinflammation. Collectively, these data indicate that the 
complex relationship between sex, stress, the immune system and mood is critical and should 
be studied further, especially in research using models of diseases with high female 
prevalence.  
 
5.6. Future Directions 
5.6.1. How Can the CORT Model of Recurrent Depression be Further Improved? 
	
As discussed in the introduction of this dissertation, it is hypothesized that individual 
sensitivity to stress grows and the stress threshold decreases with every subsequent episode of 
depression, leaving the depressed individual vulnerable to depression episode relapse 
following minor stressors (Post, 1985). Several lines of research support this hypothesis. For 
example, a relapse into a depressive episode has been correlated with minor, but not major 
life stressors (Kendler et al., 1999; Ormel et al., 2001). The preclinical literature also 
demonstrates that animals pre-exposed to stress exhibit a sensitized release of catecholamines 
and CORT following stress re-exposure (Gresch, Sved, Zigmond, & Finlay, 1994; Grippo, 
Cushing, & Carter, 2007). In addition, findings from developmental studies also revealed that 
animals stressed in utero or during adolescence display depression-like behaviors in 
adulthood (Morley-Fletcher et al., 2003; Zurita et al., 2000).  Consistently, findings in this 
dissertation also demonstrate behavioral sensitization of rats exposed to the second and third 
cycles of CORT administration. Importantly, after 21 days of CORT injections and 21 days 
of CORT-free recovery, only half of the initial CORT exposure (i.e., ten days) was needed to 
produce increases in depression-like behavior.  Therefore, it would be interesting to 
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investigate the progression of behavioral vulnerability in rats by reducing the number of 
CORT injections further. For example, in the 3rd cycle of CORT exposure, rats could be 
injected for five days only, and, in the 4th cycle, rats could be given a single dose of CORT or 
a mild stressor (restraint, noise, etc.). Such an experimental protocol would allow for a closer 
recapitulation of the human condition and a more precise evaluation of the mechanisms 
underlying stress sensitivity and vulnerability and related depressive episode recurrence. 
Additionally, the current model could be further improved by including an additional 
control group to the experimental design. In this group, the rats would not be subjected to the 
initial cycle of CORT injections, but receive vehicle for 21 days. However, after the recovery 
period, this group would be given CORT for the first time, while the other groups will be 
exposed to CORT for the second time. The addition of this “control + stress” group would 
allow for stricter control over several confounding factors in the experiment, including the 
effects of aging and weight gain. 
 
5.6.2. Other Brain Structures that may be Involved in the Pathogenesis of Depression 
	
The hippocampus is highly stress-sensitive, and therefore, it has been one of the most 
extensively studied brain regions in depressed patients and preclinical models of depression 
(Sterner & Kalynchuk, 2010). However, there are several other brain structures that are 
known to play important roles in emotion, mood, and stress, and these regions have also been 
implicated in depressive disorders. For example, decreases in PFC volume have been 
observed in individuals with multiple episodes of depression (Bora, Fornito, Pantelis, 2012; 
Hastings, Parsey, Oquendo, Arango, & Mann, 2004) and in stress-induced animal models of 
depression (Akana, Chu, Soriano, & Dallman, 2001; Cerqueira et al., 2005; Radley et al., 
2005; Wellman, 2001), which were correlated with impairments in cognitive performance on 
PFC-dependent tasks (Cerqueira et al., 2005). There is evidence that the PFC is abundant in 
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glucocorticoid and mineralocorticoid receptors, and therefore, that it contributes to negative 
feedback control of HPA axis activity (Diorio & Viau, 1993). Interestingly, altered prefrontal 
activity in depressed patients was predictive of a relapse into a subsequent episode of 
depression (Farb, Anderson, Bloch, & Segal, 2011), making this brain structure particularly 
interesting in studying the mechanisms of depression recurrence. Furthermore, alterations in 
REST protein expression were found in both hippocampus and PFC (Lu et al., 2014; Uchida 
et al., 2010), which were associated with vulnerability to developing depressive phenotypes 
in rodents (Uchida et al., 2010). Finally, more research demonstrates stress-induced structural 
remodeling of microglia in the PFC, suggesting increased levels of neuroinflammation 
(Hinwood, Morandini, Day, & Walker, 2012; Hinwood et al., 2013; Kopp, Wick, & Herman, 
2013; Tynan et al., 2010b). However, it is still not known how changes in the PFC microglia 
progress over several cycles of repeated stress, and whether such changes correlate with the 
worsening of depressive symptoms. Therefore, examining how microglia function is altered 
in the PFC is important for further substantiating its role in the pathophysiology of depressive 
disorders. 
The amygdala is another limbic structure that is potentially involved in the 
pathogenesis of major depression. Volumetric alterations and hyperactivation within the 
amygdala have been reported in individuals suffering from depression (Drevets, Price, & 
Furey, 2008; Drevets, 1999; Hastings et al., 2004; Sheline, Gado, & Price, 1998). Preclinical 
research demonstrated that chronic stress results in amygdaloid neuronal hypertrophy and 
hyperactivity, accompanied by potentiated anxiety and fear behaviors (Mitra, Jadhav, 
McEwen, Vyas, & Chattarji, 2005; Rosenkranz, Venheim, & Padival, 2010). Several studies 
revealed that chronic stress also induced changes in the activation of amygdaloid microglia 
(Wohleb et al., 2011), whereas minocycline, a microglial activation inhibitor, produced 
antidepressant effects accompanied by increases in monoamine levels in the amygdala 
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(Arakawa et al., 2012). These observations suggest that the regulation of microglial activation 
in amygdala could be important in antidepressant efficacy. Finally, investigations of REST 
protein expression in the amygdala have been very sparse. To my knowledge, only one study 
looked at REST levels in the brain following early life stress in rodents and found no 
significant changes (Uchida et al., 2010). Therefore, examining changes in REST protein 
within the amygdala using the recurrent animal model of depression would provide important 
insights into the role of REST in fear and anxiety-related behaviors, which are quite frequent 
in major depression. 
 
5.6.3. How do Antidepressants and Recovery Influence Neurobiological Changes in the 
CORT Model of Recurrent Depression? 
The experiments in this dissertation reveal novel findings of time-dependent bi-
directional changes in hippocampal REST protein expression, as well as time-dependent 
increases in microglial activation through changes in cell morphology (Chapters 3 and 4). 
Although these data are supported by other research (Otsuki et al., 2010; Tynan et al., 2010a; 
Uchida et al., 2010), little is known how these neurobiological changes are rescued by 
antidepressant treatment or reversed by prolonged stress-free recovery. Interestingly, there is 
evidence to suggest that stress-induced atrophy of dendrites of pyramidal neurons in 
hippocampus is reversed upon stress cessation (Conrad et al., 1999). But the findings in this 
dissertation demonstrate that decreases in the number of DCX+ immature neurons in the 
dentate gyrus do not recover until the last recovery period (Chapter 3). More research is 
needed to determine whether a reversal of DCX+ cell loss is possible with longer recovery or 
whether these effects are dependent on the number of glucocorticoid re-exposures. To my 
knowledge, no research has been done on the effects of antidepressant medication on brain 
levels of REST protein. Taking into consideration that REST is highly involved in the 
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process of neurogenesis, which is known to be modulated by several classes of 
antidepressants (Banasr & Duman, 2007; Malberg et al., 2000; Santarelli et al., 2003), I 
hypothesize that a significant loss of REST as a result of multiple CORT treatments would be 
prevented in response to chronic antidepressant treatments. 
Finally, several lines of evidence suggest that microglial function is modulated by 
several classes of antidepressant drugs, as well as the rapid antidepressant ketamine (Chang 
et al., 2009; Dubovický, Császár, Melicherčíková, Kuniaková, & Račková, 2014; Hashioka et 
al., 2007; Obuchowicz, Bielecka, Paul-Samojedny, 2014). However, more research is needed 
to investigate how these changes in microglial activation mediate depression-like behavior 
and hippocampal neurogenesis in a recurrent animal model of depression. Additionally, it 
would be critical to study whether microglial alterations recover following stress cessation or 
represent an irreversible damage that accumulates and contributes to depressive episode 
relapse. 
 
5.7. Conclusions 
The purpose of this dissertation was to develop an animal model of recurrent 
depression using repeated and cyclic CORT administration and to examine the 
neurobiological changes associated with depression recurrence in rats. The main and novel 
finding of this dissertation is that repeated and cyclic glucocorticoid exposure results in a 
behavioral aggravation of depression-like symptoms in rats. This result was replicated in two 
separate experiments with repeated and non-repeated behavioral testing; and moreover, 
aggravation was noted in both depression- and anhedonia-like behaviors. Examination of 
neurogenic markers in rats at different time points of the experiment revealed that the number 
and maturation rate of DCX+ immature neurons in the dentate gyrus were declined in rats 
with more CORT re-exposures. Furthermore, I found stress cycle-dependent bi-directional 
	 159	
changes in hippocampal REST protein expression, highlighting the importance of examining 
neurobiological changes across more than one exposure to stress. Changes in both 
neurogenesis and hippocampal REST levels were strongly correlated with increased 
depression-like behaviors. Finally, repeated and cyclic glucocorticoid treatment produced 
accumulative changes in microglial activation within the hippocampus, suggesting an 
additional mechanism mediating neurogenic and behavioral changes in an animal model of 
recurrent depression. In combination, the findings in this dissertation provide a novel way of 
studying recurrent depression and open new avenues of fruitful research investigating the 
neurobiological mechanisms governing depression relapse as well as new therapeutic 
approaches for preventing depressive episode recurrence.    
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